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ABSTRACT
FOLATE RECEPTOR-TARGETED DELIVERY OF SMALL INTERFERING
RNA TO CANCER CELLS
by Yilin Zhang
December 2010
The vitamin folic acid (folate, FA) has been extensively explored as a targeting
ligand to deliver a variety of diagnostic/prognostic/therapeutic agents into various tumors
through the assistance of its receptor – the folate receptor (FR). FR is over-expressed in
many types of human cancer and can mediate internalization of FA-conjugates through
an endocytic pathway. The discovery of small interfering RNA (siRNA), which is cable
of inducing potent gene silencing in a sequence-specific manner, provides an excellent
molecular tool to suppress aberrant gene expression in malignancies, and therefore
siRNA has the potential to revolutionize cancer therapeutics. Towards the goal of
developing an efficient and cancer-specific siRNA strategy, three types of FA-conjugated
molecules have been synthesized to investigate targeted siRNA delivery to cancer cells in
vitro.
In the first section, FA-linked siRNA was synthesized through our one-step in
vitro transcription using FA-HAD-AMP as a transcriptional initiator. FR-dependent
cellular uptake and moderate specific gene down-regulation (50%) were observed in a
stable cell line (Gluc-KB), which was established in this work by integrating Gaussia
luciferase (Gluc) gene to the genome of KB cells (human nasopharyngeal carcinoma).
Gluc-KB provides a platform to better evaluate gene expression changes upon siRNA
treatment.
ii

In the second section, a FA-functionalized, multivalent copolymer (FAPol13) was
introduced to: (i) complex with siRNA to form a FAPol13/siRNA complex, (ii) protect
siRNAs from enzymatic degradation, (iii) enhance cellular uptake by conjugating several
FA molecules to copolymer, and (iv) increase RNAi efficacy eventually. A typical
FAPol13 compound has three functional groups: cationic, hydrophilic, and FA moieties
for providing siRNA packaging site, water solubility, and cell-selectivity, respectively.
This nontoxic polymer successfully delivered siRNAs against Gluc, survivin (Sur),
Caspase 8 associated protein 2 (Casp8ap2) genes in KB cells and efficiently reduced
their expression (i.e., 62% and 68% downregulation from siSv and siGLuc treatments,
respectively). Strikingly, treatment of KB cells with FAPol13/siCasp8ap2 significantly
repressed cell growth and induced cells into apoptosis (24.5%, p = 0.01). Furthermore, a
real-time imaging system, employing fluorescence approaches (time-lapse, z-stacking,
and colocalization analysis), has been developed to evaluate siRNA binding, cellular
uptake, and escape from compartments, respectively. In particular, Pearson’s correlation
coefficient (PCC) was employed to quantify siRNA endosomal escape, one of the crucial
steps of siRNA intracellular trafficking. This method was further applied to the analysis
of siRNA delivery in HeLa (human cervical carcinoma) and SKOV3 (human ovary
carcinoma).
In the third section, a gold nanoparticle (AuNP) capable of packaging and
protecting siRNAs was utilized to transport siRNA to cancer cells. Cytotoxicity assay,
cellular uptake, and gene down-regulation studies of the AuNP-siRNA system indicate
that AuNP can be an efficient siRNA platform.

iii

In the fourth section, a correlation between FR expression level and the delivering
effectiveness of FA-conjugates was established by comparing cellular absorption, cellular
uptake, and RNAi efficiency among KB, HeLa, SKOV3 and A549 (human lung
carcinoma) cells.
Collectively, we have demonstrated effective FR-mediated and cancer cellspecific siRNA delivery by several approaches. Further studies may lead to the
development of therapeutic siRNA delivery systems.
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CHAPTER I
LITERATURE REVIEW
Cancer and Cancer Treatment
Cancer is a class of diverse diseases associated with uncontrolled growth of
abnormal cells where a series of genetic alterations leads to either activated oncogenes
(gain of function) or inactivated cancer suppressor genes (loss of function).1 Currently,
cancer is the second leading cause for human death with more than 10 million new cases
every year.2
After decades of persistent effort, cancer research has achieved rapid progress and
generated a large body of knowledge, revealing that malignant cells are transformed from
normal cells after a succession of genetic changes that confer cell growth advantages.1
Through progressive conversion, cancerous cells gain the capabilities to proliferate
aberrantly (anti-apoptosis, growth signal autonomy), to stimulate the formation of blood
vessels (angiogenesis), and to travel to adjacent tissues (invasion, metastasis).3
Characteristics of Cancer
Cancer cells are transformed from normal cells that have defects in regulation on
cell proliferation and homeostasis. 4A large and diverse collection of cancer-associated
genes is involved in this conversion, resulting in the observed complexity and
heterogeneity of cancer 1. However, most tumors share well-defined characteristics, such
as unrestrained cell growth, deregulated cell cycle control, anti-apoptosis (immortality),
invasion, metastasis, and angiogenesis (formation new vessels from the old ones to
supply oxygen and nutrients through blood stream).
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Proliferation of normal cells is under a strict homeostatic control of growth
signals and anti-growth signals, while in malignant cells, this balance is broken due to
genetic alterations.5 As a result, tumor cells obtain the capability to produce growth
signals, thereby reducing their dependence on stimulation from the normal tissues nearby,
and simultaneously becoming insensitive to anti-growth signals. This process is
designated growth factor autonomy — cells responding to the signals produced by
themselves. To achieve growth factor autonomy, cancer cells either overexpress receptor,
such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor
receptor (VEGFR), fibroblast growth factor receptor, (FGFR),6 folate receptor (FR),7 or
alter transcellular/intracellular signal transducers (e.g., mitogen-activated protein kinase,
MAPK pathway).8
Normal cells are under strict regulation associated with the homeostatic balance
between pro- and anti-apoptotic signaling molecules. Cancerous cells, however, acquire
abilities from genetic alternations to destruct the pro-apoptotic regulators (e.g., p53) and
induce anti-apoptotic regulators (e.g., inhibitor of apoptosis proteins, IAPs). Apoptosis ―
a process of programmed cell death ― causes a series of cellular/molecular changes in
organisms, including cell blebbing, cell shrinkage, chromatin condensation, and nuclear
fragmentation. Apoptosis is conducted by a class of intercellular proteases termed
caspases.9 Caspases harbor a critical cysteine residue at the active site and hydrolyze
target proteins on the carboxyl-terminal side of specific asparagine residues. Under
apoptosis, cells were triggered to release cytochrome C (a potent catalyst of apoptosis)
from mitochondria, destroy subcellular structures, organelles, and genome
(defragmentation).10 Numerous data have revealed that many apoptotic genes (e.g.,
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caspase 8 and caspase 9) are suppressed and anti-apoptotic genes (e.g., survivin, and
livin) are activated in various types of tumors.11 For example, survivin (an apoptosis
inhibitor), which expresses at low to undetectable levels in most normal tissues, is found
overexpressed in nearly every human tumor tested.12
Unlike normal cells but similar to stem cells, cancer cells have the ability to
migrate through the bloodstream, allowing a small population of cancer cells (presumably
cancer stem cells) to invade adjacent tissues and form tumors. This process causes 90%
of human cancer deaths.13 After decades of investigation, significant progress has been
made to characterize several classes of protein components involved in this invasive and
metastatic process, such as cell adhesion molecules (e.g., E-cadeherin, integrin) 14 and
chemokine receptors. 15 For instance, ectopic expression of integrin α4β1 in mouse
melanoma is sufficient to retain tumors in situ.16 In addition, downregulation of Ecadeherin and upregulation of vimentin (one type of intermediate filaments) enable the
migration of cancer cells through a process of epithelial-mesenchymal transition.
Moreover, several blood and solid cancers overexpress chemokine receptors to favor this
process.17
In a normal tissue, cellular function and proliferation are restricted by the
vasculature which supplies oxygen and nutrients to cells, whereas tumor tissue gains the
capability of angiogenesis, which leads to a sustained vasculature through which cancer
cells evade the limitation of nutrient supply and grow consistently. Due to the rapid and
defective angiogenesis, the vessels become leaky and increase the permeability to some
macromolecules, which facilitates the passive delivery of various anticancer drugs.18 This
phenomenon is termed enhanced permeability and retention (EPR) effects.19 Two protein
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families play critical roles in the acquisition of angiogenic capability for tumor: vascular
endothelial growth factor (VEGF) family,20 and acidic and basic fibroblast growth factor
(aFGF and bFGF) family,21 which are upregulated in various types of tumors.20a
Cancer Treatments
Although tremendous efforts have been dedicated to cancer biology research and
substantial progress has been made, approximately 1.5 million new cancer cases, and
more than 0.5 million deaths from cancer were reported in the United States in 2009.2a
Effective cancer therapy confronts at least four challenges: (1) Tumor can originate from
various tissues and as a result there are more than 100 distinct types of cancer; (2) The
fact that tumorigenesis is a combinatory outcome of genetic and epigenetic alterations
makes it impossible to have a universal treatment suitable to every scenario of tumor;
and therefore, it is proposed that cancer therapies should be as diverse as the diseases
themselves; 22 (3) Current prognostic and diagnostic techniques are insufficient; (4)
Classic chemotherapy drugs have undesired cytotoxicity, which causes the death of both
normal and cancerous cells.
Generally speaking, there are three standard approaches for cancer treatment:
surgery, radiation and chemotherapy. The type, size, location, and stage of cancer
determine which approach to be used, and in most cases, they are combinatorially
employed. Surgery is a physical process to remove a tumor if it can be clearly localized.
For several types of cancer, surgical removal of a tumor may be sufficient to cure the
cancer patient in the case that cancer cells have not invaded into other tissues and tumor
tissue has been incised as much as possible. Cancer metastasis contributes to the tumor
recurrence and is the major reason for death of cancer patients.
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Radiation therapy takes advantage of high-energy radiation (i.e., X-rays, gamma
rays, and charged particles) to cause DNA damage and thereby killing cancer cells. 23
Radiation may be employed in the form of beams outside the body (external-beam
radiotherapy) or be implanted into the tumor (internal radiotherapy). More than half of all
cancer patients receive radiotherapy during the course of treatment. In most cases,
radiotherapy is used in a combination with other types of therapeutics. However,
radioactive illumination, no matter from outside or inside the body, will do harm to DNA,
evoking mutagenesis or cell death at the nearby tissues. The mutated cells have a high
likelihood to give rise to a new tumor, which undermines the effectiveness of this
approach. The severity of side effects is dependent on the distance between the
illuminated tumor and normal tissue, and the duration/intensity of radiation beams.
Chemotherapy is perhaps the most commonly used means for cancer therapy. It is
often combinationally applied to post-surgery patients to treat the remaining or migrated
cancer cells that render tumor recurrence. Cancer drugs are hypersensitive to the rapidly
proliferating cells, including cancerous cells and a small portion of normal cells (e.g.,
blood cells). This non-targetability of chemotherapy leads to certain undesired symptoms
(side effects) including pain, diarrhea, hair loss, nausea, anemia, etc.
Most traditional chemotherapeutic drugs are derived from natural sources or
synthetic structural modifications. For example, paclitaxel (Taxol) was originally derived
from the bark of Pacific yew tree and is used for treatment of ovarian and breast cancers.
Camptothecin (CPT) is isolated from the bark and stem of happy tree. 24 Taxol can impair
the microtubule function which is critical for cell division, and therefore serves as a
mitotic inhibitor. CPT is the inhibitor of DNA topoisomerase I and shows remarkable

6

anticancer activity. Currently, two CPT analogues, topotecan and irinotecan, hold great
promise in treatment of several types of tumors for their better water solubility and less
cytotoxicity.25 Taxol and CPT are two representative chemotherapeutic drugs of this
approach.
Besides these three standard approaches, several novel strategies have emerged
and shown great potential in cancer therapy. Proton therapy derived from radiation
therapy is the latest advancement in the treatment of various types of tumors. It uses a
beam of protons to destroy cancer cells without harming healthy cells and thereby
reduces the side-effects of conventional cancer treatments.26 Gene therapy was initially
designed as a means to correct gene defects in hereditary diseases,27 and currently is one
of potential strategies for cancer treatments. The first gene therapy clinical trial began in
1990 by introducing adenosine deaminase gene to the T cells of two children with severe
combined immunodeficiency (SCID).28 From then on, hundreds of clinical studies have
been conducted with almost 70% of these studies being in the area of cancer gene
therapy.29 Because malignant transformation initiates from genetic alterations occurred in
oncogenes and tumor suppressor genes, we can in principle manipulate these genes
through cancer gene therapeutic techniques to restore the cell’s normal gene function.
Other innovative cancer therapeutic approaches include photodynamic therapy
(destroying cancer cells through a photosensitizing drug activated by specific
wavelengths of light),30 vaccine therapy (treating cancer cells by boosting immune
response),31 and targeted therapy (tumor–directed drug delivery).32
Targeted gene therapy, one of cancer therapy strategies, combines the strengths of
gene therapy and targeted therapy, thereby leading to some advantages over conventional
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cancer treatment approaches in experimental and clinical studies.33 This treatment may
have significant impact on future diagnostics, therapeutics of cancer, and others genetic
diseases.
Cancer Stem Cells
The hypothesis of cancer stem cells (CSCs) originated more than a hundred years
ago when it was proposed that the “misplaced” embryonic stem cells (ESCs) during the
embryonic development could be the source of cancer. 34 Later evidence in mice and
humans has indicated that a single cancer cell can generate a heterogeneous tumor,35
suggesting the existence of cancer stem cells. CSCs harbor the self-renewal ability and
can give rise to the neoplasm at high efficiency.36 Meanwhile, over the past few years,
researchers have isolated and identified CSCs from human and mouse leukemia, as well
as from epithelial tumors such as the skin, breast, brain, colon, head and neck tumors.37
Three models have been proposed to explain the formation of CSCs. The first
states that one critical mutation (e.g., the one that breaks the asymmetric division pattern)
triggers the “cascading transformation” from stem cells to cancer cells. The second model
regards that the accumulation of genetic alterations in stem cells leads to the
transformation of CSCs. The third considers that the dedifferentiation of cancer cells
through epithelial-mesenchymal transition results in CSCs.38 Each theory rationalizes
under a certain scenario.
Although researchers have successfully identified, isolated, and cultured the
hemacytometic CSCs, and several critical components in acquiring self-renewal of CSCs
have been demonstrated, the mechanism underlying CSCs acquired capabilities of
metastasis, and apoptosis-resistance is rarely known. 39 To address this issue, efforts have
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been dedicated by conducting gene profiling techniques (e.g., microarray to
systematically compare cancer cells and CSCs, or stem cells and CSCs.39-40
CSCs might lead to tumor recurrence because of their drug resistance and
capability of metastasis. Therefore the identification and characterization of CSCs from
various tumors are of significant importance for the improvement of cancer therapy.41
Further understanding of CSCs has implications for the development of more innovative
and efficient approaches for cancer treatment.41a
Cancer and microRNA (miRNA)
miRNA is a class of evolutionarily-conserved, endogenous, noncoding, small
RNA with 20-23 nucleotides (nt) in length.40c Since its discovery in the early 2000s,42
miRNA has walked its way into virtually every corner of the biology field. It regulates
the expression of genes involved in the control of development, proliferation, apoptosis,
and stress response at translational and posttranslational levels. miRNAs manipulate
more than 60% of human genes43 by inhibiting ribosome function, decapping the 5’-cap
structure (cleavage of 5’-cap of mRNA cause translation repression), deadenylating the
poly(A) tail, and degrading the target mRNA.44
By 2006, more than 400 miRNAs have been experimentally identified in
mammalian genomes; 45 whereas an estimate shows 1000 miRNAs or more exist in
vertebrate and about 100 in invertebrate.45-46 In addition, bioinformatics prediction shows
more than 30% human genes may be under the regulation of miRNAs.47 Strikingly, an
individual miRNA has the ability to control the expression of several to hundreds of
mRNAs it binds to through an imperfect sequence complementarity.
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Altered miRNA expression profile and several other lines of evidence indicate the
critical role of miRNAs in cancer biology.48 For example, it has been found that the
global miRNAs expression in cancer is downregulated and inhibited biogenesis of
miRNAs will lead to tumorigenesis, which suggests the suppressive role of miRNAs in
cancer.49 How miRNAs regulate tumorigenesis has remained poorly understood.
However, recent research starts to yield clues. Hannon and colleagues identified a new
family of miRNAs, miR-34a-c, through comparing miRNA expression profiles of widetype and p53-dificient (p53 is a tumor suppressor) cells. 49a Their findings suggested
miR-34 may act with other effectors to inhibit cancer proliferation through participating
p53 network that inhibited tumor formation. 49a Additionally, Piccolo and coworkers
found another miRNA family, miR-103/107, which reduces the miRNA biosynthesis by
inhibiting Dicer (a key component of siRNA/miRNA process) expression. 49b The data
demonstrate a new pathway where cancer cells downregulate miRNAs syntheses through
Dicer, which in part explains the reduced expression of global miRNAs.49b
In addition, other miRNAs have been identified and demonstrated as tumor
suppressors.50 For instance, downregulation of let-7 is associated with tumor progression
and poor prognosis of lung cancer patients. Expression of let-7 also prevents tumor
sphere formation of breast cancer cell lines and inhibits tumorigenicity in an in vivo
xenograft tumor assay.49d On the contrary, miRNAs, such as miR-21, miR-106a, and
miR-155, have oncogenic activities.51
Overall, miRNA holds potential to influence cancer therapy in different ways.
First, along with the technological advances that facilitate miRNA expression profiling in
tumors, miRNA expression signatures could be identified and utilized as helpful
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biomarkers for cancer diagnostics, which would render a powerful tool for cancer
prevention and therapeutics.52 Second, increasing lines of evidence suggest that
sequence-specific knockdown of oncogenic miRNAs would result in favorable anticancer
effects, demonstrating the promising potential of miRNA-based cancer therapy.50

RNA Interference (RNAi)
Since its discovery,53 RNAi research within biology and medicine have enjoyed
rapid development.54 RNAi process is triggered by short RNA, such as small interfering
RNA (siRNA), microRNA (miRNA), piwiRNA (piRNA), that is homologous to the
target genes being suppressed.55 Due to its sequence-specificity and knockdown potency,
RNAi has been applied to gene function and therapeutic applications.
The Discovery of RNAi
Small RNA-mediated gene silencing phenomenon was first observed in petunia
when an exogenous transgene designed to increase gene expression actually induced the
gene silencing of the homologous endogenous gene.56 Unfortunately, this unexpected and
intriguing result was ignored and explained by co-suppression or post-transcriptional
gene silencing (PTGS).57 It was not until 1998 that the secret of RNAi was uncovered by
Andrew Z. Fire and Craig A. Mello when they injected long double-stranded RNA
(dsRNA) into the nematode C. elegans as well as single strand sense or antisense RNA.53
They found that only dsRNA initiated a potent and specific degradation of endogenous
mRNA containing the same sequence as dsRNA trigger. The groundbreaking discoveries
of RNAi in nematodes let researchers rethink of PTGS in plants, and proved that RNAi
existed in both nematodes and plants.58 However, investigators could not find RNAi in
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mammals because long dsRNA induced the activation of interferon response pathway
and the inhibition of global protein synthesis.59 Tuschl and colleagues demonstrated that
short dsRNA rather than long one could inhibit gene expression.60 Soon RNAi was
observed in Drosophila melannogaster,61 trypanosima,62 and vertebrates.63 We now
understand that RNAi is an evolutionally conserved mechanism in eukaryotes. The
discovery of RNAi has revolutionized gene function research and biomedical research.
RNAi Mechanism
The RNAi pathway can be divided into two major steps: initiation and activation
as shown in Figure I-1. In the first step, a RNase III type enzyme termed Dicer 64 cleaves
the longer dsRNA to smaller RNA that is typically portrayed by ~21 base pair (bp) in
length containing 2 nt overhangs with 5’ phosphate and 3’ hydroxyl terminals.
Subsequently, one strand of siRNA duplex (guide strand) is incorporated into a complex
called RNA-induced gene silencing complex (RISC),65 which binds to complementary
mRNA substrates and manipulates gene function. If the guide strand binds to the
corresponding sequences in the open reading frame (ORF) of mRNA with a complete
base paring (e.g., siRNA or miRNA), it will induce site-specific mRNA degradation.
More precisely, RISC cleaves mRNAs at 10 nt from the 5’ end of the guide strand.60, 66 If
the guide sequence is not fully complementary to the sequence of mRNA (i.e., miRNA),
which normally occurs at the 3’ untranslated regains (UTRs), the RNA will trigger
translational repression.67 In another word, RNAi can resulted from either siRNA or
miRNA, depending on the degree of the complementarity between the guide RNA and its
target mRNA. If the complementarity is low, the guide RNA will go into miRNA
pathway, leading to translational inhibition; whereas the perfect base pairing match will
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lead to siRNA pathway, causing the cleavage of mRNA. Actually, miRNA process is
biochemically
iochemically or functionally indistinguishable from siRNA pathway because they share
some essential factors which are often encoded by multigene families conserved among
eukaryotes.67

Figure I-1. Mechanisms of RNA inference.

In addition to siRNA and miRNA, a new class of small, non-coding
coding but functional
RNA termed piRNA (piwi
iwi-interacting RNA) has been discovered recently.
recently 68 piRNA is
typically 26-31 nt in length, longer than 21-23 nt of miRNA and 21 nt of siRNA, with an
important role in mammalian spermatogenesis
spermatogenesis.68 Taken together, the vital role of
miRNA, siRNA, piRNA, and other RNA species, such as repeat
repeat-associated
associated siRNA (ra(ra
siRNA), trans-acting
acting siRNA (ta
(ta-siRNA) etc. in the regulation of chromatin
romatin structure,
gene expression, mRNA processing and splicing, mRNA stability and translational
control demonstrate the importance of uncovering and understanding the RNA world.
world 69
siRNA Design
Although any target
target-complementary siRNA could theoretically
heoretically silence its cognate
co
gene,63b only a small fraction
action of siRNAs has high effectiveness
ness and specificity.
specificity 70 A
positional shift on the target mRNA can alter siRNA function in a dramatic manner.71
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Moreover, siRNA may nonspecifically target unrelated genes with only partial sequencecomplementarity. Therefore, a rational design of siRNA sequence is a prerequisite for
performing reliable gene knockdown.72
In the early 2000s, a set of empirical rules based on the first identified functional
siRNAs was proposed and influenced siRNA design profoundly.63b Today, some of these
criteria are still being utilized in several siRNA selection/design tools. However, more
powerful, comprehensive tools have emerged based on the following advances : (i)
further understanding of RNAi mechanism, (ii) statistical analysis of libraries of siRNAs
with experimentally determined efficiency;73 and (iii) the rapid development of
bioinformatics.74 Some research groups have collected published functional siRNA
sequences and established open-access databases;75 while a few biotechnology
companies, such as Ambion, Qiagen, and Invitrogen, provide pre-designed or custom
siRNAs synthesis services.
Despite the availability of these sources, it is necessary for investigators to know
some criteria in the case of choosing an appropriate tool or selecting a siRNA candidate
from a list. There are four typical rules as an important guideline in the considerations of
effective and specific siRNA:55, 70 (1) Sequence asymmetry: siRNAs symmetry in
structure but not in sequence shows improved efficacy and specificity.55 (2) siRNA
duplex stability: siRNAs with G+C content between 30% ~ 52% keep the balance
between structure stability and release flexibility. Typically, G+C content lower than
30% will destabilize siRNA duplexes and reduce the affinity for target mRNA binding;
whereas higher than 52% may impede RISC loading and /or cleavage-product release.70
(3) Target accessibility: the local secondary structures of target mRNAs might restrict the
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accessibility of RISC, reducing or abolishing siRNA efficiency.76 (4) Sequence features:
single nucleotide at different positions will affect siRNAs performance dramatically. For
instance, U/A at position 1, A/U at position 10, C/G at position 19.55 Additionally, some
other factors, such as thermodynamic consideration and BLAST search, are contributing
to the rational design of siRNAs.
RNAi Application
The ability of siRNA to silence gene expression as a powerful investigational tool
has been intensively explored in dissecting gene function and blocking disease-causing
gene expression.65, 77
RNAi has been successfully applied to systematic genome-wide screening in
many species, such as C. elegans 78 and Drosophila 65. High-throughput techniques
combining the strengths of RNAi, bioinformatics and genomics, offer rapid annotation of
genomes with functional information on each gene readily.79 In addition, siRNAs hold
great potential as gene therapeutic agents for treating a wide range of diseases, such as
cancer, neurodegenerative disorders, and viral infection, where aberrant gene expression
occurs.80 For instance, downregulated expression of VEGF, an important factor for
pathological angiogenesis,81 through RNAi technique suppressed tumor angiogenesis and
growth in PC-3 (a human prostate cancer cell line) xerograph model.82
Overall, compared to the classic genetic and reverse genetic approaches, siRNA
has incomparable advantages in functional genomics and as therapeutic applications.83
Classical genetic approaches study the gene function by identifying gene mutations, and
conventional reverse genetic methods involve the disruption of a known gene (i.e.,
knockout) to study the effect on a function or pathway. Both are time-consuming and
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expensive. In contrast, the function of an unknown gene through RNAi technique could
be revealed in several days.80 siRNA possesses the high specificity and potency in
inducing gene silencing with a sequence-dependent manner. The accessibility of
genomics sequencing of many key organisms accelerates the development of nucleic
acid-based RNAi in gene function research.84
siRNA Delivery
An appropriate delivery strategy that enables siRNA translocation and balances
siRNA stability and activity is the key to a successful siRNA application. siRNA delivery
can be divided into two classes: in vitro and in vivo delivery. The latter include two major
routes according to biodistribution: local and systemic administration. Local
administration, as the name implies, is a route by which siRNA or drug is directly
delivered to a localized area of the body (e.g., tumor) with topical effects. This strategy
uses a low dose of substance but achieves relative high concentration at the intended site;
and therefore, reduces the risks of systemic side effects.85 In contrast, systemic
administration refers to deliver drugs or substances through either enteral (digestive tract)
or parenteral (intramuscular or intravenous injections) route. The choice between these
two administrations depends on tissues location and cell type being targeted.86
According to the endurance of RNAi effects, siRNA delivery can be sorted into
transient and stable delivery. In other words, siRNA can be delivered to cells either
exogenously as synthetic agents or endogenously as gene-encoding siRNAs.87 For the
former, RNAi effect is achieved through exogenous delivery of chemical or transcripted
siRNA and normally exists for a few days before the degradation of siRNAs. As for the
latter, siRNA is often delivered by viral plasmid vectors which have the capability of
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being integrated into the host’s genome, and thereby, RNAi effects can last for weeks or
even longer. This strategy is preferred for siRNA library construction and systematic
genome-wide functional screening. Besides, for some chronic diseases which need lasting
therapeutics and low toxicity, the stable transfection is advantageous. Short hairpin
siRNAs (shRNAs) are commonly used under this strategy. However, those methods
based on the plasmid which will be expressed under the host’s transcription system pose
a safety issue.
siRNA delivery systems can be divided into viral- and nonviral-based delivery.
Due to the high efficiency of ferrying DNA/RNA into the cells, viral delivery has been
intensively investigated for gene therapy. There are at least four classes of virus in this
arena: retrovirus, adenovirus, baculovirus, and lentivirus.88 Despite of high transduction
efficiency, viral-based delivery system in vivo is limited by safety concerns. For example,
retroviruses could be integrated into the genome of the host cells, which potentially
increases the risk of carcinogenesis. Another issue is the transduction efficiency of the
retroviral vector is correlative with the activity of cell division.
The lack of genomic integration of adenoviral vectors provides a safety advantage
over retrovirus vectors. As a result, many adenovirus-based clinical trials occur,89 and
several studies report that the local administration of adenoviral vectors has achieved
significant therapy effects. However, therapeutic effects from adenoviral vectors, which
are generally lost after several cell divisions, are moderate and short-lived compared to
those from the retrovirus vectors. In addition, this approach is impaired by dosedependent liver toxicity.90 In contrast to baculovirus, lentiviral vector is a promising
strategy owing to its relative bio-safety, less mutagenesis risk, and less pathogenesis.91
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Nonviral based delivery strategies, such as (co)polymer, Au nanoparticle (AuNP),
liposome, polyarginine, polylysine, polyethylenimine (PEI), hydrogel, dendrimer, hold
tremendous promise.92 Some liposome-based, commercial reagents (e.g., Lipofectamine,
DharmaFECT) have been routinely used for siRNA delivery into various types of cancers
in vitro.93 However, their applications in vivo are hurdled by cytotoxicity and instability
in serum.85 PEI is another widely used transfection agent for many years.94 Despite its
variable performance, it is a useful tool for delivering antisense oligodeoxyribonucleotide
(As-ODN), DNA plasmid, and siRNA etc.95 Furthermore, modified PEI increases the
efficiency and specificity of delivery.96
Most of these nano-scale carriers contain cationic groups which can bind to
anionic phosphate backbone of the nucleotides via electrostatistics and facilitate the
cellular uptake of complexes without target specificity. The complexes (i.e., lipoplex,
polyplex) can be adjusted to be cationic, anionic, or neutral in terms of nitrogen (cationic
group) to phosphate (anionic group) ratio (N/P ratio). By the nature of negatively-charged
cell membrane, cationic complexes (N/P > 1) have the tendency to penetrate the
membrane easily; whereas anionic complexes (N/P < 1) normally have poor transfection
efficiency. As for neutral complexes, they normally need hydrophilic groups, such as
hydroxyl group, to maintain water solubility.97
Delivery of siRNA is intended to downregulate abnormal gene expression through
RNAi machinery in diseased cells. Although cellular penetration of siRNA has been
achieved by efficient delivery strategies, therapeutic effects of siRNA cannot be achieved
until it is in the desired cells. For this reason, the development of cell- or tissue-specific
delivery must be resolved prior to clinical development of siRNA therapeutics.
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Targeted siRNA Delivery
Although significant progress has been made in cancer prognosis, diagnosis, and
treatment, cancer is still one of the most devastating diseases. One of the challenges we
are facing is the non-targetability of the conventional cancer treatments that cause cell
death indistinguishably in both normal and malignant tissues. This Achilles’ heel elicits
side effects and compromises the effectiveness of common treatments. To address this
issue, a number of novel strategies that aim at homing of drugs to malignant cells through
the mediation of targeting moieties have emerged and offer great promise. Targeting
ligands applicable to cancer therapy mainly include antibodies,98 peptides,6a, 99
aptamers,99a, 100 and vitamins.7b, 101
Antibody-Based Delivery
Antibodies, immunoglobulin proteins, are produced by B lymphocytes to bind
foreign objects (antigens), such as viruses, bacteria, exogenous proteins, microorganisms,
and toxins. Numerous antibodies have been generated and commercialized by injecting
an antigen into a mammal (e.g., rabbit, goats). Successful production of specific antibody
depends on several factors of antigen, such as chemical characteristics of antigen, the size
of antigen (> 5 KDa), and its difference from an animal’s own proteins.
In the past decades, development of therapeutic and diagnostic antibody is among
the fastest growth in biopharmaceutical area by the virtue of its high specificity and
affinity to target various antigens.102 More than 18 monoclonal antibodies have been
commercialized. For example, trastuzumab (Herceptin®), rituximab (Rituxan®), and
alemtuzumab (Campath®) have been routinely used in clinical treatment of breast cancer
and leukemia.103 Additionally, over 100 therapeutic monoclonal antibodies are currently
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under investigation, demonstrating the tremendous biomedical potential of this
strategy.104
Due to the exquisite specificity of target recognition and high binding affinity
between antibody and antigen, many antibodies have been conjugated to nanoparticle
carriers for targeted siRNA/drug delivery. Many therapeutic agents have been transported
into diseased cells specifically through this approach. These agents contain
chemotherapeutic drugs, siRNAs, and As-ODNs.98b, 98d, 105 For example, Song et al.
designed a protamine-antibody fusion protein for delivering siRNAs to HIV-infected
cells.98d The carrier contains the C-terminus of the heavy chain fragment of an antibody
against HIV-1 envelope protein (GP160), and polycationic protamine for complexing
siRNA. A cocktail of siRNAs against c-Myc (an transcriptional factor), MDM2 (an
negative regulator of the p53), and VEGF had been administered to tumor cells in mice
engineered to express GP160, exhibiting potent antitumor effects.98d Despite promising,
antibody-based delivery possesses some setbacks, such as immunogenicity, high cost,
and difficult conjugation chemistry.
Peptide-Based Delivery
Among many strategies for siRNA delivery, peptide-based delivery has received
significant attention.106 Such cationic and short peptides (motifs) interact with the
membrane receptors or proteoglycans which elicit cellular uptake via endocytosis.107
Although the underlying mechanisms of internalization remain controversial, those
peptides have been applied to deliver a broad spectrum of therapeutic agents.99b, 99d, 108
Peptides with arginine-glycine-aspartic acid (RGD) motif have been used to target
drugs, siRNA, imaging agents, and other diagnostic agents to the tumor cells expressing
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αvβ3 integrin. Integrin is a heterodimeric cell adhesive protein (with two subunits α and β)
anchored to the plasma membrane.109 The ligands of integrin include collagen (a fibrous
protein constituent of bone, cartilage, tendon, and other connective tissue) and fibronectin
(an extracellular matrix glycoprotein) 110 with characterized RGD motif. Importantly
integrin receptors are overexpressed on endothelial cells in a tumor vasculature due to its
crucial role in angiogenesis. For this reason, RGD-mediated targeted delivery has been
developed to deliver diagnostic or prognostic agents specifically to tumor.99c For
example, PEGylated PEI with RGD group directs the delivery of siRNA against VEGF
into tumor with significant inhibitory effects of the tumor growth and reduction of
angiogenesis after intravenous administration.111
TAT peptide, a fragment of ligands which can be incorporated into the HIVinfected cells and concentrated in nuclei, is characterized by cationic peptides,
YGRKKRRQRRR.112 TAT-siRNA conjugate has been successfully synthesized and
effectively delivered with silencing the expression of exogenous enhanced green
fluorescence protein (EGFP) and endogenous cyclin dependent kinase 9 (CDK9).113 TAT
peptide has been applied to deliver DNA 114 and protein.112
Cell penetrating peptides (CPPs) which are also known as protein transduction
domains (PTD) or membrane transduction sequences, are short (~30 amino acids)
cationic peptide chains rich in arginine and/or lysine residues.108c CPPs have the ability to
transport linked antisense and siRNA molecules as cargoes into cytosol thereby achieving
oligonucleotide-based therapeutics. Several lines of evidence have shown that CPPantisense oligonucleotide conjugates can be taken up by cells and effectively regulate
gene expression in vitro and in vivo.115 Although not as potent as cationic lipid agents in
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complexing siRNAs, CPP-based delivery strategies have substantial advantages in cell
penetration potential.115-116 This was highlighted in a recent study where the systemically
delivered siRNA-peptide conjugates crossed blood-brain barrier (BBB).117
Aptamer-Based Delivery
Aptamers are normally short nucleic acids that have stable three-dimensional
shapes and can bind to targeted molecules tightly and specifically.118 An aptamer against
a target (such as ligands, protein, chemicals, etc.) is selected and identified from
combinatorial nucleic acid libraries through a technique called systematic evolution of
ligands by exponential enrichment (SELEX).119 In the past two decades, SELEX has been
widely used, and numerous aptamers have been explored in both diagnostic and
therapeutic applications.120
Aptamer targeting cell surface proteins has been confirmed a promising delivery
strategy because of its advantages, such as lack of immunogenicity in vivo, convenient
synthesis and modification, relatively small size, rapid in vitro selection process, and
large quantities produced with relatively low cost.118 By virtue of these properties, a wide
range of cargoes has been successfully delivered in a cell-specific manner, including
siRNAs,121 enzymes,122 radionuclide,100d virus ,123 toxins,124 anti-cancer drugs.125
Aptamer against the prostate-specific membrane antigen (PSMA) is one of the
classical aptamer. PSMA is a cell surface antigen overexpressed in prostate cancer cells
and in tumor vascular endothelium.126 Several groups have constructed distinct aptamersiRNA conjugates that have been delivered into tumors with potent efficacy 121d (Figure
I-2). In another example, Neufeld and colleagues have used aptamer against a transferrin
receptor (a protein regulates the importation of iron into cells) for delivering α-L-
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iduronidase (an enzyme to remove ma
mannose 6-phosphate)
phosphate) into the lysosomes of cells
deficient in this enzyme.122

Figure I-2. Representative strategies for targeted delivery of small interfering RNA.

Recent advances in aptamer
aptamer-targeted
targeted siRNA therapeutics make it a promising
strategy for clinical application. Some other strategies for siRNA targeted delivery are
exemplified in Figure I-2,
2, including cholesterol targeted
targeted,127 and folate targeted.
targeted 128

Folat
Folate Receptor-Mediated Specific Delivery
Folate receptor (FR) 101s is a confirmed tumor-associated
associated antigen that binds
folate/folate conjugates with high affinity and transfers them into FR-bearing
bearing cancer cells
by endocytosis.101j Folate ((folic acid, FA) is a crucial vitamin (Vitamin B9) for metabolic
maintenance of carbon pathway
pathway.129 FA harbors three moieties that are pteridine, p-
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aminobenzoate (PABA), and glutamate moieties (Figure I-3). Pteroic acid (PA) is
analogous to FA without glutamate group. The pteridine ring of folate can exist in
tetrahydro-, dihydro-, and fully oxidized forms. Plant folates have γ-linked polyglutamyl
tails of up to approximately six residues.130
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Figure I-3. The structure of folate.

Folate is a vital cofactor to transfer 1-carbon groups in de novo synthesis of
nucleotides. Therefore, the deficiency of folate will induce DNA strand breakage,
increase uracil misincorporation into DNA, impair DNA repair and stimulate
apoptosis.131 In addition, folate also plays an important role in amino acid metabolism,
including serine, glycine, methionine and histidine metabolism. That is probably why
some cancer cells overexpress FR to acquire more vitamin folate, so that they can escape
the limitation of cell proliferation.132
Receptor-mediated folate uptake was first found about two decades ago.133
Cellular uptake of folate in animals is through either FR or reduced folate carrier (RFC).7a
FR is a glycosylphosphotidylinositol (GPI)-anchored glycoprotein 101s and includes three
homologous isoforms, FR-α, FR-β and FR-γ, with distinct expression patterns.134 FR-α is
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the major type expressed by tumors.135 RFC is a membrane-spanning protein,131 and most
of the antifolate drugs, such as methotrexate, ralititrexed, and lometrexol, are rapidly
transferred across the plasma membrane by RFC, leading to inhibition of their target in
both tumors and normal proliferating tissues.131
Endocytosis mediates the internalization of folate or folate conjugates in FRexpressing cells (Figure I-4). Firstly, folate conjugates bind to FR on cell surface and
induce the formation of an intracellular compartment called an endosome, to which they
internalize and traffic.101n Once an endosome transports to cytosol, it triggers
acidification under the aid of proton pumps, which decrease pH to 4.3~6.9 (most
frequently, pH~5.0).136 The change of pH results in the release of folate-drug conjugates
from FR and the breakdown of compartments (i.e., endosomal escape). FR on the
compartment could be recycled back to the plasma membrane and facilitate the next
round transportation.

Figure I-4. The process of folate conjugate uptake via receptor-mediated endocytosis.
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FR responsible for the internalization of FA conjugates has been supported by
experiments where the uptake is abolished by: (i) excess free FA, (ii) FR antibody, (iii)
FR negative cells, (iv) the cleavage of GPI anchor with phosphatidylinositol-specific
phospholipase C (PLC).137 On the other hand, inhibitor studies on several endocytic
proteins have suggested that receptor-mediated endocytosis is engaged in the entry of
folate conjugates.138
FR-mediated delivery has some great advantages: (i) Normal cells use RFC to
transport reduced FA; whereas cancer cells utilize FR to uptake oxidized folates, or
folates conjugates,139 (ii) The cargo of FA, no matter how big or small, will not affect
binding affinity (Kd = ~10-10 M) 137, 140 and endocytosis, (iii) FA conjugate could be
released into the cytosol respond to the pH changes, and consequently exert their
functions (FigureI-4),101j (iv) Due to the low molecular weight of folate, FA-conjugates
facilitate the cellular penetration in solid tumors,86 (v) The density of FR in malignant
cells appears to increase as the stage/grade of the cancer worsens,139 (vi) The carboxyl
group of glutamate(s) (Figure I-3) has structural flexibility for chemical conjugation and
release,141 (vii) FA can be alternatively substituted by Pte (Figure I-3) without
compromising binding affinity and delivery efficacy.
High expression levels of FR-α in tumor, such as ovary, cervical, mammary
gland, breast, colon, prostate, lung, kidney, nose, throat, and brain, make FR-based
delivery attractive for biomedical application. For example, MORAb-003, a monoclonal
antibody against FR-α, is under phase II clinical trial in ovarian cancer patients, which
has shown cellular cytotoxicity via non-immune mediated cell growth inhibition under
folate-deficient conditions.142 In addition, several FA-linked drugs are under phase I to
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phase II clinical trials.143 Taking FA-tubulysin derivatives as an example, this group
includes tubulysin A hydrazide (EC0510), tubulysin B hydrazide (EC0305), tubulysin B
ester (EC0302), and N,O-acetal derivative of natural tubulysin (EC0317).144 Tubulysin is
a type of tetrapeptide that has high cytotoxicity and effective antiproliferative activity
against multiple cancer cell lines.145 EC0305, one of the promising conjugates of the
group, shows dose-dependent antitumor activity (IC50 = 1-10 nM in M109) and favorably
low toxicity 144. Two other FA conjugates, EC131 (FA-maytansionid) 146 and EC145
(FA-desacetylvinblastine monohydrazide),144, 147 act as tubulin inhibitors by interfering
with the formation of microtubulin and exhibit great antitumor potential. These
undergoing investigations have demonstrated the FR-targeting delivery holds great
potential in biomedical applications.
Additionally, FA has been applied to deliver a wide range of drugs or therapeutic
or diagnostic agents into various tumors. The cargoes include siRNAs,101b ribozymes,148
anti-cancer drugs,149 radioactive/magnetic resonance imagining agents,101d, 150
oligonucleotides,151 radiotherapeutic agents,148 protein toxins, 101o, 101q chemotherapeutic
agents,101m immunotherapeutic agents,143 and liposomes with entrapped drugs.101l, 149
Typical FR-positive cancer cells include KB (human nasopharyngeal epidermoid
carcinoma cell line), SKOV-3 (human ovarian carcinoma cell line), SW620 (human
colorectal carcinoma cell line), etc. However, A375 (Human malignant melanoma cell
line), A431 (Human epithelial carcinoma cell line), and A549 (Human lung carcinoma
cell line) express little FR,101j and are normally used as FR-negative control cells in
studies.
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siRNA Targets for Cancer Therapeutics
Sequence-specific gene silencing through siRNAs has become a standard
approach for therapeutic application. Many diseases result from abnormal gene
expression. siRNA technique has the ability to restore cell’s normal gene function. In
cancer cells, genes that are associated with cell proliferation, apoptosis, metastasis,
angiogenesis, and drug resistance are potential siRNA targets for therapeutic
intervention.152 Three genes, VEGF, survivin (Sur), and caspase 8 associated protein 2
(CASP8AP2), are involved in angiogenesis and apoptosis, and are discussed below.
VEGF and Tumor-Specific Angiogenesis
VEGF, EGF, and FGF represent the most widely recognized oncogenic growth
factors.86 Among them, VEGF plays as a crucial regulator for blood vessel formation
including vasculogenesis (the formation of new blood vessels when there are no preexisting ones) and angiogenesis (the formation of new blood vessels from pre-existing
endothelium),153 showing pleiotropic responses on migration, proliferation, tube
formation, and survival of endothelial cells.154 Knockout of VEGF in embryonic cells
results in despaired vasculogenesis and embryo lethal.155 Angiogenesis is the second
phase of embryological development under physiological conditions.20b Recent evidence
indicates that VEGF signaling plays a vital role in tumor growth, intraocular neovascular
disorders and other conditions due to induced angiogenesis.156
VEGF, characterized by the intrachain and interchain disulfide bonds between
eight cysteine residues at conserved positions,153 has two monomers which form a dimer
in an anti-parallel fashion with the receptor-binding sites located at each pole of the
dimer.157
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In mammals, there are five members in this family, termed VEGF-A, VEGF-B,
VEGF-C, VEGF-D, and placental growth factor (PGF). Each member has several
different splice variants and processed forms with distinct expression pattern. Human
VEGF-A gene contains eight exons separated by seven introns,158 and has at least five
isoforms designated by their expected amino acid length, which are VEGFA121,
VEGFA145, VEGFA165, VEGFA189 and VEGFA206.153 VEGFA121 lacks the residues
encoded by exon 6 and 7; while VEGFA165 lacks the residues encoded by exon 6 and is
the predominant isoform158. The longest VEGF-A transcript in human is 3665 nt long and
encodes VEGF206. VEGF-A is a key mediator of blood vessel growth; whereas VEGF-C
and VEGF-D regulates lymphatic angiogenesis.159 In addition, VEGF-A, specifically
acting in endothelial cells, has various effects, such as mediating increased vascular
permeability, stimulating angiogenesis, vasculogenesis and endothelial cell growth,
promoting cell migration, and inhibiting apoptosis.20b
VEGF receptor family includes VEGFR1, VEGFR2, VEGFR3, and two
coreceptors, heparin sulfate proteoglycan and neuropilin, which are defined as VEGFbinding molecules, but lack of VEGF-induced catalytic function.160 VEGFR1, a soluble
or membrane-bound protein, is the receptor of PGF during angiogenesis;161 whereas
VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and
lymphendothelial cells, respectively.
Malignant cells up-regulate the expression of VEGF(R) to induce the formation of
blood vessels through which oxygen and nutrients are transported to tumor and
eventually facilitate it escaping the limitation of growth supplies. Therefore,
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downregulation of VEGF or/and VEGFR expression can diminish angiogenesis by
cutting down blood vessel development, and ultimately shrink a tumor.162
This rationale has been applied to treat various cancers and neovascularization
age-related macular degeneration (AMD) 163 with pharmaceutical success.153 Two drugs
aimed at VEGF, bevacizumab (Avastin), a humanized monoclonal antibody, and
pegaptinib (Macugen), a PEGylated aptamer has been approved by U.S. Food and Drug
Administration (FDA) to treat various types of cancer and AMD, respectively.2b Two
other drugs, sorafenib (Nexavar) and sunitinib (Sutent) as molecular antagonists of
VEGFRs have also been approved by FDA for treatment of kidney and liver cancer.2b
Apart from these commercialized drugs, a multitude of VEGF(R)-targeted,
siRNA-based therapy are currently being investigated.85 For example, a siRNA
compound, Sirna-027, has disrupted the VEGF pathway and reduced neovascularization
by a direct intravitreal (inside an eye) administration.164 Moreover, Kim and colleagues
reported that cocktailed siRNAs targeting three genes (VEGFA, VEGFR1, and VEGFR2)
could block angiogenesis from herpes simplex virus (HSV) infection, which caused
neovascularization or stromal keratitis.165 Taken together, VEGF and its receptors are key
regulators of the process of angiogenesis, which makes them attractive therapeutic targets
with demonstrated success.
Survivin and Anti-Apoptosis
Since the discovery of survivin in 1997,166 a keen interest and intensive attention
have been focused on this unique protein because of its dual-function as a suppressor of
apoptosis and a regulator of cell division. 167 Survivin is a member of inhibitor of
apoptosis proteins (IAPs) family and a component of a chromosome passenger complex
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(CPC). It regulates several important biological processes, including mitotic spindle
checkpoint, angiogenesis, chemoresistance, and apoptosis.168
Survivin, a homodimer, is the smallest member (142 amino acid) of IAP
family.169 IAP regulates apoptosis by blocking the activities of ccaspases
aspases (i.e.,
(i.e. caspase 8,
caspase 9), contains eight other members: X
X-linked
linked IAP (XIAP), cIAP1, cIAP2, neuronal
apoptosis inhibitor protein, melanoma IAP, IAP
IAP-like
like protein 2, livin, and apollon.
apollon 167b
The anti-apoptotic
apoptotic functionality of survivin needs two cofactors, hepatitis B XX
interacting protein (HBXIP) and XIAP
XIAP.167b Activated by pro-apoptotic
apoptotic signaling, survivin
is released from the mitochondria into cytosol and form survivin/HBXIP and
survivin/XIAP, which cooperatively inhibit the activity of caspase 9, and eventually
downregulate apoptosis (Fig
(Figure I-5).

Figure I-5. The role of survivin in anti
anti-apoptotic pathway. Survivin activates with
cofactors, HBXIP (hepatitis B X
X-interacting protein) and XIBP (X-interacting
interacting inhibitor of
apoptosis protein) and inhibit the function of Caspase 9, one of effectors of apoptosis.
apoptosis 167b

Survivin expresses during embryonic development and is absent in differentiated
tissues.170 However, it is highly expre
expressed in most human tumors with unveiled
mechanisms accompanied by aggressive phenotype, shorter survival time, and decreased
response to chemotherapy. Moreover, its expression exhibits prognostic relevance with
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some tumors and it appears to be involved in cancer resistance. Based on these findings,
survivin has been proposed as an attractive target for cancer therapy. Some preclinical
studies have demonstrated that downregulation of survivin expression reduced tumor
growth potential, increased the apoptotic rate, and improved the sensitivity of malignant
cells to chemotherapeutics.171 In addition, several survivin inhibitors have been
developed as anticancer therapeutic tools and entered clinical trials.167b YM155, one of
them, was discovered through screening assay with a survivin-promoter luciferase
experiment.172 It specifically suppresses survivin transcription and translation in several
cancer cell lines with robust antiproliferative activity in vitro and in vivo.173
However, in some preclinical experiments, downregulation of survivin expression
and function through RNAi technique results in modest antitumor activity, indicating the
need of synergic treatment. Following this notion, several components, such as
topoisomerase inhibitors,174 alkylating agents,175 and UCN-01 (a small molecule inhibitor
for protein kinase C, and cyclin-dependent kinase),176 have been identified and
combinatorially utilized with survivin-specific siRNA to increase the inhibitory effects on
cancer cell proliferation.
Inhibition of survivin expression does not induce significant apoptosis. Instead, it
leads to aberrant chromosome and aneuploidy, suggesting its role as a mitotic regulator
associated with CPC. CPC contains at least four proteins: survivin, aurora, borealin, and
INCENP.177 The interaction between aurora and survivin is supported by the correlation
of decreased survivin and mislocalized aurora B in dying cells.178 Data also show that
repression of survivin expression will render cell mitotic catastrophe, a form of cell death
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that results from aberrant mitosis.179 In these cells, the location of survivin on
chromosome is altered and severe spindle defects emerge.4, 179
Caspase 8-Associated Protein 2
Caspase 8-associated protein 2 (CASP8AP2) is a human apoptotic protein,
homologous to FLASH (FLICE-associated huge protein) in mouse and CED-4 in C.
elegans. Currently, we know little about CASP8AP2, and major knowledge about this
protein comes from studies of FLASH.
FLASH was first identified in 1999 by screening a mouse T-cell complementary
DNA (cDNA) library with two-hybrid system and tandem dead effector domains (DEDs)
of caspase 8 as a probe.180 FLASH is constitutively expressed in adult mouse tissue as
two transcripts of approximate 4.7 kb and 7 kb, and translated into a ~220 kDa
protein.180-181 FLASH contains a DED-recruiting domain, which is able to bind to DED(s)
of caspase 8 and Fas-associated protein with dead domain (FADD).182 Studies suggested
that FLASH may be a component of the death-inducing signaling complex (DISC) 183
that includes Fas receptor, Fas-binding adapter, and caspase 8, and plays a regulatory role
in Fas-mediated apoptosis.
Presently there is some research on CASP8AP2. For example, Kittler et al.
generated a genome-scaled, endoribonuclease-prepared short interfering (esi)RNAs
library to screen the genes essential for the cell division.184 CASP8AP2 was identified
through cell viability screening followed by video-microscopy assay with 36 other genes
that are critical for cell mitosis.184 Downregulation of CASP8AP2 caused cell death,
indicating the role of CASP8AP2 as an apoptotic co-repressor. Interestingly, the function
of CASP8AP2 in acute lymphoblast leukemia patients appears different. Flotho et al.
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found that low expression level of CASP8AP2 was correlative with a high rate of
leukemia relapse. By contrast, high expression level was associated with a reduced
capacity of leukemic lymphoblasts to grow in vitro.185 Their interesting results implied
that CASP8AP2 was a prognostic factor for leukemia relapse.186
These “contradictory” results indicate the dual function of CASP8AP2, similar to
FLASH which is capable of regulating apoptosis induction and activation of the antiapoptotic NF-κB (an important transcriptional factor) pathway.181, 187 The data from
FLASH studies indicate that the subcellular compartmentalization of this protein could
play a critical role in its function determination.181 When FLASH locates in cytoplasm, it
mediates apoptotic function in association with caspase at mitochondria; while in the
nucleus, it mediates the NF-κB pathway or is assembled into Cajal bodies (a suborganelle found in the nucleus of proliferative cells),187b fulfilling the non-apoptotic
function.

Transcription-Coupled RNA Conjugation System
Our lab has been interested in RNA catalysis, conjugation, and function.101a, b, 128,
188

A versatile transcription system has been developed recently using a functional group

linked adenosine analog (R-A, R: functional group, A: adenosine) as a transcriptional
initiator (FigureI-6). Through this approach, more than 80% transcript RNA may be
linked with R through one-step in vitro transcription under the T7 Φ2.5 promoter.188e
Moreover, a number of R-A conjugates have been synthesized for 5’-RNA labeling. The
R groups include folate,128 amines, coenzyme, FAD, NAD,188g, h biotin,188f and
fluorophore.188b
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T7 Class II Promoter

5' TAATACGACTCACTATTAGGAATTATGCTGAGTCATAATCCTR-A; NTPs
T7 RNA polymerase

DNA template
possessing T7
promoter

Trancription starts
from the A in red

R-AGGA-

RNA transcript

R-A = Adenosine Derivative
R group can be folate, biotin, CoA, fluorophore, NAD, etc.
Figure I-6. Adenosine derivative-initiated, one-step in vitro transcription.

In addition, our lab has discovered an RNA bioconjugation method under aqueous
solutions where thio-RNA (HS-RNA) can be linked to functional groups by imidazole
catalysis with up to 100% yields in 10 minutes.188j The preparation of thio-RNA gives us
another way to modify RNA simply and efficiently by transcription under T7Φ 2.5
promoter.188e
Although chemical synthesis of siRNA is an easy way with high purity, in vitro
prepared RNA is cheaper and more flexible.188f, 189 Typically, the procedure is described
as following: (i) DNA templates possessing the T7 Φ2.5 promoter and the sequence for
siRNA are rational designed and chemically synthesized; (ii) DNA then is utilized as
transcriptional templates to generate two strands of RNA by T7 polymerase; (iii) two
strands of RNA are annealed to form a duplex.
This strategy has been applied to synthesize a diverse functional group conjugated
RNAs for function or imaging studies. For example, a chimeric FA conjugated pRNA-
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siRNA has been generated by this method and shown significant RNAi efficacy.128, 190
Overall, this facile and efficient approach combines RNA synthesis with
modification/labeling through one-step transcription, thereby making the method
particularly useful in RNA bioconjugation and analysis.
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CHAPTER II
OJECTIVES OF RESEARCH
Taking the advantage of the great advantages (i.e., specificity, and efficiency) of
RNAi technique, siRNA-based cancer therapeutics has progressed rapidly and moved
into clinical trials. Nevertheless, RNAi clinical application is still impeded by lacking of
cell- and tissue-specific delivery. Capitalizing on overexpressed FR in cancer cells but
not in normal cells, RNA labeling/conjugation chemistry by one-step transcription, and
synthesis of FA-block copolymer, we have a great opportunity to combine these advances
to develop cancer cell-targeted siRNA delivery technique and achieve specific gene
knockdown.
We hypothesize that FA-linked siRNA or siRNA complexes with FA-copolymer
would enter cancer cells with FR-dependency and targetability, activate RNAi pathway,
and knockdown targeted gene (e.g., survivin and CASP8AP2) expression, through which
we can suppress cancer cell proliferation or induce cancer cell into apoptosis. The overall
goal of this research is to develop a strategy that can achieve FR-mediated siRNA
targeted delivery to cancer cells with demonstrated inhibitory effects on cell growth. The
specific objectives of this research are:
1. Preparation of FA conjugated siRNA (FA-siRNA) with potent RNAi efficacy.
To achieve this goal, each siRNA targeting a specific gene has to be rationally
designed through a selective tool that has integrated a set of proper criteria for
increasing the efficiency, specificity, and reducing off-target effects. Both FA
conjugated and non-conjugated siRNA will be synthesized by our efficient onestep in vitro transcription under T7 Φ2.5 RNA promoter.
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2. Delivery of FA-siRNA and FA-polymer/siRNA to FR-expressing cancer cells.
To better assess siRNA delivery, a luciferase reporter gene was introduced and
integrated into the genome of FR positive KB cells to establish a stable
transfected cell line. Taking advantages of bioluminescence, we examine and
optimize the transfection condition for both FA-siRNA and FA-polymer/siRNA
with enhanced sensitivity and accuracy of detection. Furthermore, several
analyses will be conducted. For example, fluorophore-labeled siRNA will be
utilized to dissect the internalization of siRNAs through confocal laser scanning
microscopy (CLSM) and flow cytometer. On the other hand, polymer
encapsulation provides protection of siRNA against enzymatic degradation and
therefore increases the half-life of siRNA which can be analyzed by gel
electrophoresis and UV/vis spectrometry. In addition, FR-dependency of the
delivery is one of the predominant advantages of our delivery system over the
other non-specific delivery strategies. FR-assisted siRNA delivery will be
examined by experiments where the internalization of FA-siRNA or conjugates is
blocked by: (i) competition from excess free FA; (ii) substitution of FR negative
cells (e.g., A549) for FR positive cells (e.g., KB); (iii) substitution of non-FA
conjugated siRNA and polymer for their FA conjugated counterparts.
3. Achieving significant gene knockdown by delivery of FA-polymer/siRNA
complexes and cell growth inhibition/apoptosis.
Once the complexes enter cells through endocytosis, they will escape from the
endosome and release the siRNA cargo, which will be processed by Dicer,
incorporated into RISC and trigger homologous mRNA degradation. Therefore
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potent gene downregulation is the goal of our targeted delivery, which will be
tested by real-time PCR and luciferase assay. Moreover, due to the pivotal role of
our selected siRNA targets in tumor angiogenesis (i.e., VEGF), and anti-apoptosis
(i.e., survivin, CASP8AP2), downregulation of their expression will inhibit tumor
proliferation, which will be evaluated by morphological observation, cell viability
assay, and apoptosis assay. in vivo (i.e., xenograft model) assessment is one of the
future goals.
4. Application of the FA-copolymer/siRNA delivery system.
Theoretically, rationally designed and efficiently internalized siRNA could
knockdown the expression of any gene in the genome; furthermore, our targeted
siRNA delivery system could facilitate siRNA regardless of sequence and pattern
to enter any FR-expressing cancer cells. To examine its rationality, three types of
FR positive cells (KB, HeLa, and SKOV3), and six siRNA targeted genes
(Survivin, CASP8AP2, VEGF, VEGFR, Luciferase, and GFP) have been
investigated.
5. Monitor siRNA uptake and intracellular trafficking processes.
The efficiency of siRNA cellular delivery is one of the key factors for the efficacy
of RNAi. An evaluative system should answer the following questions: (i)
whether siRNA complexes have bound to and entered cells; (ii) how to
distinguish specific and non-specific binding; (iii) how to confirm siRNA is inside
the cell; (iv) whether siRNA has been escaped from the endolysosome; (v) more
importantly, how to quantitate cellular events whereby we can optimize siRNA

39

delivery. A CLSM-based real-time imaging platform will be used to assess these
processes.
6. Establishing the correlation between FR expression level and delivery efficiency
of FA-conjugates.
FR-dependence is the key for siRNA specific delivery in our investigation.
Therefore clarification of the correlative relationship between FR expression and
uptake efficiency is of practical importance. To achieve this goal, experiments
will be performed that compare the efficiencies of binding, internalization, and
gene knockdown upon transfection of FAPol13/siRNA in three cell lines (KB,
HeLa, and SKOV3) that exhibit different FR expression levels.
Successful completion of these objectives is outlined in the following chapters.
For example, synthesis of FA-linked siRNA and specific delivery of FA-siRNA in GlucKB (objective 1 and part of objective 2) are described in Chapter IV. Cancer specific
siRNA delivery via FA-conjugated polymer (objectives 2 and 3) is detailed in Chapter V.
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CHAPTER III
MATERIAL AND METHODS
Instrumentation and Equipment
Name – Model (Company)
Accumet Basic pH meter – AB15 (Fisher Scientific)
Analytical Balance – HR 60 (A & D Co)
Autoclaves – 2021 and 3031 S (Amsco Eagle series)
Balance – XP 1500 (Denver Instrument)
Electrophoresis Power Supply – EC 154 (E-C Apparatus Corporation)
Freezer –20 ˚C (Frigidaire)
Freezer –86 ˚C (Forma Scientific)
Geiger Counter – GSM 110 (Wm. B. Johnson and Associates, Inc.)
Gel Documentation System with Transilluminator – EDAS 290 (Kodak)
Gel Documentation System – Universal Hood II (BioRad)
Biohazard Safety Cabinet – LA2-4A2 (ESCO)
CO2 Incubation – MCO-17AC (SANYO)
Confocal Laser Scanning Microscope – LSM 510 (Carl Zeiss)
Flow Cytometer – C6 (Accuri)
Fluorescent Microscope – Eclipse 50i (Nikon)
Heating Block – 12359030 (VWR)
Incubator (Labline Instruments Inc.)
Liquid Scintillation Counter – 425 034 (Hidex)
Microcentrifuge – 5415 C and 5451 D (Eppendorf)
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Microcon Centrifugal Filter Devices – M10 & M30 (Millipore)
Phosphorimager/Molecular Imager FX – 729 (BioRad)
Phosphorimager/Fluorimager – Typhoon 9400 (Amersham Biosciences)
Pipettes – P-1000, P-200, P-20, and P-2 (Gilson)
Pump – D 25 (Precision Scientific)
Pump – RV3 (BOC Edwards)
Scintillation Counter – 425 034 (Hidex)
Spectrophotometer – V 530 (Jasco)
Stirrers and Heaters (Nuova Thermolyne and Corning)
Thermocycler – Mastercycler (Eppendorf)
Vertical Gel Apparatus – V16 (GibcoBRL)
Heating Circulator – WA01A11B (PolyScience)
Horizontal Electrophoresis System – FB-SB-710 (Fisher Scientific)
Horizontal Electrophoresis System – Mini-sub Cell GT (BioRad)
Vortexer – G560 (VWR)
Microplate Reader – Synergy 2 (BioTek)
Real-time PCR Machine – MX3000p (Stratagene)
Spetrophotometer – ND-1000 (Nanodrop)
Steam Sterillizer – 3031-S (Amsco)
Steam Sterillizer – Lab 250 (Amsco)
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Chemicals, Reagents, and Kits
Name (Company)
3'-Mercaptopropionic acid (Sigma-Aldrich)
Acrylamide (40%) (BioRad)
Agar (DIFCO)
Agarose (Fisher Scientific)
Beta-Mercaptoethanol (Sigma-Aldrich)
Bromophenol blue (Sigma-Aldrich)
Calcium Chloride (Sigma-Aldrich)
DAPI (Sigma-Aldrich)
DharmaFECT (Dharmacon)
DMSO (Sigma-Aldrich)
DTT (Promega)
EDTA (Sigma-Aldrich)
Ethanol (Sigma-Aldrich)
Folic Acid (Sigma-Aldrich)
Glycerin (Fisher Scientific)
HEPES (Sigma-Aldrich)
Hoechst 33258 (Sigma-Aldrich)
Hydrochloric Acid (Fisher Scientific)
Lipofectamine 2000 (Invitrogen)
Lysotracker Green (Invitrogen)
Magnesium Chloride (Fisher Scientific)
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Manganous Chloride (Sigma-Aldrich)
MMLV reverse Transcriptase (Promega)
Opti-Mem cell Medium (Gibco)
pAcGFP-Mem-Hyg (Clontech)
Parafilm (Pechiney)
Paraformaldehyde (Sigma-Aldrich)
pCMV-Gluc (New England Biolab)
Potassium Chloride (Fisher Scientific)
Potassium Phosphate dibasic (Fisher Scientific)
Propidium Iodide (Abcam)
Riboshredder (Epicentre)
RNasin (Promega)
SDS (Sigma-Aldrich)
Sodium Acetate (Sigma-Aldrich)
Sodium Chloride (Fisher Scientific)
Sodium Hydroxide (Sigma-Aldrich)
Sodium Phosphate Dibasic (Fisher Scientific)
Sodium Phosphate Monobasic (Fisher Scientific)
T4 RNA Ligase (Promega)
T7 RNA Polymerase (Epicentre)
Taq DNA Polymerase (Promega)
Tetramethylethylenediamine (TEMED) (USB)
Top10 One Shot Competent E. coli Cell (Invitrogen)

44

Tris (Fisher Scientific)
Tris/Borate/EDTA (TBE) Buffer (10x) (BioRad)
Triton X-100 (Sigma-Aldrich)
Trizol (Invitrogen)
Trypan Blue (Sigma-Aldrich)
Tryptone (DIFCO)
Urea (Fisher Scientific)
Yeast Extracts (DIFCO)
Cell Culture Materials
100 mm Cell Culture Dishes (FALCON)
35 mm Cell Culture Dishes (FALCON)
6-Well Cell Culture Plates (FALCON)
12-Well Cell Culture Plates (FALCON)
24-Well Cell Culture Plates (FALCON)
48-Well Cell Culture Plates (FALCON)
96-Well Black Plates (Costar)
96-Well Plates (FALCON)
96-Well White Opaque Plates (Costar)
Antibody against Human Folate Receptor (Abcam)
Chambered Slide (Nunc)
Glass-Bottomed Cell Culture Dishes (MatTek)
Fetal Calf Serum (Hyclone)
Folate Deficiency RPMI 1640 Medium (Gibco)
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G418 (Sigma-Aldrich)
Heparin (Sigma-Aldrich)
Hygromycin (CalBiochem)
M-PER Mammalian Protein Extraction Reagent (Thermo)
Phosphate Buffered Saline (Hyclone)
Penicillin (Millipore)
RPMI 1640 medium (Gibco)
Streptomycin (Millipore)
Trypsin (Invitrogen)
Kits
AmpliScribe T7 High Yield Transcription Kit (Epicentre)
Celltier 96 Aqueous One Solution Cell Proliferation Assay (Promega)
Gaussia Luciferase Assay (New England Biolabs)
Micro BCA Protein Assay (Thermo)
T7 Transcription Kit (Epicentre)
Wizard® Plus Minipreps DNA Purification System (Promega)
Wizard® SV Gel and PCR Clean-Up System (Promega)
Dual-Luciferase Reporter Assay System (Promega)
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Buffers and Commonly Used Reagents
Table III-1. 5X RT Buffer (1mL pH 8.3)
Components

5X Concentration 1X Concentration

250 µL 1 M Tris, pH 8.3

250 mM

50 mM

250 µL 1 M KCl

250 mM

50 mM

50 µL 1 M MgCl2

50 mM

10 mM

20 µL 1 M DTT

2 mM

0.4 mM

430 µL Water

Table III-2. Denaturing Gel Running Dye (10 mL)
Components

Concentration

4.2 g Urea

7M

1 mL 10X TBE buffer

1X

Bromophenol blue

0.05%

Xylene Cyanole

0.05%

4 mL Water
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Table III-3. Native Gel Running Dye (10 mL)
Components

Concentration

5 mL

glycerol 50%

1 mL 10X TBE buffer

1X

Bromophenol blue

0.05%

Xylene Cyanole

0.05%

4 mL Water

Table III-4. Denaturing Gel Mix (1 L)
Components

Concentration

420 g Urea

7M

100 mL 10X TBE buffer

1X

200 mL 40% Bis-acrylamide (19:1)

8%

Add water to 1 L

Table III-5. Native Gel Mix (1 L)
Components

Concentration

1 mL 10X TBE buffer

1X

200 mL 40% Bis-acrylamide (19:1)

8%

700 mL water
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Table III-6. SOC Medium (250 mL, pH 7.0)
Components

Concentration

5 g tryptone

2%

1.25 g yeast extract

0.5%

625 µL 4 M NaCl

10 mM

156 µL 4 M KCl

2.5 mM

240 mL Water
Note. Autoclave at 121°C for 20 min, cool down to ~40 ºC and then add 2.5 mL of filter sterilized 2 M MgCl2 and 5 mL of filter
sterilized 1 M glucose. Prior to autoclaving, adjust the pH to ~7.0 with sodium hydroxide.

Table III-7. LB Liquid Buffer (1 L, pH 7.5~8)
Components

Concentration

10 g Tryptone

1%

5 g Yeast extract

0.5%

10 g NaCl

1%

800 mL Water
Note. Autoclave at 121 °C for 20 min, cool down and store in 4 °C refrigerator. Prior to autoclaving, adjust the pH of LB with sodium
hydroxide. For solid LB medium preparation, just add 15 g of agar (1.5%) to the above liquid (1 L) before autoclaving. When the
temperature of medium is approximate 40 ºC, add proper antibiotics (i.e Ampicillin or Kanamycin), and pour it into plates (25
mL/plate) in the hood. Allow it cool down to room temperature. Invert and store in 4 °C refrigerator.
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Table III-8. RNA Precipitation Buffer (10 mL)
Components

Concentration

50 µL 0.2 M EDTA

1 mM

1 mL 5 M NaAC

0.5 M

8.95 mL Water

Table III-9. 10X DNA Anneal Buffer (10 mL, pH 8.0)
Components

10X Concentration 1X Concentration

500 µL 0.2 M EDTA

10 mM

1 mM

1 mL 5 M NaCl

0.5 M

50 mM

1 mL 1 M Tris, pH 8.0

0.1 M

10 mM

7.5 mL Water

Table III-10. T7 RNA Transcription (100 µL)
Components

Concentration

10 µL 10X T7 buffer

1X

5 µL 0.1 M DTT

5 mM

4 µL 25 mM NTPs

0.1 mM

10 µL 4 µM DNA template

0.4 µM
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Table III-10 (continued).
Components

Concentration

10 µL 50 u/µL T7 RNA polymerase

5 unit/µL

61 µL water

Note. Incubate the above reaction mix at 37 ºC for 4 h. To get RNA with 5' adenosine-folate, add 1 µL of 40 mM FA-HDAAMP and
replace 25 mM NTPs with 1:4 NTPs (25 mM GTP, 25 mM CTP, 25 mM UTP, and 6.25 mM ATP).

Table III-11. High Yield T7 RNA Transcription (100 µL)
Components

Concentration

10 µL 10X T7 buffer

1X

10 µL 0.1 M DTT

10 mM

30 µL 25 mM NTPs

0.75 mM

5 µL 4 µM DNA template

0.2 µM

10 µL AmpliScribe Enzyme Solution

10% v/v

35 µL water
Note. Incubate the above reaction mix at 37 ºC for 2 h.

Table III-12. Reverse Transcription (20 µL)
Components

Concentration

4 µL 5X RT Buffer

1X

51

Table III-12 (continued).
Components

Concentration

0.8 µL 25 mM dNTPs

1 mM

0.4 µL 50 µM Primers

1 µM

1 µL 1 µM Total RNA

50 nM

1 µL of 10u/µL MMLV reverse transcriptase

0.5 u/ µL

12.8 µL water
Note. Incubate at 85 ºC for 2 min. Cool down. Add 4 µL 5X RT buffer and 1 µL of 10u/µL MMLV reverse transcriptase. Incubate at
42 ºC for 1 h.

Table III-13. Real-Time PCR (20µL)
Components

Concentration

10 µL 2X SYBR Solution 1 X
2 µL 2 µM Primers

0.2 µM

0.2 µL cDNA

N/A

7.8 µL Water

Note. Amplification was started at 95°C for 10 min to activate the DNA Polymerase, followed by 40 cycles of PCRs: at 95°C for 10 s,
at 60°C for 20 s, and at 72°C for 30 s, and one more cycle of PCR: at 95°C for 60 s, at 55°C for 30 s, and at 95°C for 30 s.
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Experimental Protocols
Cell Culture
All cell lines were maintained in folate free RPMI 1640 (Gibco) cell medium
supplemented with 10% fetal calf serum (FCS) (HyClone), 100 units/mL penicillin, and
100 µg/mL streptomycin (Millipore) at 37 °C in 95% air humidified atmosphere and 5%
CO2.
Preparation of Polymer/siRNA Complexes
FAPol13(Pol13)/siRNA. Neutral polyplexes (N/P = 1) were prepared as followed.
Briefly, 3 µL of 10 µM Cy3-labled anti-human survivin siRNA or anti-luciferase siRNA
(59 nt) was mixed with 1.5 µL of 50 µM FAPol13 or 1 µL of 50 µM Pol13 at an N/P ratio
equal to 1.0. Polyplexes were immediately vortexed to ensure homogenous mixing and
equilibrated at room temperature for 10 min before addition to the cell medium (300 µL).
AuNP/siRNA. Complexes (Au nanoplexes) were prepared by adding 1.36 µL of a
25 µM survivin siRNA stock to the 6.64 µL solution of AuNPs. Complexation solutions
were immediately vortexed following RNA addition and allowed to incubate at room
temperature for 30 min before cell testing or electrophoresis analysis.
Transfection
The siRNAs were transfected into mammalian cells by commercial agents (i.e.,
DharmaFECT; Lipofectamine 2000) according to manufacturer’s recommendations as a
positive control. Typically, cells were plated into the dish or plate 24 h prior to treatment
with approximate 40% confluency. Two microliter of Lipofectamine and 6 µL of 10 µM
siRNA were mixed with 50 µL of Opti-Mem medium at room temperature for 5 min;
then two solutions were mixture together and sit for 20-30 min before adding into 500 µL
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of medium (total 600 µL, therefore, [siRNA] = 100 nM, Lipofectamine = 0.33% (v/v)).
The medium was replaced with fresh one and cells were kept culture for predetermined
time.
Confocal Microscopy
For imaging, cells were plated in chambered coverglass wells, transfected with
fluorophore-labeled siRNAs, rinsed, and visualized by a Zeiss LSM 510 confocal laser
scanning microscope (Carl Zeiss Inc., Thornwood, NY) with 40×/1.3 or 63×/1.4NA oil
lens. A 405-nm diode laser was used to excite Hoechst and fluorescence emission was
detected with a band pass filter of 420-480 nm. For Cy3, an excitation wavelength of 543
nm (He-Ne laser) was used and fluorescence emission was obtained using a long pass
filter of 560 nm. For FAM, an excitation wavelength of 488 nm (Ar laser) was used, and
fluorescence was obtained utilizing a long pass filter of 505 nm. Images were processed
via LSM image Examiner software (Carl Zeiss Inc., Thornwood, NY). Further analysis of
associated fluorescence was carried out using ImageJ software 191 as following: total
associated fluorescence was determined from 30-50 cells (for 63× lens), 75-100 cells (for
40× lens) in at least 5 distinct fields per treatment and corrected by subtracting local
background fluorescence from nearby cell-free area.
Time-Lapse and Z-Stack Imaging
KB cells were seeded on chambered coverglass to ~45% confluency for 24 h.
Polyplexes were then directly added to the cell medium to give a final siRNA
concentration of 20 nM. The dish was immediately put into a heated block holder set at
37 °C. The focal plane was fixed on a cleared bright field plane and confocal images
were taken every 10 min for a total of 80 min. Prior to z-stack scanning the cells were
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allowed to incubate for 40 min, after which the cells were washed 3 times with prewarmed phosphate buffer saline (PBS) and the cell medium was replaced. Hoechst 33258
was added to stain the nuclei (1 µg/mL) 20 min before observation. Z-stack scanning was
then performed by adjusting the focal plane from the bottom to the top of the cells in 2
µm or 1 µm increments.
Colocalization
KB cells were first cultured for 24 h on chambered coverglass before the addition
of polyplexes. Polyplexes were added to the cell medium to give a final Cy3-labled
siRNA concentration of 100 nM and allowed to incubate for 1 h. After 1 h treatment the
cell medium was replaced, thereby removing any unbound or free polyplexes from
solution. Confocal images were taken at different incubation times, 1 h, 6 h, 24 h, and 48
h. In order to visualize the endosomal compartments, lysotracker was added 30 min prior
to each imaging event. The chambered coverglass was placed onto a heated sample
holder at 37 °C and imaging process was about 40 min each time. After each imaging
event the cell medium was replaced and the cells were returned to the cell culture
incubator for another time period observation.
Synthesis of siRNA against Gaussia Luciferase
siRNA against Gluc was synthesized through in vitro transcription according to our
published procedure. 188e-h DNA template oligonucleotides containing the T7 φ 2.5 promoter
sequence were purchased from Integrated DNA Technologies. In vitro transcription was
conducted with AmpliScribe T7 high yield transcription kits using the following DNA
templates (Sequences refer to 2.5). RNA transcripts were gel-purified, quantified by UV/Vis
spectrometry, annealed and then stored at -80 °C.
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Total RNA Extraction
Adhesive cells were washed with PBS once before being lysed in Trizol by
repetitive pipetting. Use 0.5 mL of reagent per 3.5cm dish (~ 106 cells). Incubate the
homogenized samples for 5 min at 15-30° C to permit complete lysis. Add 0.1 mL of
chloroform per 0.5 mL of Trizol reagent. Transfer the samples into tubes, cap them
securely. Shake tubes vigorously by hand for 15 seconds and incubate them for 5 min.
Centrifuge the samples at 12,000 × g for 15 min. Following centrifugation, the mixture
separates into a lower red, phenol-chloroform phase, an interphase, and a colorless upper
aqueous phase. RNA remains exclusively in the aqueous phase. The volume of the
aqueous phase is about 60% of the volume of Trizol. Transfer the supernatant (the upper
phase) carefully to a new tube (the organic phase would be saved for DNA/protein
isolation according to the manual). Precipitate the RNA from the aqueous phase by
mixing with isopropyl alcohol. Use 0.25 mL of isopropyl alcohol per 0.5 mL of Trizol.
Incubate samples at 15 to 30°C for 10 minutes and centrifuge at 12,000 × g for 10 min.
Remove the supernatant. Wash the RNA pellet once with 1mL of 75% ethanol. Vortex
and centrifuge at 7,500 × g for 5 min. Dry the RNA pellet briefly (do not too dry) and
dissolved it in DNase/RNase-free H2O and quantitate by Ab260. The quality of the
extracted RNA would be evaluated by A260/280 ratio.
Real-Time PCR
Total RNA was extracted from 4 types of cells with Trizol following the
manufacture’s protocol and mRNAs were converted to cDNA through reverse
transcription with MMLV reverse transcriptase (Promega). Finally, real-time PCR was
performed with on MX3000P (Stratagene). A typical reaction mixture (20 µL) includes:
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10 µL of 2X SYBR Green Mix (Sigma-Aldrich), 2 µL of 2 µM primer pair (final
concentration = 200 nM), 0.2 µL of cDNA, and 7.6 µL of DNase/RNase-free H2O.
Amplification was started at 95°C for 10 min to activate the DNA Taq, followed by 40
cycles of PCRs: at 95°C for 10 s, at 60°C for 20 s, and at 72°C for 30 s, and one more
cycle of PCR: at 95°C for 60 s, at 55°C for 30 s, and at 95°C for 30 s.
DNA/RNA Purification
Precipitation. If the DNA/RNA is relative pure, we can precipitate them by adding
3 parts of 0.5 M of NaAc (pH 5.2) and 7 parts of ethanol. After mixing and incubation for
at least 30 min at -20 ºC, the sample is centrifuged for 6 min at 14,000 RPM. Remove
ethanol and dissolve the sample in DNase/RNase-free H2O.
Column filtration. Load sample volume up to 0.5 mL on to microcon M10 or M30
and centrifuge at 14,000 RPM till the filter is almost dry. Wash the filter with two times
of 200 µL water. Invert filter into a clean 1.5 mL Eppendorf tube and spin briefly (~10
seconds) to collect the sample.
PAGE purification. DNA or RNA sample is first separated by 8% denaturing
PAGE. The objective sample band is visualized, cut from the gel and then transferred to a
fresh 1.5 mL Eppendorf tube. The gel is then crushed and DNA or RNA is extracted from
the gel by adding 400 µL of 0.5 M NaAc in 1 mM EDTA and heating at 70ºC for 7-10
min to melt the gel. Centrifuge and transfer the liquid to a clean tube. Add 900 µL of
ethanol to the tube and incubate the solution at -20 ºC for at least 30 min. Remove
ethanol and dissolve the sample in DNase/RNase-free H2O.
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Flow Cytometry
The expression levels of human folate receptor in cells, the absorption of
polyplexes in cells, and the inhibition of polyplexes binding to cells were assessed by
flow cytometer. For human folate receptor quantification, cells plated in 12-well plate
were harvested, washed, and resuspended to approximately 1~5 × 106 cells/mL in icecold PBS. Add 100 µL of cell suspension to the tubes and mix with 1 µg/mL folate
binding protein antibody (AbCam). The tubes were put on the ice in dark for 30 min, and
the cells were spin down at 2000 g for 5 min and washed with ice cold PBS twice. The
cells were then suspended in PBS with 1 µg/mL (400× dilution) goat anti-mouse FITCIgG antibody (Santa Cruz Biotechnology Inc) for 30 min at room temperature in dark.
The cells were collected by centrifugation at 1,200 × g for 5min, washed with ice-cold
PBS three times before flow cytometer detection. The cells were gently vortexed and
introduced into a C6 flow cytometer (Accuri, Ann Arbor, MI) equipped with a 488-nm
solid state laser. Data for 10,000 fluorescent events were obtained before or after gating
by recording forward scatter (FSC), side scatter (SSC) through channel 1 (530/15 nm) for
FAM and FITC, or channel 2 (585/20 nm) for Cy3 using CFlow Plus software (Accuri).
For absorption and inhibition experiments, cells were prepared by plating cells in
12-well plates 24 h prior with ~40% starting confluency. Cells were transfected with
neutralized (N/P = 1) polyplexes of FAM-labeled siRNA or Cy3-labeled siRNA (final
siRNA concentration = 100 nM). Two hours of incubation or twenty four hours of
incubation were performed for binding and inhibition experiments. After that, the cells
were detached, centrifuged, washed with PBS twice, and ready flow cytometer detection.
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Preparation of Plasmid DNA
E. coli (TOP10, Invitrogen) were transformed with plasmid DNA (i.e., pCMVGluc) and selected in an ampicillin rich LB solid medium (or SOC medium) at 37ºC
overnight. A single clone of transfected E. coli was proliferated in LB liquid media in
37ºC overnight with vigorous agitation. The cells were harvested and plasmid isolation
and purification were performed consequently with Wizard® Plus Minipreps DNA
Purification System kit (Promega) according to the manufacturer’s protocol as followed.
Transfer the E. coli cells cultured in LB or SOC medium into 1.5 mL Eppendorf
tubes, and centrifuge them at 10,000 × g for 1 min. Remove the medium completely, and
add 200 µL of cell resuspension solution for 1 min. Add 200 µL of lysis solution and
invert the tube 4 times. Then 200 µL of cell neutralization solution was added and mixed
gently to avoid break the DNA. You may see the precipitation appearing. Centrifuge the
lysate at 10,000 × g for 7 min. During this time, connect the minicolumn with the barrel
of a syringe, add in 1 mL Resin solution (Note: make sure there is no crystal inside,
otherwise heat the solution by 37ºC water bath and cool down to 30ºC before using).
Transfer the supernatant clear solution into the barrel, and use the plunger to push the
resin and lysate mixture go through the minicolumn. Wash the plasmid with 2 mL of
column wash solution (add 320 mL of 95% ethanol before first usage). Dry the column
by centrifuge at 10,000 × g for 1 min. Dissolve the plasmid DNA by adding 40 µL of
DNase/RNase free H2O followed by spinning down at 10,000 × g for 20 seconds.
The purity of plasmid DNA was determined by both A/A280 and A260 ratio and
agarose gel electrophoresis. The concentration of plasmid DNA was determined by
spectrometer and the purified plasmid was stored at -20ºC until use.
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Preparation of Stable Cell Line (Take SKOV3-KB as an Example)
SKOV3 cell line that stably expresses Gaussia luciferase (Gluc-SKOV3) was
established. Firstly SKOV3 cells were transfected with pCMV-Gluc by DharmaFECT
followed by manufacturer’s manual. One day later, the medium was replaced with the
one containing 0.5 mg/mL antibiotics G418. Cells were first cultured in a 10 cm dish for
2 weeks. At this time point, the majority (>90%) SKOV3 cells were killed off by G418
because of lacking the expression of neo. However, a few percent of SKOV3 cells that
had integrated the pCMV-Gluc plasmid detoxified G418 and survived. Because the
resistance to the G418 only indicated the insert of neo gene into the genome of SKOV3,
but necessarily meant the integrated of Gluc gene, the selection of Gluc activity was
carried out by seeding the surviving cells at very low density (~1 cell/0.1 mL) and plating
onto 96-microplates (0.1 mL/well). The selection pressure from the Gl418 remained for
another 7 days. Positive colonies expressing Gaussia luciferase were screened by
luciferase assay, propagated, and stored for further experiment.
Cell Treatment with FAPol13/siRNA Polyplexes for Gene Downregulation Studies
Gluc-KB cells were seeded in 96-well plates in folate free RPMI 1640
supplemented with 10% FCS 24 h prior to experiments. Cell treatments included free
siRNA and FAPol13/siRNA, Pol13/siRNA, and DharmaFECT/siRNA complexes. The
concentration of siRNA against Gaussia luciferase is 100 nM. Cells were treated for 6 h,
washed by PBS, and cultured for 2 days. For DharmaFECT group, transfection was
carried out according to manufacturer’s protocol. Briefly, 10 µL of Optimum buffer
mixed with 0.25 µL of DharmaFECT solution and 1 µL of a 10 µM siRNA were mixed
with 10 µL of Opti-Mem buffer separately. After 5 min. the two solutions were mixed
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and equilibrated for 20 min. The resulting solution was then added to 80 µL of cell
medium (total 100 µL) and the cells were treated for 6 h before changing medium.
Gaussia Luciferase Activity Assay
Gaussia luciferase protein level was measured according to the manufacture’s
protocol with minor modification. Aliquots (15 µL) of the cell culturing supernatants
were transported into a white opaque 96-well plate and mixed with 40 µL of Gaussia
luciferase assay solution. The resulting bioluminescence was immediately measure by a
Synergy 2 microplate reader (BioTek) and analyzed by Gen5 software (BioTek).
Cell Viability
Cell viability tests were performed using CellTiter 96 Aqueous One Solution cell
proliferation assay (Promega). Five thousands of KB cells were seeded into the 96-well
microplate 24 h before incubation with FAPol13. FAPol13 was subsequently mixed with
the cellular medium at final concentrations ranging from 10 nM to 6 µM. Cells were
cultured for 2 days before adding 20 µL of CellTiter reagent to each well. After reagent
addition the cells were further incubated for 2 hours followed by measuring the
absorbance at 490 nm by a microplate reader (Synergy2, BioTek) and Gen5 (BioTek).
Agarose Gel Electrophoresis
Neutral complexes were prepared at room temperature. Agarose gel (1%) was
prepared by: 0.4 g of Agarose mix with 40 mL of 1× TBE buffer, heat them, and pour
them into the casting tray. The gel was pre-run for 30 min. The complexes were mixed
with gel loading buffer (0.2% bromophenol blue, 1× TBE buffer and glycerol) and loaded
into the wells. Gel was run for 30 min at 90 V. After staining by ethidium bromide, the
agarose gel was imaged by a Universal Hood II CCD camera (BioRad).
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Imaging Processing
All confocal images were processed via LSM image Examiner software. Further
analysis of Cy3 and lysotracker fluorophores to examine the fluorescence intense or the
distribution was carried out using ImageJ software (http://rsbweb.nih.gov/ij/) and JACoP.
Statistical Analysis
Analysis of the statistical significance of FR expression was performed by
Graphpad Prism software using t test. Individual flow cytometric, confocal microscopic,
and folate-binding assays were repeated at least 3 times to ensure accuracy of results, and
representative data are shown.

Primers and siRNAs
Table III-14. Primers for Real-Time PCR
Gene Name
Human Folate Receptor Alpha (hFRα)

GenBank ID
NM_016725

Sequences (5'-3')
GGAGGCTCAGACAAGGATT
TGGTAGAACAGCAGGCATT

Human Actin Beta (ACTB, ACTβ)

NM_001101

CATGTACGTTGCTATCCAGGC
CTCCTTAATGTCACGCACGAT

Human Survivin (Sur, Sv)

NM_00101227

AGCCCTTTCTCAAGGACCAC
TCCTCTATGGGGTCGTCATC

Human Vascular Endothelial Growth Factor A

NM_001025366

(VEGF-A)
Human VEGF Receptor 1 (VEGFR-1)

TTGCTGCTCTACCTCCAC
GATGTCCACCAGGGTCTC

NP_002010

CTTCGAAGCATCAGCATAAGAAACT
TGGTCATCAGCCCACTGGAT
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Table III-14 (continued).
Gene Name
Human Integrin Alpha V (ITGAV)

GenBank ID
NM_002210

Sequences (5'-3')
GTGGACAGTCCTGCCGAGTA
GGCTGGGTGGTGTTTGCG

Human Integrin Beta 3 (ITGB3)

NM_000203.2

CTGGAACAACGGTGGAGA
TGGCAGGTAGCAGTAAAGAA

Human ATP-Binding Cassette Subfamily B

NM_000927.3

(ABCB1,MDR1)

GTCTACAGTTCGTAATGCTGACGT
TGTGATCCACGGACACTCCTAC

Human Ribonucleotide Reductase M2 (RRM2)

NM_001034.3

GCCGCTGCTGAGAGAAAACC
TTACTATGCCATCGCTTGCTGC

Human Caspase 8 Associated Protein 2

NM_012115.3

(CASP8AP2)

CTCCTGCTAAAAAGCAACC
TCACTGCTAGCCGAGCAACC

pCMV-Gluc Vector (Gaussia Luciferase, Gluc)

AY015993

ACGGATCTCGATGCTGAC
TCCTATTCCTCCCTGTGC

pGL3 Vector (Firefly Luciferase, Fluc)

U47296

AACACCCCAACATCTTCG
CGTCCACAAACACAACTCC

pRL-tk Vector (Renilla Luciferase, Rluc)

AF362545

CGAACTGAGATGCCTACAGC
CGACAGGACTATAAAGATACC

Table III-15.DNA Templates for siRNA Transcription
Gene Name
VEGF-A

Stands
Sense

Sequences (5'-3')
CGTAATACGACTCACTATTAGGGCAGAATCATCACGGGACGCATCT
AGATGCGTCCCGTGATGATTCTGCCCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATCCGGTTCGTGATGATTCTGCCCTTT
AAAGGGCAGAATCATCACGAACCGGATCTCCTAATAGTGAGTCGTATTACG
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Table III-15 (continued).
Gene Name
Gluc

Stands
Sense

Sequences (5'-3')
CGTAATACGACTCACTATTAGATGTGCAACTTTTGCTACCGCATCT
AGATGCGGTAGCAAAAGTTGCACATCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATGCGGTAGCAAAAGTTGCACATCTTT
AAAGATGTGCAACTTTTGCTACCGCATCTCCTAATAGTGAGTCGTATTACG

GFP1

Sense

CGTAATACGACTCACTATTAGCGCACCATCTTCTTCGACCGCATCT
AGATGCGGTCGAAGAAGATGGTGCGCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATGCGGTCGAAGAAGATGGTGCGCTTT
AAAGCGCACCATCTTCTTCGACCGCATCTCCTAATAGTGAGTCGTATTACG

GFP2

Sense

CGTAATACGACTCACTATTAGGGCGATACCCTGGTGAATCGCATCT
AGATGCGATTCACCAGGGTATCGCCCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATGCGATTCACCAGGGTATCGCCCTTT
AAAGGGCGATACCCTGGTGAATCGCATCTCCTAATAGTGAGTCGTATTACG

EGFP

Sense

CGTAATACGACTCACTATTAGCGCACCATGTTCTTCAATTGCATCT
AGATGCAATTGAAGAACATGGTGCGCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATGCAATTGAAGAAGATGGTGCGCTTT
AAAGCGCACCATCTTCTTCAATTGCATCTCCTAATAGTGAGTCGTATTACG

RRM2

Sense

CGTAATACGACTCACTATTAGGAGAGAGTAAGAGAAATCCGCATCT
AGATGCGGATTTCTCTTACTCTCTCCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATGCGGATTTCTCTTACTCTCTCCTTT
AAAGGAGAGAGTAAGAGAAATCCGCATCTCCTAATAGTGAGTCGTATTACG

CASP8AP2

Sense

CGTAATACGACTCACTATTAGGAGTACTTCACATTTACCCGCATCT
AGATGCGGGTAAATGTGAAGTACTCCTAATAGTGAGTCGTATTACG

Antisense

CGTAATACGACTCACTATTAGGAGATGCGGGTAAATGTGAAGTACTCCTTT
AAAGGAGTACTTCACATTTACCCGCATCTCCTAATAGTGAGTCGTATTACG
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Table III-16. siRNA Sequences
siRNAs
Gaussia Luciferase

GenBank ID
AY015993

Sequences (5'-3')
AGAUGUGCAACUUUUGCUACCGCAUCU
AGGAGAUGCGGUAGCAAAAGUUGCACAUCUUU

Renilla Luciferase

AF362545

GGUGCCAAGAAGUUUCCUATT
UAGGAAACUUCUUGGCACCTT

Firefly Luciferase

U47296

GGUGUCGCUCUGCCUCAUATT
UAUGAGGCAGAGCGACACCTT

RRM2

NM_001034.3

AGGAGAGAGUAAGAGAAAUCCGCAUCU
AGGAGAUGCGGAUUUCUCUUACUCUCUCCUUU

CASP8AP2

NM_012115.3

AGGAGTACUUCACAUUUACCCGCAUCU
AGGAGAUGCGGGUAAAUGUGAAGUACUCCUUU

Human Survivin

NM_00101227

AGCCCUUUCUCAAGGACCACCGCAUCU
AGGAGAUGCGGUGGUCCUUGAGAAAGGGCUUU

VEGF-A

NM_001025366

AGGGCAGAAUCAUCACGGGACGCAUCU
AGGAGAUCCGGUUCGUGAUGAUUCUGCCCUUU
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Cell Lines
Table III-17. Cell Lines
Designation

Description

ATCC No. or source:

Purpose

KB

Human nasopharyngeal carcinoma

CCL-17

FR positive cells

KB-GFP

Derivative of KB

Generate from KB

testing platform

KB-Gluc

Derivative of KB

Generate from KB

testing platform

HeLa

Human cervical carcinoma

CCL-2

FR positive cells

HeLa-EGFP

Derivative of HeLa

Gift from Dr. Phil Sharp

testing platform

A549

Human lung carcinoma

CCL-185

FR negative cells

SKOV3

Human ovary carcinoma

HTB-77

FR positive cells

SKOV3-Gluc

Derivative of SKOV3

Generate from SKOV3

testing platform

A2780

Human ovary carcinoma

From Dr. Thomas Hamilton

MDR testing

OVCAR-3

Human ovary carcinoma

HTB-161

MDR testing

OVCAR-7

Human ovary carcinoma

From Dr. Thomas Hamilton

Integrin testing

OVCAR-10

Human ovary carcinoma

Gift from Dr. Thomas Hamilton

Integrin testing
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CHAPTER IV
DELIVERY OF FA-SIRNA TO CANCER CELLS
AND DOWNREGULATION OF GENE EXPRESSION
Introduction
Conventional anticancer drugs, such as cisplatin, paclitaxel, doxorubicin, and
methotrexate, have been the major chemical agents for cancer treatment. Although they
all display significant anticancer activities, patients normally suffer side effects due to
drugs’ cytotoxicity and non-specificity (no gene-targeting specificity and cell-targeting
specificity).151, 192 In other words, these small molecular drugs treat normal cells and
malignant cells indiscriminately, which limits the effectiveness of these treatments. The
recently discovered siRNA can trigger RNAi pathway and induce mRNA degradation
with high sequence specificity, low cytotoxicity, and potent gene downregulation
efficiency. By virtue of these properties, siRNA has been utilized as a molecular drug for
diseases treatment.193
Although siRNAs hold incomparable advantages and show great promise, the
inefficient cellular uptake and poor bioavailability of siRNA remain the major obstacles
that compromise siRNA’s therapeutic application. Moreover, without efficient cellspecific delivery, biomedical application of siRNA is limited. Employing targeting
moieties thus provides an opportunity for directed siRNA delivery with enhanced
efficiency in vitro and in vivo. Valid targeting groups include aptamers,121 antibodies,98c
peptides,99d, 194 cholesterol, 195 α-tocopherol, 196 and folate. 101b, 128, 197 Among them, FA
shows unsurpassable advantages as mentioned in Chapter I.
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The use of folate as a therapeutic director has been popularized due to
overexpression of the folate receptor in several types of tumors (i.e., ovary, brain, lung,
breast, kidney).198 FA has been successfully employed to deliver siRNAs, ribozymes,
anti-cancer drugs, imaging agents and antisense oligonucleotides.197, 199 Several lines of
evidence demonstrate FA-directed siRNAs delivery into cancer cells or tumors. For
example, a polyvalent, FA-linked, chimeric pRNA (a 117-nt bacteriophage phi29encoded RNA, playing a novel and essential role in DNA packaging) had been
constructed with siRNAs against human apoptosis inhibitor gene — survivin.128 The
effectiveness and specificity of this chimeric siRNA vehicle has been confirmed by both
in vitro and ex vivo experiment.128 Zhang et al and his colleagues reported a similar
strategy involved in the noncovalent attachment of siRNAs to FA-conjugated
oligodeoxynucleotides via nucleic acid base-paired interactions, and resulted in cell-typespecific delivery of functional siRNAs into cells with moderate gene knockdown.197
In addition to the efforts for improving the targeted siRNA delivery, an accurate,
fast, and convenient method for assessing the RNAi effects is prerequisite. Conventional
techniques, such as real-time PCR (or quantitative PCR), and Western blot can hardly
meet these expectations. Thus, a reporter protein-assisted evaluative system based on
fluorescence (e.g., green luciferase protein, GFP) and bioluminescence system (e.g.,
luciferase) is constructed and described in this chapter.
GFP and its analogs, such as red fluorescence protein (RFP), yellow fluorescence
protein (YFP), have revolutionized our understanding of many biological processes at the
molecular and cellular levels. 200 With suitable GFP fluorescence probes and
instrumentation (e.g., confocal laser scanning microscope) for functional imaging, we can
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identify and measure biological events in whole organism in real time. Another rapid and
accessible reporter system is bioluminescence where luciferases convert chemical energy
into light.201 Combining with charge coupled device cameras that detect light transmitted
through tissues/cells has opened the door to sensitive measurements of gene expression
changes upon RNAi.
Although fluorescence system has several advantages, such as direct detection of
fluorescence, easier visualization, it also has some setbacks compared to luciferase
system for quantitation of RNAi effects, e.g., non-quantitative, no read-out.202 On the
other hand, despite indirect read-out, enzymatic assay-based detection, and repeated
measurement, luminescence system is comparably convenient in quantifying the signal
changes. For these reasons, two systems have been utilized in my research with
preference to the luminescence system.
About four decades ago, a series of luciferase that catalyzed luciferin reaction and
emitted light in the visible range under physiological conditions was discovered and
characterized.203 Various luciferases share sequence homology in different organisms,
such as bacteria, fungi, dinoflagellates, radiolarians.204 Firefly (Photinus pyralis)
luciferase (FLuc), sea pansy (Renilla reniformis) luciferase (RLuc), and Gaussia (Gaussia
princeps) luciferase (Gluc) are most commonly used luciferases for monitoring gene
expression.204b, 205 Among them, Gluc catalyzes the oxidation of substrate coelenterazine
to produce light (470 nm),206 and has been engineered to highly express in mammalian
cells.206b In addition, compared to FLuc and RLuc, Gluc is a more attractive reporter for
studying gene expression because of some unparalleled features. Firstly, Gluc generates
over 1000-fold higher bioluminescent signal intensity than RLuc does. Secondly, Gluc
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possesses a secretory signal process, and therefore the expression of Gluc can be detected
from cell medium, omitting the usual cell lysis step. Thirdly, secreted Gluc is very stable
and can be stored for several days at 4 °C without the loss of activity, which enables the
convenient multiple samples measurement at different time points.
Capitalizing on RNA conjugation chemistry through one-step transcription, and
FR-mediated siRNA targeted delivery to cancer cells, I propose to prepare and study the
cellular delivery of FA-linked siRNA and assess RNAi effects through reporter system.
Specifically, I intend to achieve the following goals (Scheme IV-1): (i) rational design of
siRNA with potent potential to induce gene silencing through the proper online tools; (ii)
synthesis of the FA-conjugated siRNAs taking advantage of in vitro transcription and
FA-HADAMP 207 as the transcription initiator; (iii) the specific uptake of FA-siRNA by
FR-bearing human cancer cells; (iv) FR-dependent internalization; (v) gene
downregulation as the result of the internalized FA-siRNA via RNAi process; (vi) the
convenient and fast assessment of RNAi efficiency by introduction of a reporter system.
To test these hypotheses, the experiments were rationally designed and performed.

70

Scheme VI-1. Schematic illustration of the internalization of transcripted FA-siRNA
conjugate into Gluc-KB cells through FR-dependent endocytosis.
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Folate-HDAAMP is chemically synthesized and serves as the transcriptional initiator
under the T7 Φ2.5 promoter. Two single-stranded RNA are synthesized separately. FAHDAAMP could be added in either sense strand or antisense strand; most of time it will
be add into the synthesis of antisense strand. Two strands RNA will be annealed to form
double-stranded, FA-linked siRNA. The siRNAs specific for Gaussia luciferase, and
GFP and a non-silencing control siRNAs used in the studies are generated by this method.
Following internalization into the FR-bearing cells (KB cells in this case) via FRmediated endocytosis, the FA-siRNA is released from the endosome, processed by Dicer,
incorporated into RISC, and eventually induces the silencing of targeted genes.
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Result and Discussion
Design and Synthesis of FA Conjugated siRNA
This first step for specific siRNA delivery is to design siRNA sequences. We can
then synthesize them by one-step in vitro transcription. Based on the experience of
rational siRNA design accumulated in our laboratory, we chose siRNA selection
programs 208 to design siRNA against the genes responsible for pathological disorders.
This online tool has an option of a searching pattern which can be customized according
to users’ purposes with different sequence length and different nucleotide at particular
position. As a result, we set down the pattern N2AGN7UN8AN2 in consideration of
transcription promoter requirements 188h and base preferences.70 In this 23-nt search
sequence, N, A, G, and U strand for any nucleotide, adenosine, guanosine, and uridine
respectively, and the number after the N means the length of the nucleotides. AG at 3 to 4
position is for our transcription system,188h and U at 12 and A at 21 is used to meet the
sequence preferences rules.70
After confirmation of the search pattern, we either paste mRNA sequence or input
the accession number (e.g., NM_001025366 for human VEGF-A) into a frame and start
search candidate siRNAs with some established filters. Subsequently, a list of siRNA
candidates with position in the mRNA sequence, thermodynamics, GC% content and
other information will pop out for our reference. To minimize the off-target effects of the
siRNA, BLAST (basic local alignment search tool) of selected siRNA sequences against
Genbank is highly recommended afterwards to ensure that only the interested gene is
targeted. Through this procedure, siRNAs against several genes have been designed, and
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importantly the significant gen
genee downregulation efficiency demonstrates the feasibility of
the siRNA selecting method.

transcription (A)
Figure VI-1. The formation of folate conjugated siRNAs by in vitro transcription.
The schematic illustration of FA conjugated dsRNA. Two dsDNA templates bearing T7
Φ 2.5 promoters and well
well-designed
designed siRNA sequence were chemically synthesized. Two
ssRNAs were synthesized, and the conjugation of FA or other functional groups to RNA
wass controlled simply by adding FA
FA-HDAAMP.
HDAAMP. The ssRNAs were annealed by
complementary sequences and formed FA
FA-siRNAs. (B)) PAGE analysis of sense,
antisense RNA (lane 1 and 2), FA
FA-antisense RNA (lane 3), and FA-siRNA
siRNA (lane 4).
Likewise, the FA-sense
sense RNA and FA
FA-sense
sense labeled siRNA could also be generated.
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After selection of siRNA sequences, their synthesis via our in vitro transcription
is followed (Figure IV-1). Firstly, four DNA strands bearing siRNA sequence and T7 Φ
2.5 promoter were synthesized commercially. Next complimentary DNA strands were
annealed to form two pairs of double-stranded DNA, which were used as templates to
transcript two single-stranded RNAs. The synthesis of FA conjugated and nonconjugated RNA was adjusted by addition of transcriptional initiator: FA-HDAAMP
(Scheme IV-1) which was chemically synthesized and purified by HPLC.128 After gel
purification and UV/Vis quantification, equimolar single stranded RNAs were hybridized
to form a FA-conjugated or unconjugated RNA as illustrated in Figure IV-1A. The
formation of RNA duplex and FA conjugation were confirmed by PAGE analysis (Figure
IV-1B).
In Figure IV-1B, we can see 27-nt sense strand RNA in lane 1, 32-nt antisense
strand RNA in lane 2. The antisense RNA with FA (MW = ~441) conjugation (in lane 3)
is bigger in size compared to the RNA without conjugation (lane 2), and displays about
one nucleotide shift. Besides, a small portion of unconjugated antisense strand is seen in
lane 3 as expected. The FA-linked RNA duplex is in lane 4. The clear bands suggest the
successful purification and hybridization of two strands.
Comparison of FR Expression in KB and A549 Cells
Once FA-siRNA is synthesized, its internalization into FR-expression cells is
examined. Two human cancer cells lines, KB cells (human nasopharyngeal carcinoma)
and A549 cells (human lung carcinoma), are used because KB cells highly express FR;
whereas A549 has non-detectable expression. 146, 209 To test that, real-time PCR and flow
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cytometry were utilized to analyze human FR-α (hFRα) expression in both mRNA and
protein levels in those two cell lines (Figure IV-2).
To compare hFRα expression in gene level, total RNA was extracted from two
types of cells; reverse transcription was conducted; and real-time PCR was carried out.
The representative amplification curves of hFRα in two cell lines were shown in Figure
IV-2A. Because the amplification curves of human β-Actin gene (internal control) in KB
and A549 are nearly overlapped; and therefore they are not displayed in Figure IV-2A.
Statistical analysis from three repeats was presented in Figure IV-2B. The data exhibit
~15 Ct value differences in two cell lines, indicating ~ 30,000 times variation in mRNA
level. To confirm this result, flow cytometry was applied to quantitate the hFRα protein
level in these two cell lines. The primary antibody against the hFRα was added into the
medium and specific bound to the FR expressed at the plasma membrane surface. A
FITC labeled second antibody which binds to the primary antibody was then added. Cells
were washed and collected, followed by detection by flow cytometry. A typical result of
FR quantification in KB was presented in Figure IV-2C. The black, red, blue, and yellow
lines represented the KB cells without and with antibody staining, A549 cells without and
with antibody staining respectively. It is obvious the black and red line lines are not
overlapped. The shifted red line indicates the expression of hFRα in KB. By contrast, the
blue and yellow lines in A549 are almost overlapped, suggesting the non-detectable
protein expression of hFRα in A549. The distinct expression of this protein in two cell
lines was further confirmed in Figure IV-2D, where more than 300-fold expression
difference was displayed. Through these analyses, the data clearly exhibit the significant
expression difference of hFRα in KB and A549 cells. Regarding the hFRα protein is the
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direct executor for FA or FA conjugates uptakes, approximate 300 fold difference of this
protein might better reflect the real situation. The fold differences in real-time PCR and
flow cytometer would partially result from post-transcriptional modification or other
reasons. Collectively, the result has shown that KB cells highly express FR while A549
cells have only background FR level. Therefore, KB and A549 cells can be used as FRpositive and negative cells in our experiments.
We propose to use GFP and luciferase system to study gene expression upon FAsiRNA treatment because of its accuracy and sensitivity. Among various luciferases,
Gaussia luciferase (GLuc) is utilized because: (i) it is a secreted protein, therefore cell
lysis step is escaped; (ii) GLuc has the 1000 fold sensitivity over Fluc. The utility of Gluc
was first in a transient transfection system (Figure IV-3) and a stable transfection system
where a cell line based on KB was constructed that express Gluc stably (Figure IV-4).
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Figure IV-2. Comparison of hhuman FR-α (hFRα) expression in KB and A549 cell lines.
lines
(A) Representative amplification plot
plots of hFRα in KB and A549 cells through real-time
real
PCR. (B) Statistic
tatistic analysis of real
real-time
time PCR results shows the relative hFRα
hFR gene
expression in two cell lines. (C) Representative fluorescence bbinding
inding plot of anti-hFRα
anti
antibody in KB and A549 cells via flow cytometer; (D) Statistic analysis of flow
cytometer results shows the relative hFR
hFRα protein expression in two cell lines. Each bar
represents mean ± S.D. (n=3
(n=3-4).

Activity through Transient Transfection
Downregulation of Gluc A
As for transient system, cancer cells were transfected with plasmids (pCMV(pCMV
Gluc) encoding Gluc and siRNAs against Gluc (siGLuc) by Lipofectamine consecutively.
Six hours after transfection of plasmid, the second transfe
transfection
ction was performed to
introduce siRNA against Gluc (siGLuc) into the cells. A siRNA control (siCon) that has
no targeted gene in human genome is used. As expected, siCon will not cause any gene
silencing. In contrast, the cells transfected with siGluc wil
willl downregulate Gluc
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expression. Luciferase will be expressed after the first transfection within a few days (at
least 3 days), and thus provides targeted mRNA for RNAi. The medium samples were
collected approximately every 8 hours and measured by luciferas
luciferasee activity assay (Figure
(
IV-3).
3). The cells treated with siCon (the solid circle) serve as the mock group and show
increasing Gluc activity along with time ((Figure IV-3A).
3A). In contrast, the cells upon
siGLuc treatment (the solid square) display lower Gluc act
activity,
ivity, indicating gene
downregulation from RNAi pathway.

Figure IV-3. Downregulation of luciferase activity in KB cells by transient transfection.
(A) KB cells were transfected with pCMV-Gluc plasmid first, then with either siRNA
targeting Gluc (Plasmid + siGLuc, solid square) or siRNA control (Plasmid
Plasmid + siCon,
siCon
solid circle). Cellular medium
edium containing the secreted was collected at the different time
points, and quantified through luciferase activity assay. Due to RNAi effects, the cells
transfected with siGLuc showed less luciferase activity; while the control group showed
increased luciferase activity
activity. (B) Relative siGLuc efficiency was presented.
The relative siGLuc efficiency was plotted in Figure IV-3B.
3B. The data show the
maximum siGLuc efficiency, 668% of downregulation, occurs at 42 hour after transfection
(HAT), and average RNAi efficiency is approximate 60%. Interestingly, the RNAi
efficiency of 12 HAT appears to be 70%. That may not reflect the truth regarding of the
unequal expression rates of the plasmid and the processing of RNAi. In other words, the
plasmid is expressed in control group (plasmid + siCon); whereas RNAi effect is limited
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in treatment group (plasmid + siGLuc). In addition, the plasmids are transfected into the
cells prior to siRNAs. Likewise, transient transfection of siRNA first prior to plasmids
plasm
has been conducted. Similar maximum siRNA efficiency (~70%) at around 48 HAT
indicates transient transfection is sufficient for determination of the best siRNA
efficiency.
Overall, the data have demonstrated that: (i)) transcriptionally synthesized siGLuc
siG
can silent the Gaussia luciferase expression potently; (ii)) under the transient transfection
conditions we studied, the max siRNA efficiency is 68% at 42 HAT; (iii)) the transient
transfection is not an ideal system for dynamic analysis of RNAi effects.
Downregulation of Gluc A
Activity through Stable Transfection

Figure IV-4. The construction of Gluc
Gluc-KB cell line. (A) Plasmid map of pCMV-Gluc
pCMV
which had been transfected with KB cells. (B) Gel electrophoresis analysis of prepared
pCMV-Gluc. (C) The schem
schematic illustration of stable cell line establishment. KB cells
were transected with pCMV
pCMV-Gluc and then incubated with G418 for 4 weeks.
weeks Those cells
capable of tolerating G418 and expressing Gluc constitutively are termed Gluc-KB cells.
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To address this issue, a stable transfection is applied, through which the Gluc
gene is integrated into the genome of KB cells and the Gluc will express stably. The
plasmid pCMV-Gluc vector map (Figure IV-4A), electrophoresis analysis of plasmids
(Figure IV-4B), and the procedure for establishment of a stable cell line (Figure IV-4C)
are presented in Figure IV-4.
Basically there are two important genes encoded within the humanized sequence
of pCMV-Gluc (5764 base pairs) (Figure IV-4A) Gaussia luciferase and aminoglycoside
phosphotransferase (neo) under the strong promoters of cytomegalovirus (pCMV) and
simian virus (pSV40), respectively. Neo is a selectable marker, conferring the transfected
cells resistance to antibiotics Neomycin in prokaryotic cells, or genticin (G418) in
eukaryotic cells, through which stable cell lines (usually mammalian cell lines)
expressing reporter proteins or cloned proteins are established. To get sufficient amount
of pCMV-Gluc for transfection purpose, the plasmid preparation was performed via
transformation of E. coli. The extracted pCMV-Gluc was confirmed by 0.8% agarose/
EtBr gel electrophoresis (Figure IV-4B), the first lane is the original plasmid (100 ng, 2
µL of 50 ng/µL), and the other 9 lanes are amplified plasmid. The procedure of the stable
expression cell lines is illustrated in Figure IV-4C. Firstly, KB cells were transfected with
pCMV-Gluc by DharmaFECT followed by manufacturer’s manual. One day later, the
medium was replaced with one containing 0.5 mg/mL antibiotics G418. Cells were first
cultured in a 10 cm dish for 2 weeks. At this time point, the majority (> 90%) KB cells
were killed off by G418 because of lacking the expression of neo. However, a few
percent of KB cells that had integrated the pCMV-Gluc plasmid detoxified G418 and
survived. Because the resistance to the G418 only indicated the insert of neo gene into
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the genome of KB, but necessarily meant the integrated of Gluc gene, the selection of
Gluc activity was carried out by seeding the surviving cells at very low density (~1
cell/0.1 mL) and plating onto 96-microplates (0.1 mL/well). The selection pressure from
Gl418 remained for another 7 days. Positive colonies expressing Gaussia luciferase
(Gluc) were screened by luciferase assay, transferred to a 12-well plate for propagation.
The cells are designated as Gluc-expressing KB cells (Gluc-KB).
Gene down-regulation studies were carried out in Gluc-KB cells with siGLuc
(Figure IV-5) and FA-siGLuc (Figure IV-6). In Figure IV-5A we can see the continuous
expression of Gluc in Gluc-KB cells. Without the interference of siRNA, Gluc expression
correlates with time (mock group). The cells transfected with different concentration of
siGLuc display downregulated expression of GLuc. The data from Figure IV-5A is
converted to Figure IV-5B to show the siGLuc efficiency within the 72 hour after
transfection (HAT). From the figure, the dose-dependence pattern is obvious: siRNA
efficiency from 30 nM > 20 nM > 10 nM. At 72 HAT, 76%, 67% and 66% of Gluc
activity has been reduced from treatments with 30 nM, 20 nM and 10 nM of siGLuc
respectively. Due to the limitation of cell confluency (cell density in a cell culture
container), the longer incubation time will cause error since 40% confluency is start point
before transfection. Therefore, we have not observed the disappearance of siRNA
efficiency here, which can map out the best RNAi efficiency of siGLuc.
Nevertheless, the results have demonstrated: (i) after being integrated into the
genome of KB cells, Gluc functions as an endogenous gene and is expressed by Gluc-KB
cells constitutively; (ii) 60%-70% of Gluc activity is reduced by Lipofectamine-mediated
transfection of siGLuc within the 36-72 HAT; (iii) dose-dependent downregulation.
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Figure IV-5. Downregulation of luciferase activity by siGluc in Gluc-KB
KB cells.
cells (A)
Gluc-KB cells were transfected by Lipofectamine with 10 nM, 20 nM, and 30 nM of
siGLuc.. (B) The relative siGLuc efficiency was plotted by normalization with non-treated
non
group (mock).
Based on the above results, we tested whether: (1) FA-siGLuc
siGLuc would be
internalized into Gluc-KB
KB cells and silence the Gluc activity; (2)
2) the delivery of siRNA is
FR-mediated
mediated and has the cell
cell-specific feature. The Gluc-KB
KB cells are maintained in
Folate deficient medium all the time and seeded onto the dished with 40% confluency
one day before the addition of FA
FA-siGLuc
siGLuc (final concentration = 20 nM, the same
concentration was used afterwards) into the medium. No more additional treatment was
performed. Every
ery day the medium samples were collected and measured and the time
course data was plotted into Figure IV-6 which suggested the best siRNA efficiency
occurred after 5 days of incubation with ~50% downregulation. It is notable that the best
siRNA efficiencyy shows up after a relatively long period of time which is similar to the
results of Dassie et al. who deliver PSMA aptamer
aptamer-modified
modified siRNA chimeras into the
human prostate tumors and observe the best siRNA efficiency at 4 days post incubation
121d

. This phenomenon would result from the delayed naked siRNA escape from the

endosome, which would compromise the efficiency of siRNA.
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Several groups of control ((Figure IV-6B) were tested
sted along with FA-siGLuc
FA
in
Gluc-KB
KB cells, including Lipofectamine/siGLuc, FA
FA-siGLuc
siGLuc with 1 mM of free folate,
FA-conjugated
conjugated siRNA control, siGLuc without FA conjugation. The results showed 55%
and 23% Gluc activity remained from the FA
FA-siGLuc and Lipofectamine
tamine/siGLuc
treatment. The presence of high concentration of free FA competed the binding sites (FR)
with FA-siGluc
siGluc and blocked the internalization of FA
FA-siGLuc,
siGLuc, thus the Gluc expression
from this groups was unaffected. In addition, transfection of siRN
siRNA
A control (siCon)
which has no gene target in the mammalian cells showed no RNAi effects. siGLuc
without FA conjugated cannot enter Gluc
Gluc-KB
KB cells and gene downregulation was
observed under this condition. Thus combination of controls demonstrated FR-mediated
FR
siRNA delivery.

Figure IV-6. Downregulation of luciferase activity by FA
FA-siGLuc
siGLuc in Gluc-KB
Gluc
cells (A)
The time course of relative Gluc expression was assessed at 3 to 6 days after transfection
(siRNA concentration = 20 nM)
nM).. (B) Several controls including cell without treatment
(mock), FA-siGLuc
siGLuc plus 1 mM free folate, FA
FA-linked
linked control siRNA (siCon),
Lipofectamine-mediated
mediated transfection of siGLuc, and siGLuc, were explored along with
the FA-siGLuc.
siGLuc. The concentration of siRNA in the study was 20 nM, and the
measurement was carried out at the 5day after incubation. The data represents mean ±
S.D (n=3-4).
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Reduction of GFP Expression through Transient Transfection
Besides the bioluminescence system, the possibility of utilizing GFP as a reporter
was also exploited in our research as shown in Figure IV-7. Similarly, KB cells
consecutively expressing humanized GFP (GFP-KB) was established by transfecting KB
cells with plasmid pAcGFP1-MemHyg (5846 bp) and selecting with antibiotics
Hygromycin B. The screening of GFP expression positive colonies was performed
through typhoon scanner. Due to lack of a spectrofluorophotometer, the fluorescent
signals cannot be quantified. Instead, confocal imaging (Figure IV-7) and real-time PCR
(Figure IV-7B) were applied to measure the GFP expression reduction after transfection
of siRNA against GFP. As shown in Figure IV-7, we can see the high expression level of
GFP in GFP-KB cells, and the expression is not influenced by transfection siCon. In
contrast, siGFPa and siGFPb (two siRNAs both target the GFP gene) can significantly
reduce the GFP expression by 97% and 95% (Figure IV-7B). This second example
confirms: (1) our designed and prepared siRNAs can efficiently reduce the expression of
targeted gene; (2) the reporter-stably transfected cell is an optimal system to assess gene
expression, especially upon RNAi.
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Figure IV-7. Downregulation of GFP expression in GFP
GFP-KB
KB cells by Lipofectamine. (A)
Confocal analysis of reduced fluorescence by transfection of two siRNAss against GFP,
siGFPa and siGFPb. In contrast, the non
non-treated
treated cells and the cells transfected with
siRNA control (has no targets in human genome) show unaffected GFP expression. (B)
Real-time PCR analysis of gene expression
expression.

Conclusions
Here we synthesized FA functionalized siRNA through in vitro transcription
system. The FA-HAD-AMP
AMP as the transcriptional initiator is the key to this conjugation.
Subsequently, to better monitor the gene expression changes upon the siRNA treatment,
luciferase
ase reporter, especially Gaussia luciferase, system was introduced. A stable
transfection cell line based on FR
FR-expressing
expressing human cancer cell KB was established and
denoted Gluc-KB.
KB. Firstly, Gluc
Gluc-KB
KB cells were transfected with siGLuc through
transfection agents
ents to test the efficiency of siGLuc; secondly, Gluc
Gluc-KB
KB cells were
incubated with FA-siGLuc.
siGLuc. FA
FA-siGLuc
siGLuc at 20 nM reduced Gluc activity to 50% after 55
day incubation, indicating the internalization of siRNA through FR
FR-mediation
mediation and RNAi
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pathway-dependent gene silencing (siRNA control group). More importantly, several
control groups had demonstrated the FR-dependent delivery because extra free FA could
block the gene downregulation, and the siGLuc without FA modification can not enter
cells. Moreover, the utilization of reporter systems and the establishment of GFP-KB and
Gluc-KB cell lines render a fast and convenient platform for monitoring gene expression
visually and quantitatively, and assessing siRNA efficiency.
In spite of FR-mediated siRNA delivery and gene downregulation (50%), the
RNAi efficacy is relatively low and may not meet the needs of biomedical application.
The key here is to increase the gene downregulation efficiency by improving delivery
strategy. Firstly, naked siRNA would be degraded in a short period of time by
extracellular and intracellular RNase. It has been reported the half-life of unmodified
siRNA is ~10 min in 100% human serum. Secondly, evidence shows that monovalent
folate conjugate (containing one attached FA) compared to its multivalent counterpart
(with several FAs) has less efficiency in triggering pH changes in early endosome, which
is a crucial for siRNA release into cytoplasm. Another important reason for improvement
the strategy comes from the consideration of systemic administration. Because of small
molecular weight (59 nt, ~20 kDa) and size (~ 3 nm) of siRNA, it will be rapidly excreted
through urine when circulated in blood stream.86
To address these issues, we need a system cable of protecting siRNA and
increasing the size of siRNA (i.e., form a complex) to achieve enhanced delivery
efficiency and RNAi efficacy. Fortunately, through collaboration, we have developed a
series of polyvalent, FA-conjugated copolymers with advantageous solubility, protection
and complexation functionalities, which will be discussed in the next chapter.
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CHAPTER V
CANCER-SPECIFIC SIRNA DELIVERY VIA FAPOL13
Introduction
siRNA therapeutics have to overcome several major challenges including delivery
efficiency, target cell specificity, in vivo stability, and appropriate intracellular siRNA
release mechanism from delivery vehicles before it enters biomedical applications.92a, 210
To address above issues, significant efforts have been dedicated to synthesize various
nanoparticles as siRNA carriers which have become particularly attractive because of
their flexibility of available conjugation chemistries, and capabilities of increasing siRNA
stability, biocompatibility.211
Cationic (co)polymers, such as PEI, polylysine and polyarginine, have been
broadly used because they can package siRNA, or other oligo-/polynucleotides, through
electrostatic interactions, thus providing the bound polynucleotide protection from
detrimental nucleases.212 Although cationic complexes can protect siRNA and remain
aqueous soluble, the cationic surface charge leads to non-specific cellular adsorption and
thus transfection of both healthy and unhealthy cells.213 Furthermore, cationic complexes
can associate with anionically charged serum proteins resulting in aggregation and
eventual phagocytic clearance.214 Utilizing hydrophilic-block-cationic copolymers for
siRNA complexation, neutral complexes can be formed circumventing problems
associated with cationic carriers. The cationic block still provides packaging and
protection for siRNA, while the hydrophilic block provides biocompatibility and
solubility for the complex. This neutral hydrophilic block also prevents unwanted
aggregation and non-specific cellular adsorption through steric stabilization. Since neutral
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carriers do not electrostatically adsorb to cellular surfaces, the carrier must be directed to
or accumulated at a specific tissue or cellular site. A promising route to direct and trigger
cellular uptake is to incorporate cellular targeting moieties to either the copolymer
backbone or end-groups.
Due to progress in numerous polymerization methods, (co)polymers with
advanced architectures and predetermined chain-end and side-chain functionalities can be
specifically designed for targeted delivery applications. Incorporation of such
functionalities allows facile post-polymerization conjugation of cellular targeting
moieties. In principle, targeted delivery systems mitigate side effects, improve bioavailability, and enhance therapeutic efficacy. Targeting ligands applicable to cancer
therapy include antibodies, peptides, aptamers, and folate.103, 109, 215 The overexpression
of FR in various types of tumors, such as, uterus, brain, kidney, breast, ovary,198 makes it
as a cancer-cell-surface receptor, and confer the use of folate as a therapeutic director for
homing FA-conjugates to tumors. Folate has been successfully employed to deliver
diverse drugs, siRNAs, therapeutic, diagnostic and prognostic agents,197, 199 and at least
four FA-linked drugs are under phase I or II clinical trials.143
Several research groups, including our own, have successfully developed
(co)polymer systems with utility in siRNA delivery.101b, 211b, 216 Although these reports
demonstrate gene down-regulation, cellular trafficking events (i.e., binding, uptake, and
endosomal release) prior to gene suppression are typically overlooked or ignored.
Furthermore, evidence shows that efficient internalization of siRNA does not necessarily
result in favorable gene down-regulation.217 For example, trafficking or degradation
events after uptake, such as endosomal entrapment, exocytosis or recycling, or enzymatic
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inactivation of the siRNA, can lead to suboptimal gene suppression. For these reasons,
investigation of cellular trafficking processes, specifically endosomal escape, are crucial
for gene down-regulation efficacy.217 Real-time monitoring of such events would allow
early detection of carrier drawbacks, optimization of delivery and formulation conditions,
dynamic visualization, and easy assessment of endosomal entrapment/release. Therefore,
there is a need to develop imaging techniques to follow and visualize the siRNA carrier
during various cellular trafficking events. Herein, I describe real-time monitoring for
siRNA delivery processes utilizing a multivalent folate-functionalized copolymer
(FAPol13) as the carrier. Cellular trafficking events monitored via confocal fluorescence
microscopy include (1) receptor binding, (2) polyplexes internalization, and (3)
endosomal release. siRNA delivery to multiple cancer cell types, copolymer
biocompatibility, and gene down-regulation are also demonstrated. In addition to the
development of real-time imaging methods, the result also demonstrates the utility of this
polymeric carrier in site specific gene delivery applications.

Result and Discussion
Cellular Binding and Internalization of FAPol13/siRNA Polyplexes in KB Cells
Previously our laboratories synthesized a series of well-defined block copolymers
capable of delivering siRNA specifically to FR-expressing cancer cell lines.101b These
copolymers were prepared via a controlled radical polymerization technique known as
reversible addition-fragmentation chain transfer (RAFT) polymerization.101a, b, 101e, 172, 188a,
218

The RAFT-synthesized block copolymer utilized in this report consists of three

monomer components. The first block (HPMA315-stat-APMA13; Mn = 47400 g/mol;
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PDI=1.10) was prepared through the aqueous RAFT copolymerization of N-(2hydroxypropyl)methacrylamide (HPMA) and N-(3-aminopropyl)methacrylamide
(APMA). 101b HPMA was chosen because its corresponding polymer is biocompatible
and water soluble, while APMA was selected to introduce primary amine functionalities
for conjugation with folate derivatives. HPMA315-stat-APMA13 macro chain transfer
agent was then successfully chain extended with the cationic tertiary amine containing
monomer N-[3-(dimethylamino)propyl]methacrylamide (DMAPMA) to yield (HPMA315stat-APMA13)-b-DMAPMA23 (Mn = 51300 g/mol; PDI = 1.14),101b thus facilitating the
electrostatic complexation between the copolymer and siRNA. The APMA units were
then directly conjugated to N-hydroxysuccinimide activated folate, and 11 to 13 out of 13
possible APMA units were modified.101b Due to the presence of 13 APMA units,
unmodified (HPMA315-stat-APMA13)-b-DMAPMA23 was given the name Pol13 and
multivalent folate conjugated (HPMA315-stat-APMA13)-b-DMAPMA23 was named
FAPol13. FAPol13 allows the formation of neutral (nitrogen to phosphate ratios, N/P = 1)
complexes, thereby circumventing problems associated with charged complexes, while
the presence of multiple folates in the aqueous stabilizing block directs this siRNA carrier
to cancer FR-expressing cell lines.
FAPol13 has a small molecular size (hydrodynamic diameter, Dh = 10.8 ± 0.3
nm), and cationic change (Zeta potential = 25.4 ± 0.7 mV).101b After complexation with
siRNA (59 nt, Dh = 2.95 ± 0.34 nm)188a, the size of FAPol13/siRNA complex is still
nanoscale (Dh = 15.2 ± 2.4 nm). Compared to macromolecular siRNA carriers (i.e.,
antibody, aptamer), this property is advantageous in terms of tumor penetration
potential.219 Additionally, the neutral complexes (Zeta potential = -3.88 ± 0.21 mV)
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remain sterically stable due to the presence of the hydrophilic block, which increases the
delivery efficiency compared with anionic complex, and enhanced targetability compared
with cationic complex.101b Therefore, the neutral FAPol13/siRNA complex is an ideal
model for study the delivery process (Scheme V-1), including cellular binding, entry
(endocytosis), endosome escapes.
After successful preparation of FAPol13 and subsequent formation of neutral
FAPol13/siRNA polyplexes, cell binding and intracellular uptakes of these carriers were
confirmed by confocal laser scanning microscopy. Fluorescence and thus visualization of
the uptake process was made possible by employing either a FAM-labeled or a Cy3labeled siRNA. To elucidate the specificity of delivery, several control studies were first
performed (Figure V-1). Time-lapse analyses were carried out to monitor siRNA binding
to KB cells (Figure V-2), followed by z-axis scanning to confirm internalization of the
siRNA/FAPol13 polyplexes (Figure V-3). Experiments were performed on
polymer/siRNA polyplexes prior to (Pol13) and after FA (FAPol13) conjugation.
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Scheme V-1. Schematic depiction of siRNA delivery processes via FAPol13.

FApol13 functionalized with FA carries siRNA into the FR expressing cells and release it
once inside. FAPol13 and siRNA form a comp
complex
lex electrostatically which will a) bind to
the FR+ cells, b) enter the cells through FR
FR-dependent
dependent endocytosis, c) escape from the
endosome after pH decreasing, and d) dissociate siRNA into the cytoplasm, which it will
be processed by Dicer, incorporated iinto
nto the RISC, and induce the homologous mRNA
degradation (RNAi pathway is not shown here).
Control experiments were first carried out to establish the ability of FAPol13 to
deliver FAM-labeled
labeled siRNA (FAM
(FAM-siRNA)
siRNA) to KB cells. KB cells were treated with
naked FAM-siRNA,
siRNA, Pol113/FAM
Pol113/FAM-siRNA polyplexes, FAPol13/FAM-siRNA
siRNA polyplexes,
or Lipofectamine/FAM-siRNA
siRNA complexes. Minimal fluorescence upon treating KB cells
with naked FAM-siRNA
siRNA and Pol13/FAM
Pol13/FAM-siRNA
siRNA polyplexes was observed and attributed
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to non-specific binding. In contrast, the fluorescence intensity from FAPol13/FAMsiRNA polyplexes was stronger, suggesting that the conjugated FA promoted specific
cellular associations through the FR. As a positive control FAM-siRNA was delivered via
Lipofectamine, a commercial transfection reagent that can effectively perform
intracellular siRNA delivery independent of the cellular receptors present. In addition to
standard fluorescence imaging, siRNA binding and uptake were verified by time-lapse
and z-stack scanning analyses. For the remaining imaging experiments Cy3 labeled
siRNA was chosen over FAM because of its resistance to photobleaching.
Real-time monitoring of siRNA-cell binding process is important as it allows for
dynamic visualization of the cellular receptor binding/adsorption process, determination
of the time required for cellular binding and cellular surface saturation by the therapeutic
carrier, as well as a rapid a straightforward analysis to prescreen the designed carrier.
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Figure V-1.. Confocal images of specific binding of FAPol13/FAM
FAPol13/FAM-siRNA
siRNA to KB cells.
KB cells were treated with A) no treatment, B) FAM
FAM-siRNA,
siRNA, C) Pol13/siRNA, D)
FAPol13/siRNA polyplexes, and E) Lipofectamine/siRNA complexes (total [siRNA] =
20 nM) and incubated for 40 min (A-D)
D) or 1.5 h for E. Images were taken via confocal
microscopy after washing the cells with pre
pre-warmed
warmed PBS two times. The N/P ratio for
each micrograph is 1.0. The panel indicated by FAM was FAM fluorescence images,
while the DIC panel represented ddifferential
ifferential interference contrast or bright field images.
Scale bar = 100 µm.
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During the following real-time monitoring the temperature was maintained at 37
°C by a heated sample holder and micrographs were taken in 10 min intervals for 80 min.
Time-lapse images for the incubation of FAPol13/siRNA polyplexes in the KB (+FR)
and A549 (-FR) cell lines are shown in Figure V-2. It is apparent that the cell
fluorescence from Figure. V-2A (KB cells with FAPol13/siRNA polyplexes) was much
stronger than Figure. V-2B (KB cells with Pol13/siRNA polyplexes), indicating siRNAcell binding events due to ligand-receptor interactions between the FAPol13/siRNA
polyplexes and the FRs expressed at the cell surface. Further evidence for specific ligandreceptor interactions is provided by comparison of Figure V-2A to Figure V-2C (A549
cells with FAPol13/siRNA polyplexes). The absence of fluorescence in Figure 2C is
related to negligible FR-expression in the A549 cell line. The absence of FR expression
precludes specific association of the FAPol13/siRNA polyplexes with from A549 cells.
For the above three conditions, fluorescence intensities as a function of time are
presented in Figure V-2D. Upon treatment of KB cells with FAPol13/siRNA polyplexes,
an increase in cell-associated fluorescence was apparent after 20 min. Maximum
fluorescence was reached near 40 min and kept for the remainder of the time-lapse. On
the other hand, cell-associated fluorescence over the same time course was negligible for
both treatments of KB cells with Pol13/siRNA polyplexes (Figure V-2B) and A549 cells
with FAPol13/siRNA polyplexes (Figure V-2C).
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Figure V-2. Time-lapse
lapse imaging of polyplexes in KB and A549 cells. Cells were treated
with A) FAPol13/siRNA polyplexes in KB cells (FR-positive),
positive), B) Pol13/siRNA
polyplexes in KB cells, and C) FAPol13/siRNA polyplexes in A549 cells (FR-negative).
(FR
siRNA was labeled with Cy3 (red) ([siRNA] = 20 nM). Images were taken every 10 min
for 80 min. The overlaps of fluorescence image and bright field image are shown here.
Scale bar = 10 µm. D) Associated fluorescence versus time for FAPol13/siRNA
polyplexes with KB cells ((■), Pol13/siRNA polyplexes with KB cells (●),
●), and
FAPol13/siRNA polyplexes with A549 cells (▲). The associated fluorescence
rescence is
calculated from 10 individual cells and background corrected. Error bars are represented
by ± S.D (n=3).

Although Figure V
V-2
2 demonstrates binding of FAPol13/siRNA polyplexes to the
cell surface of FR-expressing
expressing KB cells, subsequent intracellular uptake cannot be verified
through time-lapse
lapse analysis. Therefore, siRNA internalization was studied separately by
scanning cell sections
ctions vertically through the zz-axis
axis via confocal microscopy, which can
verify if the fluorescence signal comes from the interior or exterior of the cell, or both.
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Z-axis sectional images were taken by adjusting the focal plane from the top to the
bottom of the cells in 3 µm increments (Figure V-3). As a negative control (Figure. V3A), incubation of KB cells with Cy3-labeled Pol13/siRNA complexes (-FA) resulted in
weak but observable background fluorescence. In addition, the weak fluorescence was
present only on the cell surface. No internalization was visible. On the contrary,
internalization of the FAPol13/siRNA polyplexes in KB cells (Figure V-3B) was
evidenced by the relative strong fluorescence that was not only associated with the cell
surface but also present inside cells. The largest fluorescence difference between Figure
3A and Figure 3B existed not on the cell surface but within cells. While Figure 3A
displays no visible fluorescence inside cells, relative strong fluorescence can be seen in
the intracellular volume of Figurer 3B. As a positive control (Figure V-3C),
Lipofectamine was also used to show cellular internalization (no cell specificity) of Cy3labeled siRNA. KB cells treated with Lipofectamine/siRNA complexes were incubated
for 2 h following the manufacturer’s suggestion. As expected, incubation of cells with
Lipofectamine-complexed Cy3-siRNA led to strong fluorescence over the whole cell
Collectively, these results demonstrate both cell binding and intracellular uptake
of FAPol13/siRNA polyplexes in KB cells, due to the presence of the conjugated FAs
that promote siRNA cell binding and internalization. In addition to cellular uptake,
endosomal release of internalized siRNA from carrier complex would be necessary for
efficient RNAi/gene downregulation.217a, 220 Therefore, further analysis by fluorescence
microscopy was utilized to characterize and visualize endosomal release events during
FAPol13-assisted siRNA delivery.
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Figure V-3. Z-stack
stack scanning analysis of internalized polyplexes in KB cells. Treatment
of KB cells with A) FAPol13/siRNA polyplexes (1 h), B) Pol13/siRNA polyplexes (1 h),
and DharmaFECT/siRNA (2 h). siRNA was labeled with Cy3 (red) with a concentration
of 100 nM for all images. Hoechst 33258 (blue) was added to reach 1 µg/mL 20 min
before observation. The focal plane was moved from the bottom to top of the cells in 2
µm increments. Scale bar = 20 µm.
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Endosomal Escape of FAPol13/siRNA Polyplexes
Inefficient siRNA release from endosomal compartments is the major reason for
subpar gene downregulation.217a, 220-221 Poor release leads to entrapment of the therapeutic
carrier and cargo inside the endosome, potentially causing either their recycling back to
the cell surface 217a or their degradation by lysosomal enzymes. Therefore methods to
directly monitor endosomal escape are critical for gene downregulation assessment and
the rational design of gene delivery vehicles. In the current system, we performed colocalization analysis of FAPol13/Cy3-labeled siRNA polyplexes and lysotracker (a
membrane permeable dye that only fluoresces in the endosomal or lysosomal
compartment) during endocytotic trafficking (Figure V-4).222 Co-localization is
determined by merging the Cy3 (red) and lysotracker (green) fluorescent images. If
siRNA is contained within an endosomal compartment this image overlap will produce a
yellow signal. Co-localization between two fluorescent probes, Cy3-siRNA and
lysotracker, was quantified by the Pearson’s correlation coefficient (PCC) through a
toolbox under ImageJ and JACoP (Figure 4E). PCC typically has a scale between -1 to 1,
with -1 having no correlation whatsoever and 1 indicating a perfect overlap of fluorescent
signals. 223
KB cells were first treated with FAPol13/Cy3-labeled siRNA polyplexes
([siRNA] = 100 nM) for 1 h after which the cell medium was replaced. Prior to
fluorescent imaging, lysotracker (100 nM) was added to the cell medium. Cells were
imaged at 1 h, 6 h, 24 h, and 48 h after FAPol13/siRNA polyplex treatment. Colocalization of lysotracker and siRNA in the endosome, after 1 h treatment, is evidenced
by the yellow and localized signals seen in Figure V-4A, indicating that most of the
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siRNA is confined to endosomal compartments. After 6 h and 24 h treatment (Figure V4B and 4C), separation between the Cy3 and lysotracker signals become apparent and are
marked by arrows in Figure 4. The loss of co-localization, or return to individual red
(Cy3 siRNA) and green (lysotracker) signals, suggests endosomal escape of the
FAPol13/siRNA polyplexes. After 48 h treatment (Figure V-4D), the fluorescent signal
from siRNA has become more evenly distributed throughout the cytosol and more red
signal (siRNA) has separated from the lysotracker signal. At the same time, less yellow
signal is present, further indicating endosomal escape of FAPol13/siRNA polyplexes. For
comparison, similar treatment of FR-negative A549 cells with lysotracker and
FAPol13/siRNA polyplexes led to the observation of green signals only, without the
presence of red signals within the cells, as expected from the results in Figure V-2.
In addition to visual observation of spatial distribution of Cy3-siRNA and
lysotracker (Figure V-4), PCC is utilized to statistically and quantitatively measure the
endosomal escape process. A PCC equal to 1 implies that the FAPol13/siRNA polyplexes
and the endosome are completely co-localized. In our case, the PCC from 1 h treatment
is 0.99 indicating that the FAPol13/siRNA polyplexes were endocytosed and remained in
the endosomal compartments. As treatment time increased, the PCC for the 6 h time point
decreased to 0.77. This decrease suggests that a portion of the FAPol13/siRNA
polyplexes have escaped from the endosome as visualized in Figure V-4B. The PCCs of
the 24 h and 48 h images are 0.64 and 0.49, respectively, suggesting that the
FAPol13/siRNA polyplexes continually escape the endosome over time. Notably, the
decrease from 0.99 (1 h) to 0.77 (6 h) is the largest among two consecutive time points,
suggesting that the highest escaping efficiency occurs between 1 h and 6 h.
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Figure V-4. Colocalization analysis of polyplexes and endolysosome in KB cells.
cells The
cells were incubated with FAPol13/Cy3-labeled
labeled siRNA (red) polyplexes for A) 1 h, B) 6
h, C) 24 h, and D) 48h. The endolysosome w
was stained with lysotracker green 30 min
prior to imaging. Yellow fluorescence seen in the overlay images indicates coco
localization of siRNA and lysotrac
lysotracker
ker in the endosome. Concentrations of siRNA and
lysotracker were held at 100 nM. Cells were washed with pre
pre-warmed
warmed phosphate buffer
solution three times prior to observation. Scale bar = 10 µm. Arrows mark separating or
separated red and green signals. E
E) The
he Pearson’s correlation coefficient versus time. The
calculation is based on 3 independent images, within each containing 77-12
12 cells in each
time point. Error bars are represented by ± S.D.
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These co-localization studies establish that FAPol13/siRNA polyplexes are
internalized and can subsequently escape the endosome over time. Endosomal escape has
been confirmed both visually and quantitatively by fluorescence microscopy and
determination of PCC, respectively. Release of siRNA from the endosome was not
unexpected since gene down-regulation was observed in our previous report 101b.
Although the imaging methods were developed utilizing FAPol13/siRNA polyplexes in
KB cells, the methods may be applied to other fluorescently labeled siRNA carrier
systems and cell lines for direct observation of endosomal escape. This direct monitoring
can provide insight into the efficacy of endosomal escape, thereby offering some
guidance on development of efficient siRNA carrier systems.
Another factor facing efficient siRNA delivery is the unpackaging of siRNA from
the polymeric carrier. In theory, siRNA release from the carrier can be visualized through
the development of a FRET reporter system. For example, the conjugation of quencher
dye to the copolymer backbone would absorb the fluorescence emission from the Cy3labeled siRNA. Upon release, the fluorescence becomes visible allowing the researcher to
image and determine the cellular location of release. Such a system is currently being
developed within our laboratories.
Internalization of FAPol13/siRNA Polyplexes into HeLa and SKOV3 Cells
The above studies established both cellular uptake, via FR-mediated endocytosis,
and endosomal release of FAPol13/siRNA polyplexes with KB cells (FR+), along with
A549 cells (FR-) as the negative control. Additional FR-positive cell lines, HeLa and
SKOV3 cells, were utilized to demonstrate the capacity of this polymeric vehicle to
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deliver siRNA to other FR
FR-positive
positive cancer cell lines. siRNA delivery to HeLa and
SKOV3 cells was studied via confocal microscopy.
Cellular internalization of FAPol13/siRNA polyp
polyplexes
lexes in both HeLa and SKOV3
cells can be compared by the confocal microscopy images as shown in Figure
Fig
V-5. For
contrast, the nuclei were stained with Hoechst (blue fluorescence). In addition, z-stack
z
analysis clearly indicates internalization of FAPol13
FAPol13/siRNA
/siRNA polyplexes into HeLa and
SKOV3 cells. Furthermore, the uniformity of red fluorescence throughout the cytoplasm
further suggests effective cellular internalization FAPol13/siRNA polyplexes. Finally, it
is noted that the fluorescence signal decreases from KB cells to HeLa cells to SKOV3
cells, which is consistent with the cellular uptake capacity of other folate conjugates in
these cell lines.224 Quantitation of the rrelative
elative FR expression at both mRNA and protein
levels in KB, HeLa, and SKOV3 cells, indicates FR expression level of decreasing order:
KB > HeLa > SKOV3 (refer
efer to Chapter VII).

Figure V-5. Confocal analysis of cellular absorption of polyplexes with cancer
canc cells. A)
KB, B) HeLa, C) SKOV3
SKOV3, and D) A549 cells were incubated with FAPol13/Cy3-siRNA
FAPol13/Cy3
(N/P = 1,, siRNA concentration = 100 nM) for 40 min before imaging. The nuclei were
stained by Hoechst 33258 (blue fluorescence) 20 min prior to imaging. Scale bar = 20
µm.

Next, time-lapse,
lapse, zz-axis
axis scanning and colocalization analysis were conducted in
HeLa and SKOV3 cells as shown in Figure V-6. Firstly, in Figure V-6A
6A and 6D, the
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polyplexes bind to the HeLa and SKOV3 cells along with the time, indicating the
interaction between the FR and FA moiety. Certain cells exhibit rapid absorbance of
polyplexes; while some show slower uptake, probably due to different FR expression
level and heterogeneity of the cell lines. Moreover, under the condition studied, the
fluorescence intensity has not reached the maximum after 60 min incubation (the data not
shown here). Secondly, the z-axis scanning (Figure V-6B and 6E) clearly indicates the
cytoplasmic distribution of polyplexes after 6 h incubation, which is in agreement with
the results in KB cells. More importantly, colocalization of polyplexes (red) and
lysotracker green (Figure V-6C and V-6F) suggests the polyplexes escape from
endolysosome after 24 h incubation. The endosomal release efficiencies indicated by
PCC in HeLa and SKOV3 are 42% and 34% respectively, close to the 36% in KB cells.
Taken together, these results suggest that FAPol13/siRNA polyplexes could bind
to the FR-positive cells depending on the presence of cell surface FR; and polyplexes are
internalized by endocytic pathway and released from endolysosome into cytoplasm after
24 h incubation with approximate 40% efficiencies among these three FR+ cell lines.
Furthermore, the data reveal the potential application of this useful approach to evaluate
the trafficking process of fluorophore-labeled complexes in different cell lines or
different drug delivery systems.
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Figure V-6. Confocal studies of polyplexes trafficking in HeLa
HeLa,, and SKOV3 cells. Timelapse imaging (A and D), zz-axis scanning (B and E), and colocalization analysis (C and
F) were applied here. The images of time
time-lapse
lapse were taken every 20 min and presented
in an overlap of fluorescence (Cy3 and Hoechst) and bright field. For zz-stack
stack analysis,
cells were incubated with polyplexes for 6 h before imaging and the overlaps of Cy3 and
Hoechst fluorescence are presented here. The 24 h incubation for colocalization imaging
was chosen and presented here. Scale bar = 10 µm.
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Copolymer Cytotoxicity and Gene Downregulation of Luciferase
Prior to gene down-regulation experiments the cytotoxicity of FAPol13 was
determined utilizing a cell viability assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS). Conversion of MTS
to formazan by dehydrogenase enzymes can only be accomplished if cells are
metabolically active. Therefore, the absorbance of formazan at 490 nm is a direct
measurement of cell viability. As shown in Figure V-7, FAPol13 has low to negligible
toxicity over the complete range of concentrations tested, suggesting that the copolymer
is biocompatible and suitable for gene delivery applications. These results are consistent
with microscope observation (no cell death). This low toxicity and biocompatibility are
advantageous when compared to conventional liposome-based vehicles, which have been
shown to be cytotoxic. 225 This, in principle, allows for multiple treatments of cells with
FAPol13/siRNA polyplexes due to the non-toxic nature of the copolymer.
1.2
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Figure V-7. Cell viability of KB cells at increasing concentrations of FAPol13. KB cells
were first seeded into a 96 well plate and incubated for 24 h prior to introduction of
FAPol13. Five different copolymer concentrations ranging from 10 nM to 6 µM were
tested and allowed to incubate for 48 h. Untreated KB cells were utilized as a control.
After incubation, a solution of MTS was added and the absorbance at 490 nm was
measured after two hours. All measurements were directly compared to untreated KB
cells All experiments were performed in triplicate, and error bars represent ± S.D (n=3).
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To assess gene down-regulation of these polyplexes, Gluc-KB cells, which stably
express Gaussia luciferase protein,188d were treated with neutral FAPol13/siRNA
polyplexes ([siRNA] = 100 nM; N/P = 1) for 6 h, followed by 48 h incubation. siRNA
targeted against Gaussia luciferase was utilized for these studies due to its convenience
and sensitivity of the measurement. The facile manner in which luciferase protein level
can be determined (i.e., by luminescence) makes this protein an ideal target for
testing/optimizing gene downregulation.226 Following 48 h of incubation, the luciferase
protein expression level was quantified and presented in Figure V-8.

Relative Gluc Expression

1.2
1.0
0.8
0.6
0.4
0.2
0.0
Cell

FAPol13

Pol13

DharmaFECT

Figure V-8. Relative Gaussia luciferase protein expression level in Gluc-KB cells. The
control (marked Cell) contained free siRNA and Gluc-expressing KB cells. The
remaining three experiments (FAPol13, Pol13, and DharmaFECT) were Gluc-expressing
KB cells treated with FAPol13/siRNA polyplexes, Pol13/siRNA polyplexes and
DharmaFECT/siRNA complexes. siRNA concentration was kept at 100 nM. Polyplexes
were prepared at an N/P = 1.0. Protein expression levels were measured 48 h after
treatment. All experiments were repeated in triplicate and the error bars represent ± S.D.
(n=3).
The luciferase protein level was normalized to untreated Gluc-KB cells. Upon the
treatment of FAPol13/siRNA polyplexes, the luciferase expression reduced to 32%, while
minimal gene down-regulation for cells treated with polyplexes prior to FA conjugation
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was observed. This result matches the above studies in that the conjugation of FA to the
polymeric carrier is required for cellular uptake (Figure V-1 to V-3). Treatment of GlucKB cells with DharmaFECT (commercial transfection reagent, positive control) lead to
83% down-regulation of luciferase. The similar gene down-regulation efficiency
between DharmaFECT and FAPol13 and the enhanced biocompatibility of the latter
demonstrates the potential utility of FAPol13 for specifically delivering siRNA to FRbearing cancer cells. These results are consistent with gene down-regulation studies of
human survivin gene by real-time PCR (Figure V-9). 101b

Figure V-9. Real-time PCR analysis of downregulation of human Survivin gene upon
treatment with FAPol13 complexed anti-survivin siRNA (siSv). The control contained
either KB cells incubated with siSv or A549 cells incubated with siSv. The other three
experiments (marked KB, KB/Free FA, and A549) were treated with FAPol13/siSv
complexes in the presence (KB/Free FA) or absence (KB, A549) of 1 mM free folic acid
(FA). All experiments were done in triplicate and error bars represent ± SD 101b.

Kinetic Analysis of the Absorption of FAPol13/siRNA Polyplexes in KB Cells
This low toxicity and biocompatibility of FAPol13 make multiple treatments of
cells with polyplexes with minimal side-effects possible. To follow this notion, we
conduct the kinetic analysis to determine the effective incubation time (Figure V-10).
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KB cells were treated by DharmaFECT (positive control) and FAPol13
complexed, Cy3-labeled siRNA in vitro, and the mean fluorescence intensity (MFI) was
assessed by flow cytometry as a function of time. In Figure V-10, the kinetics of KB
accumulation is quantified. KB cells appear to saturate by DharmaFECT/Cy3-siRNA in
~10 h (half time, t1/2 = ~2.8 h), by FAPol13/Cy3-siRNA in ~13h (t1/2 = ~5.3 h). The result
is consistent with Figure V-1 and V-3, which indicate the higher absorption efficiency of
commercial transfection agents.
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Figure V-10. Kinetic studies of Cy3-siRNA uptake in KB cells by flow cytometry. Cy3siRNA (final concentration = 100 nM) were delivered by DharmaFECT (solid circles)
and FAPol13 (solid squares). The uptake of siRNA by KB cells was monitored as a
function of time (1h, 2h, 4h 8h, and 24h) by flow cytometry. The data represents mean ±
SEM (n=3).

Induction of Apoptosis by Transfecting KB Cells with siRNA against CASP8AP2 (siCAS)
As discussed in Chapter I, Caspase 8 associated protein 2 (CASP8AP2) is
involved in apoptosis. Downregulation of this gene expression through RNAi technique
would cause cell death. 184 Therefore we choose this gene as siRNA target to enhance the
cellular effects upon siRNA treatment. Firstly, DharmaFECT was used to deliver
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transcription-synthesized siRNA against CASP8AP2 (siCAS) into KB cells to test the
feasibility of this target (Figure V-11), and subsequently, FAPol13 was used to carry
siCAS into the cells specifically (Figure V-12).
Morphological changes, such as, cell shrinkage and DNA fragmentation (pointed
by arrows), occur in KB upon siCAS treatment for 24 h (Figure V-11A). This indicates
apoptotic cells and demonstrates the important role of CASP8AP2 for cell survival.
Furthermore, cell viability (Figure V-11B) and dead cells (floating in the cell medium)
(Figure V-11C) were measured via MTS assay and flow cytometry. From Figure V-11B,
less than 40% KB cells after 24h-treatments are alive. By contrast, KB cells incubated
with and without DharmaFECT are unaffected. Cell death induced by siCAS treatment
was further validated by counting the floated cells (death cells) collected from the cell
medium. Several thousands of cells died after treatment, compared to a few hundreds of
dead cells in normal situation (without any treatment) and DharmaFECT treatment.
Overall, the data demonstrate that CASP8AP2 is a favorable target for inducing apoptosis
through siRNA-triggered downregulation.

110

Figure V-11. Transfection of KB cells with siRNA against CASP8AP2 (siCAS).
(siCAS) A)
Confocal (63X oil lens) studies of morphological changes between the 1h and 24h post
transfection. The defragmented DNA is pointed by arrows. The nucleoli were stained by
Hoechst 33258 30 min before the imaging. Scale bar = 20 µm. B) Viability studies (MTS
assay) of the alive
ive cells after 48 h treatment of DharmaFECT/siCAS (concentration = 100
µM). The readout had been normalized to the non
non-treated
treated cells. C) Flow cytometer
counting of the dead cell after 48 h treatment. The medium and 22-time
time washed PBS were
collected and resuspended.
uspended. Equal volume of the samples was detected.

After confirming the crucial role of CASP8AP2 in maintaining cell survival,
FAPol13 was applied to delivery siCAS into KB cells ((Figure V-12)) and apoptosis was
assessed by Annexin V assay. Annexin V has a strong and specific affinity for
phosphatidylserine which is normally located at the inner (cytoplasmic) leaflet of the
plasma membrane. During the apoptotic process, phosphatidylserine will be translocated
from inner to outer leaflet and detected by FI
FITC-labeled
labeled annexin V conjugate. Therefore
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Annexin V assay is an easy and convenient method to evaluate and validate apoptosis by
fluorescence microscopy or flow cytometry. Besides, co-staining apoptotic cells with
propidium iodide (PI), a nucleic acid dye, can distinguish the cells that undergo apoptosis
at the early stage and last stage.
In Figure V-13A, x-axis is the fluorescence intensity from Annexin V-FITC
staining, whereas y-axis is the fluorescence intensity from PI staining. Q1-LL stands for
the live cells, Q1-LR and Q1-UR means early apoptotic cells and late apoptotic or
necrotic cells respectively. The data shows 93.4%, 44.3%, and 78.5% of cells are alive
upon non treatments, DharmaFECT/siCAS, and FAPol13/siCAS 2.5-day after treatment.
Statistical analysis of this assay (Figure V-12B) exhibits 92.4%, 45.5%, and 76.5%
accordingly. Intriguingly, approximate 24.5 % of KB cells have entered apoptotic
pathways upon FAPol13/siCAS treatment. By contrast, in normal situations, only 8% of
cells are under apoptosis.
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Figure V-12. Flow cytometric analyses of apoptosis upon FAPol13/siCAS treatment. KB
cells were planted into the 12
12-well
well plate 24 h with ~40% confluency. Cells were
transfected with the siCAS complexed with the DharmaFECT (Positive control, in the
middle panel), and FAPol13 (Right panel) according to the standard procedure (final
siRNA concentration = 100 µM) and treated for 2.5 days. The cells were detached,
rinsed, and stained with annexin V
V-fluorescein
fluorescein isothiocyanate (FITC) and propidium
iodide
odide (PI) before flow cytometer detection. A) The representative result from the coco
staining was plotted into the two
two-parameter
parameter histograms. The right part (Q1-up
(Q1
right (UR)
and Q1-low
low right (LR)) stood for collection of the apoptotic cells. B) Statistical analysis
of the survived KB cells after treatment. Mean ± SEM. (n=3). Student t-test
test was
performed by Graphpad Prism. *** (P<0.001), * (P<0.05).

Conclusions
siRNA-based
based therapy holds great potential to treat many types of diseases
including cancer. Efficient
ient and target cell
cell-specific
specific siRNA internalization to the cytoplasm
is the key for future therapeutic applications of siRNA.
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In this chapter we have demonstrated: (1) the efficient siRNA delivery via
FAPol13 into FR+ cells (i.e., KB, HeLa, and SKOV3); (2) the dose-dependent and FRdependent siRNA Delivery; (3) the significant gene down-regulation upon FAPol13
delivered siRNA against human survivin (~60%) and Gaussia luciferase (~70%); (4) the
non-toxicity of the FAPol13; (5) induction of KB cells into apoptosis upon FAPol13
delivered siCAS; (6) a CLSM-based effective system to assess siRNA intracellular
trafficking processes (cellular binding, endocytosis, and endosomal escape).
Taken together, the non-immunogenic and biocompatible folate-conjugated
copolymer FAPol13 may be used to construct efficient siRNA delivery systems for
cancer therapeutic applications.
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CHAPTER VI
CORRELATION OF FOLATE RECEPTOR EXPRESSION LEVEL
AND FAPOL13/SIRNA DELIVERY EFFICIENCY
Introduction
Folate receptor (FR), a glycosylphosphotidylinositol (GPI)-anchored glycoprotein,
specifically binds to its ligand, folate, with high affinity. 101s FR in human has at least
three homologous isoforms, hFR-α, hFR-β and hFR-γ with 70-80% amino acid similarity
in sequences 227 and distinct developmental expression patterns.134
The reduced-folate carrier (RFC) 228 is another folate transporter. RFC is a
membrane-spanning protein 131 and transports reduced folate into cells via carriermediated mechanism, distinct from receptor-mediated endocytosis of FR. Most of
classical antifolate drugs are rapidly transferred across the plasma membrane by this
mechanism, leading to inhibition of their target in both tumors and normal proliferating
tissues. 229
FR overexpresses in some epithelial tumors, such as ovary, cervical, mammary
gland, breast colon, prostate, lung, kidney, nose, throat, and brain etc; whereas it has a
restricted distribution in normal tissues. In addition, FR can bind with FA conjugates with
similar binding affinity and assist their transport across the plasma membrane via
endocytosis. These unique properties have been utilized to facilitate the delivery of a
broad range of therapeutic agents into various cancers.
Thus, FR-mediated system can specifically, efficiently deliver folate-drugs into FRpositive cancer cells to correct or eliminate aberrant gene expression. The expression of
FR on cell surface is the prerequisite to the success of therapeutics. Recently, evidence
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shows that a subtype of macrophage cell has elevated FR expression when encountered
stimuli, and importantly, its expression could vary upon the environment or situation
changes accordingly.101c Other finding displays that the expression of FR is also affected
by the surrounding FA concentration. 134 For example, the mRNA level of FR in KB and
JEG-3 cells doubles when folate concentration reduces. 134 In addition, FR expression
increases along with tumor progressing, 230 and FR expression patterns in tumor cell lines
could not reflect the virtual FR expression in vivo. 134 These findings suggest that the FR
expression level or patterns is critical for evaluating the utility potential of FR-mediated
delivery and predicting the outcomes of FR-targeted therapeutics.
A large body of evidence has shown high expression level of FR in KB cells and
negligible expression level in A549 cells, 231 which explains researchers use this pair of
cell lines as a model to illustrate the delivery of FA-conjugates. HeLa and SKOV3 are
both FR positive cell lines. In Chapter V, we have presented data to support the FRmediated delivery of FRPol13/siRNA into KB, HeLa, and SKOV3 cells. The findings
show the relatively low expression level of FR in HeLa and SKOV3 cells compared to
that of KB cells. However, the relationship of FR expression with binding efficiency,
uptake efficiency, and the overall RNAi efficacy remains elusive.
To address those issues, comparative studies have been employed among KB,
HeLa, SKOV3, and A549 cells. Firstly, FR mRNA and protein levels were quantified
through real-time PCR and flow cytometry. Secondly, the binding (2 h incubation) and
internalization (24 h incubation) of FAPol13/fluorophore labeled siRNAs were measured
via microscopy and flow cytometry. Thirdly, free FA competition assay were carried out
to “mimic” less FR availability would abolish the internalization of polyplexes. Lastly,
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luciferase assay was utilized to demonstrate that the RNAi effects from the internalized
siRNAs were also correlated with the FR expression in both transient and stable
transfection systems.

Result and Discussion
Quantification of FR Expression in Human Cancer Cell Lines
Firstly, real-time PCR was utilized to measure the human FR alpha gene (hFRα)
expression in KB, HeLa, SKOV3, and A549 cells (Figure VI-1A). As reported in Figure
IV-1, the A549 cells rarely express hFRα. Thus, the Ct value (the number of cycles
required for the fluorescence signals across the threshold) of hFRα in A549 about 15
cycles bigger than that of KB cells, indicating the nearly undetectable hFRα in this cell
line. Compared to the expression level of a human housekeeping gene, hFRα mRNA
level in A 549 cells is ~1.5 × 10-4 % of β-Actin mRNA level; whereas in KB cells hFRα
is 41% (Figure VI-1A).
Because FR protein is the direct executor for FA transportation, after determining
the mRNA expression level of hFRα, its protein level in 4 cell lines was further assessed
by flow cytometer (Figure VI-1B). To perform this experiment, a monoclonal antibody
against the human FR was utilized to recognize proteins on cell membrane, then the
secondary antibody, goat anti-mouse FITC conjugate antibody, was sequentially bind to
the primary antibody (mouse origin). The fluorescence from the FITC was detected by
flow cytometer. Through this procedure, the total FR protein level was obtained. To
facilitate the comparison, the ratio of FITC-fluorescence (Signal, S) over the autofluorescence (Noise, N, background) was plotted. The ratio should be correlative with the
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FR protein level. The S/N ratios in KB, HeLa, SKOV3 and A549 are 329.1, 166.0, 6.9,
and 1.7 respectively.

Figure VI-1. Comparison of hhuman folate receptor expression in cancer cells. (A) Realtime PCR analysis. (B) Flow
low cytometry quantification. The dataa represents mean ± S.D.
S
(n=4).

Comparison of thee expression of hFR
hFRα in mRNA and protein levels shows
similarity: KB>HeLa>SKOV3>>A549. Interestingly, in protein level, there is 4-fold
4
difference between SKOV3 and A549 cells. Whereas, in mRNA level, this is 9 Ct value
difference. Assuming PCR amplification efficiency is 100%, nine cycles equal to 200200
fold. This discrepancy would be explained by post
post-transcriptional
transcriptional modification, or postpost
translational modification mechanisms. Additionally, a group reported that hFRα
hFR mRNA
from KB cells is 4 fold of that in SKOV3 cells quantitated by PCR
PCR. 134 In our experiment,
there is 4.8 Ct difference (~32 fold). Regarding the heterogeneity of cells, the maintained
cell lines, the sensitivity
nsitivity of the regular PCR and real
real-time
time PCR, different expression level
from two groups is understandable.
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Quantification of the Absorption of FAPlo13/Cy3-(FAM-) siRNA in Cell Lines
Once we determined the different FR expression level among cell lines,
considering the FR-dependent delivery, we propose that different binding, uptake
efficiency of FAPol13/siRNA in cell lines would be variable accordingly. In addition, my
previous imaging studies had shown unequal associated fluorescence intensities from
these 4 cell lines. To confirm this hypothesis, the absorption (Figure VI-2) and
internalization (Figure VI-3) of FAPol13/siRNA polyplexes were evaluated in 4 cell lines
via fluorescence microscopy and flow cytometry.
In Figure VI-2, the data show that FAPol13/Cy3-siRNA (Figure VI-2 A-D) and
FAPol13/FAM-siRNA (Figure VI-2 E-H) bind with the FR+ positive cells after 2h
incubation. The associated fluorescence exhibited different intensities. KB cells have the
highest fluorescence intensity (FI), then the HeLa, and SKOV3. There is barely
fluorescence seen in A549 cell some from the nonspecific binding, which is common and
has been discussed in previous chapters. The associated fluorescence is then quantitated
by ImageJ software and plotted into the Figure VI-2 I (Cy3) and Figure VI-2 J (FAM).
All the FI has been subtracted to the background FI and normalized to the FI of A549 (FI
of A549 = 1). In Figure VI-2I, the relative FIs on KB, HeLa, and SKOV3 cells are 4.2,
3.4, and 1.8 respectively. Likewise, the relative FIs from FAM dyes on KB, HeLa, and
SKOV3 cells are 3.2, 2.8, and 2.6, which displays the same trends of absorbed
complexes: KB > HeLa > SKOV3 > A549.
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Figure VI-2. Fluorescence
luorescence intensity analysis of cellular bound FAPol13/siRNA.
FAPol13/siRNA The
siRNA is either Cy3 labeled (A
(A-D) or FAM labeled (E-H).
H). KB (A, E), HeLa (B, F),
SKOV3 (C, G) and A549 (D, H) cells were seeded onto glass
glass-bottomed
bottomed wells 24h before
transfection. FAPol13/siRNA complexes (final siRNA = 100 nM) incubated the cells for
2 hours. Cells were washed and imaged. (I, J)The
The associated fluorescence intensities (FI)
were quantified by ImageJ software, and plotted. The data represents mean ± SEM (n=4).
(
Scale bar = 10 µm.

Quantification of the Uptake
ptake of Polyplexes in Cell Lines
The absorption of the polyplexes by the cells will be followed by internalization if
the binding is specific. In Figure VI-2
2 we have demonstrated the different degrees of
binding of polyplexes in 4 cells lines. The distinct uptake/internalization of polyplexes
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follows the rationality and is examined here (Figure VI-3). Flow cytometer was applied
to quantitate the intercellular FAPol13/FAM-siRNA after 24 h incubation.
In Figure VI-3A, the black lines stand for the cell background (no treatment),
whereas the red lines are the samples. If the red line is on the right of black line, that
indicates the stronger fluorescence intensity. The internalization of polyplexes accounts
for this augment. In addition, the degree of right-shift in KB cells is slightly bigger than
that in HeLa cells and in SKOV3 cells. In A 549 cell, two lines are nearly overlapped,
suggesting non-internalization of polyplexes occurs in this FR negative cells.
The medium fluorescence intensity (MFI) from three repeats is measured and
plotted into Figure VI-3B, displaying 2666.9, 2408.0, 1782.2, 488.4 units in KB, HeLa,
SKOV3, and A549 cells respectively. If those numbers are normalized to A549, then the
ratios will be 5.5, 4.9, 3.7, and 1. This number can be depicted as, for example, 5.5 fold
polyplexes have been internalized into KB cells compared to A549 cells.
The trend of the internalized fluorescence and the trend of the bound fluorescence
are the same: KB> HeLa> SKOV3>A549. The difference, however, is not exactly the
same. That would result from FR expression variation from different cell passage
number, incubation time-associated the FR changes. Nevertheless, the trend from the
associated siRNA and internalized siRNA are consistent with FR expression level among
those four cell lines, indicating the correlation between the FR levels with the siRNA
delivery.
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Figure VI-3. Quantification of the internalized polyplexes in human cancer cells.
cells KB,
HeLa, SKOV3, and A549 were plated into plates one day before transfection with ~40%
confluency. FAPol13/FAM
FAPol13/FAM-siRNA
siRNA polyplexes (final siRNA concentration = 100 nM)
treated the cells for 24h before detection. A) The representative histogram plots of 4 cell
lines were exhibited. The black lines are the background signal (cellular autoauto
fluorescence); whereas the red lines are the signals from the samples. B) The mean
fluorescence intensity (MFI) from repeated experimen
experiments
ts was plotted. The data represents
mean ± SEM (n=3).

Inhibition of the Cellular
ellular Internalization of Polyplexes by Free Folic Acid
cid
In the previous results, we have demonstrated that the entry of FAPol13/siRNA to
KB is FR-dependent
dependent because: (1) the polyplexes
xes cannot enter the FR deficient A549 cells;
cells
(2)
2) the Pol13 (the copolymer carrier without FA conjugation) cannot deliver the siRNA;
(3)
3) the presence of FA (1 mM) blocks gene downregulation. However, the relationship of
FA concentration and inhibitive effe
effects
cts are not clear, especially in different cells with
various FR expression level.
To examine the correlation, free FA was added into the medium 1h before
transfection of FAPol13/FAM
FAPol13/FAM-siRNA
siRNA polyplexes (siRNA concentration = 100 nM) to
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make the final concentration of 1 mM, 0.2 mM, and 0.04 mM along with the control (no
treatment). After 24 h incubation, the cells were trypsinized and the internalized
complexes were evaluated by flow cytometer (Figure IV-4). As expected, the presence of
free FA greatly reduced the uptake of the polyplexes in the FR+ cells. In contrast, it
showed non-detectable effects in A549 cells. It is noted that a higher concentration of
free FA led to stronger inhibitive effects on the internalization.
6000
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4000
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Figure VI-4. Free folate inhibition assay. KB, HeLa, SKOV3, and A549 were seeded in
plates 24 h before transfection with ~40% confluency. One hour prior to the transfection,
free FA were added into the medium to make the final concentration 1 mM, 0.2 mM, and
0.04 mM. FAPol13/FAM-siRNA polyplexes treated and incubated the cells for 24h
before flow cytometry detection.

A calculation was performed based on the assumption that 1 mM of FA could
invariably block >99% of binding/uptake of FA conjugate 232. The results show that 95.7%
and 90.1% internalization of polyplexes in KB cells, 91.5% and 81.9% internalization of
polyplexes in HeLa cells; 85.6% and 54.7% internalization of polyplexes in SKOV3 are
blocked by incubation of 0.2 mM and 0.04 mM FA respectively. As for the expression
levels (Figure VI-1), a correlation is indicated that a higher expression of FR (e.g., in KB)
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is correlated with more activated FR-mediated uptake, and therefore stronger inhibition
effects from the competitor—FA. In other words, cancer cells with higher FR expression
are susceptible to the competition from free FA.
Studies of Gene Downregulation Efficiency in Cell Lines
Previous data indicate that the binding/update of polyplexes (Figure VI-2 and VI3) is correlative with the FR expression level (Figure VI-1), and the inhibition effect
from free FA is also relative to the FR expression level (Figure VI-4). RNAi effects from
the internalized siRNA should also follow this rule. To test it, both transient (Figure VI5) and stable (Figure VI-6) transfection have been implemented. The Gaussia luciferase
reporter system is utilized here because of its accurate, rapid, and sensitive measurement.
The principle and utility of transient transfection system have been discussed and
detailed in Chapter VI. In this case, four cell lines were transfected with the plasmid
pCMV-Gluc that encodes the Gaussia luciferase by conventional transfection agent —
DharmaFECT. The cells were rinsed 6 h later and waiting for second transfection. The
polyplexes (FAPol13/siGLuc) were added into the medium and incubated with cells for a
period of time (1 to 4 days) before the luciferase detection.

RelativeGluc Activity (%)
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Figure VI-5. Transient transfection of pCMV-Gluc and siGLuc in human cancer cells.
KB, HeLa, SKOV3, and A549 were seeded on the plates one day before the transfection
with ~40% confluency. The cells were first transfected with DharmaFECT/pCMV-Gluc
(1 µg) for 6 h. The medium was replaced and the cells were rinsed and incubated for 2 h.
FAPol13/siGLuc polyplexes (siRNA concentration = 100 nM) were prepared and added
into the medium. The Gluc activity was assessed at 1, 2, 3, and 4 day. The Relative Gluc
activity was normalized to non-siGLuc treated (plasmid transfected) control. The data
represents mean ± SEM (n=3).

As shown in Figure VI-5, the relative Gluc activity in A549 is barely affected
upon the siGLuc treatment in 4 days because FA-linked polyplexes cannot enter into FR
negative cells. In contrast, in all three FR positive cell lines, the relative Glu activities
have been reduced. In addition, along with time processes, RNAi effects increase. For
instance, in KB cells, 76%, 64%, 54%, 49% of Gluc activity remains after 1, 2, 3, and 4
day treatment. Importantly, at each time point, RNAi effect is correlated with the FR
expression level. For example, after 3-day incubation, Gluc activity has been reduced to
59%, 65%, 74%, and 91% in KB, HeLa, SKOV3 and A549 cells respectively. This
correlation between the RNAi effects and FR expression level suggests: (1) the FR-
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mediated siRNA uptake; (2) the FR expression level determines the therapeutic efficacy
of the delivered drugs.
To confirm the correlation between RNAi effects and FR expression, a new stable
cell line, SKOV3 cells that constitutively expresses Gluc, is established and denoted as
Gluc-SKOV3. Therefore, experiments were conducted in Gluc-KB and Gluc-SKOV3,
which have different expression level of FR. If the FR expression level is the key factor
for determining the downstream RNAi effects, the degrees of gene downregulation from
transfection of polyplexes should be distinct, and KB-Gluc should have better RNAi
efficacy.
To test this hypothesis, FAPol13/siGLuc (siRNA concentration = 100 nM)
polyplexes were transfected into Gluc-SKOV3 and Gluc-KB and the relative Gluc
activity was determined at 1 day and 2 days. As shown in Figure VI-6, after 2d
incubation of polyplexes, 35% and 65% Gluc activities remained in Gluc-KB and GlucSKOV3 respectively. Approximately, 60% and 80% Gluc activity remains in Gluc-KB
and Gluc-SKOV3 cells at 1d incubation. The findings shows better RNAi efficacy in
Gluc-KB cells compared to Gluc-SKOV3, suggesting a good correlation of FR
expression level with RNAi effects from FR-mediated siRNA delivery.
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Figure VI-6. Comparative studies of gene downregulation upon FAPol13/siGLuc
treatments in Gluc-KB and Gluc-SKOV3 cells. Cells were plated in plates one day before
transfection with ~40% confluency. Cells were transfected with polyplexes (siRNA
concentration = 100 nM) and incubated for two days. The Gluc activity was detected
after one and two day incubation by Gluc assay. The relative Gluc activity was calculated
by normalization of non-transfected controls. The data represents mean ± SEM (n=3).

Conclusions
Increasing lines of evidence show that FR expression on cell surfaces would vary
upon condition changes. High expression level of FR might be a key factor for successful
delivery of therapeutic drugs in tumors through FR-mediated strategies. To demonstrate
this concept, we take advantage of four human cancer cell lines: KB, HeLa, SKOV3 and
A549, which have different FR expression level, to study binding, internalization of
FAPol13-assisted siRNA delivery. Utilizing fluorescence microscopy and flow
cytometry, we have demonstrated a correlation between FR expression and efficiency of
binding and internalization of polyplexes in different cells. Subsequently, transient and
stable transfection systems combined with luciferase reporter were employed to study the
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gene downregulation of Gluc activity upon transfection with siRNA. The findings
confirmed the previous conclusion and strongly indicate that high FR expression level is
crucial for significant RNAi effects in FR-dependent siRNA delivery systems. The
competition studies suggest that low FR expression level or less available FR on the cell
surface will compromise the delivery efficiency.
Taking FAPol13 as a model, our results reveal a correlation between FR
expression and absorption/internalization of FA-functionalized therapeutic agents;
highlighting the importance of clarification of FR expression level when performing FRdependence drug delivery strategies. The finding suggests that we can increase delivery
efficiency and thereby enhance therapeutic effects through inducing FR expression (e.g.,
stimulation, folic acid starvation).

128

CHAPTER VII
DELIVERY OF AU NANOPARTICLE-SIRNA IN CANCER CELLS
Introduction
The nonviral siRNA delivery system, 92b, 233 such as liposome, dendrimers,
polycations (i.e., PEI), copolymers, and Au nanoparticles (AuNPs), harbors the several
advantages over the viral system, such as bio-safety, non-immunogenicity. 97a, 234
Typically, the nonviral siRNA carriers are cationic for the purpose of complexing with
anionic nucleic acid and increasing the transfection efficiency. Although the cationic
carrier/siRNA complexes (N/P > 1) have the higher delivery efficiency by the nature of
plasma membrane, their interactions with membrane and serum proteins that are required
for cell maintenance would result in non-specific binding or internalization, which
compromise the targetability of delivery. While the neutral complex (N/P = 1) hold the
equilibrium between the transfection efficiency and specificity: having higher delivery
efficiency than anionic complex, and higher specificity than cationic complex.
Over the past decades, AuNPs have been widely employed in chemistry, biology,
engineering, and medicine 235 by virtue of controllable size, shape, facile surface
modification, and unique optical properties. 235b Therefore, they have been applied to
imaging, optical and electrochemical sensing, diagnostics, and diseases therapy (e.g.,
cancer, Alzheimer, AIDS, hepatitis, arthritis, diabetes). 236 Recently, a few lines of
evidence display its great potential in delivering siRNA for cancer treatment. For
instance, Mirkin group synthesized and characterized a polyvalent AuNPs that are
modified with thiolated RNA duplexes and capable of inducing the RNAi pathway. 237
These highly anionic particles can enter into cells through absorbing of serum proteins
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(opsonization), rather the transfection reagent, which confers the cellular uptake and
sequential gene downregulation in HeLa cells. 237 Nagasaki group generated a type of
AuNP with poly(ethylene glycol)-block-poly(2-(N,N-dimethylamino)ethyl methacrylate)
copolymer (PEG-PAMA), which was further functionalized by immobilization of siRNA
bearing a thiol group. 238 The RNAi activity from the uptake of this AuNP-siRNA was
demonstrated in HuH-7 cells. 238
One main advantage of AuNPs as a scaffold for siRNA delivery is its high
loading capacity. For example, in case of FAPol13 (refer to Chapter V), there are 2-3
copolymer molecules per one 59-nt siRNA. However, an AuNP with ~13 nm gold core
can easily load up to dozens of siRNA cargoes. Through this, we can achieve much
higher intracellular siRNA concentration if the equal amounts of siRNA complexes have
been internalized.
Although promising, AuNPs have some drawbacks in synthesizing their
stabilizing ligands, which have the poorly-defined molecular weight (MW) control of
polymerization. Nevertheless, reversible addition-fragmentation chain transfer
polymerization, a controlled polymerization technique, has the abilities to control MW,
synthesize complex architectures (i.e., blocks, stars, grafts), and maintain a narrow
polydispersity. 188d, 239 A polymer stabilized AuNP had been rationally designed and
synthesized by this technique in our collaborative laboratory. 188d
In this AuNP, a copolymer poly(N-2-hydroxypropyl methacrylamide70-block-N[3-(dimethylamino)propyl] meth- acrylamide24) (P(HPMA70-b-DMAPMA24)) (Mn =
15000, PDI = 1.08) 188a is utilized as a AuNP stabilizing ligand. 188d P(HPMA) block is
chosen because: (1) its hydrophilicity prevents AuNP aggregation; (2) its stability confers
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the steric protection of siRNAs against the enzymatic degradation; (3) its neutral property
diminishes opsonization. On the other hand, the cationic DMAPMA block renders the
sites for the electrostatic complexation of anionic siRNA. These advantages of copolymer
have been elaborated in Chapter V when we discuss the properties of FAPol13.
As a result, this AuNP can encapsulate the therapeutic potential siRNAs
electrostatically and form neutral a soluble polyplexes, AuNP/siRNA. The AuNP/siRNAs
display significant stability in biological medium because the enzymatic tests
demonstrate approximately 100 times increased protection effects compared with free
siRNAs. 188d Additionally, AuNP/siRNAs readily enter a series of human cancer cells
without assistance from transfection agents, and knowdown Gluc expression in Gluc-KB
cells. 188d

Result and Discussion
The Characterization of AuNP
The surface charge and relevant hydrodynamic diameter (Dh) of the P(HPMA70-bDMAPMA24) and AuNP were measured by zeta potential and dynamic light scattering
(DLS) respectively. The zeta potential of P(HPMA70-b-DMAPMA24) and AuNP are 19
mV and -1.1 mV. As expected, P(HPMA70-b-DMAPMA24) has a positive surface change
due to the presence of cationic DMAPMA block. In contrast, P(HPMA70-b-DMAPMA24)
stabilized gold nanoparticle exhibits near-neutral zeta potential, indicating the DMAPMA
repeats are segregated close to the Au and hidden inside AuNPs as depicted in Scheme
VII-1. On the other side, the Dh of AuNP is 29 nm, significantly larger than the Dh of
P(HPMA70-b-DMAPMA24) which is 3.8 nm, further confirming the formation of
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complexed architecture as illustrated in Scheme VII-1. The augmented Dh of AuNPs is
presumably because after DMAPMA block interacts with the Au co
core,
re, the polymer
chains become extended due to steric repulsion
repulsion. Additionally, the diameter of Au core
(DAu) determined by transmission electron microscopy (TEM) and small
small--angle X-ray
scattering is 6.5 nm and 7.8 nm respectively 188d.

Scheme VII-1. Schematic depiction of AuNP/siRNA complexes formation.
formation 188d

Complexation of AuNP and siRNA
To test whether this AuNP has the ability of a gene delivery carrier, the
complexation with siRNAs was first explored. Due to the cationic property of the
t
DMAPMA, the siRNA will bind to this block and be close to the gold core as illustrated
in the Scheme VII-1. Because a fraction of the DMAPMA groups has been used to
reduce and activate Au, the preparation of N/P1
1 AuNP/siRNA polyplexes can’t be only
basedd on the calculated charge of AuNP. In another words, the actual N/P ratio of
complexes should be greater than 1.
To determine the neutral point, a series of AuNP/siRNA polyplexes were
complexed and analyzed by gel electrophoresis with ethidium bromide (EtBr)
(E
stain. The
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data show that the N/P ratio for neutral complexes is between 1.8 and 1.9 where siRNA is
restricted in the wells, suggesting approximate 46% of DMAPMA repeats have been
utilized for Au reduction, and 54% is available for siRNA complexation
complexation. 188d
Once the neutral point is determined, the available cationic change of DMAPAM
would be figured out and applied to future neutralization. Besides its ability of
complexing siRNAs, AuNP could also form a complex with plasmid DNAs as shown in
Figure VII-1.. Two plasmids, pCMV
pCMV-Gluc (5764 bp) and pAcGFP1-MemHyg
MemHyg (5846 bp)
which are used for stable cell line establishment discussed in Chapter IV are utilized to
exemplify it.

Figure VII-1. Agarose/EtBr electrophoresis analysis of AuNP
AuNP/plasmid complexes. Twp
plasmids, pCMV-Gluc
Gluc (left) and pAcGFP1
pAcGFP1-MemHyg (right), were complexed with
AuNP to form neutral
tral complexes according to the cationic change
ange of AuNP.
AuNP The
complexes were analyzed along with the uncomplexed plasmid. Each lane contains 33
pmol siRNA. Each lane contains approximate 166 ng plasmid DNA.

After complexation with the AuNP, siRNA acquires the capability to resist
RNase, which is confirmed by degradation studies
studies. 188d Briefly, the free and AuNP
complexed siRNA were exposed to a mixture of nucleases, RiboShredder RNase, and
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then assessed by UV/Vis spectroscopy monitored at 260 nm wavelength. If the
nucleotides are degraded, the absorbance increases. The results demonstrate that AuNP
confer ~100 fold long half-life time than that of the free siRNAs.188d
Uptake of AuNP/siRNA Complexes by Human Cancer Cells
The internalization of AuNP/siRNA complexes in several human cancer cells was
evaluated by fluorescence microscopy (Figure VII-2). The cell lines include KB, HeLa,
SKOV3 and A549 (refer to Chapters V and VI). The neutral complexes were prepared by
mixing AuNP and Cy3-labeled siRNA against human Survivin gene and added into
medium for 40 min. Following incubation, cells were rinsed thoroughly with pre-warmed
PBS for three times to remove free complexes and fixed by polyformaldehyde and
stained with DAPI. As seen in Figure VII-2 A-D, all cell lines treated with siRNA/AuNP
complexes exhibited red fluorescence, indicating internalization of siRNA. Since lacking
of FA conjugation, the complexes cannot distinguish the folate receptor positive cells
(KB, HeLa, SKOV3) and FR negative cell (A549), which is a principal difference
between this AuNP/siRNA and aforementioned FAPol13/siRNA. By contrast, the KB
cells treated with uncomplexed Cy3-siRNA display negligible fluorescence (Figure VII2E), suggesting the prerequisite of AuNP in siRNA delivery. Generally, some nonspecific
binding signals from the free fluorophore-labeled siRNA incubation will be observed
from such control panel. Here, such background has been normalized by adjusting the
contrast settings to all the images.
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Figure VII-2. Imaging analysis of the cellular uptake of AuNP/Cy3-siRNA
siRNA. (A) KB
cells, (B) HeLa cells, (C) SKOV3 cells, and (D) A549 cells were incubated with
complexes.. (E) KB cells incubated with uncomplexed Cy3
Cy3-siRNA
siRNA serves as a control.
The cells were plated onto the glass
glass-bottom
bottom wells 24 h before transfection. Then the
neutral complexes (N/P = 1.85) were added to the cell media to give 100 nM
concentration of cy3-labeled
labeled siRNA. After 40 min incubation, the cells were washed,
fixed with 4% paraformaldehyde, mounted, and stained with DAPI. The imaging was
conduct through Zeiss LSM 510 confocal with 40X/1.3 oil lens. Scale bars = 20 µm.
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Our data also show, surprisingly, serum proteins are dispensable for the uptake of
AuNP/siRNA complexes from the studies of fluorescence microscope and gene
downregulation (Figure VII-3). In contrast to the serum-dependent AuNP reported by
Mirkin group, 237 the difference presumably stems from the distinct surface properties of
complexes. In their work, thiolated siRNA is covalently conjugated to AuNPs which is
further coated with oligoethylene glycol-thiol (OEG-thiol) for stabilization; 237 while in
our system, siRNA electrostatically bind to cationic DMAPAM at Au core, and therefore
is physically excluded from serum proteins by extended, neutral, hydrophilic HPMA
blocks. In terms of that, our AuNP/siRNA is more stable and has less possibility to cause
non-specific uptake. Nevertheless, the mechanism for AuNP/siRNA internalization is not
well understood here and need to be further exploited.
Gene Downregulation by AuNP/siRNA Treatments in Gluc-KB Cells
Gene downregulation of a Gluc gene was performed to determine whether siRNA
could be released from the AuNP carrier once internalized. The reasons we choose this
reporter system has been elaborated in previous chapter. As well, a KB cell line stably
expressing Gaussia luciferase (Gluc-KB) was utilized here.
Complexes of the AuNP and siGLuc were prepared according to the results from
electrophoresis studies and incubated the Gluc-KB cells ([siGLuc] = 100 nM) for 6 h
before changing the cell medium. To test the potential opsonization effect from serum
proteins, cells were treated with complexes in the presence and absence of serum. The
luciferase assay was conducted with the medium samples by the virtue of the secretion of
the Gaussia luciferase after one-day incubation.
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In addition to the AuNP/siGLuc treatment, the cells have been tested with positive
and negative controls which contain Gluc-KB cells, siGLuc only, DharmaFECT
complexed control siRNA (has no siRNA target in mammalian cells), and DharmaFECT
complexed siGLuc. All the results have been normalized to the untreated Gluc-KB cells.
As shown in Figure VII-3, the Gluc activity has been reduced to 53% and 52% after
AuNP/siGLuc treatment with and without serum protein presence, confirming the update
of the complexes and the release of siRNAs from the complexes after internalization. As
expected, incubation of Gluc-KB with DharmaFECT/siCon and siGLuc only does not
induce the gene downregulation as a result of lacking of siRNA target and internalization
respectively. Additionally, siGLuc delivered via transfection agent DharmaFECT reduce
the Gluc activity to 48% of non-treatment control after one-day incubation, and to ~25%
after two-day incubation 101b, demonstrating the well-designed siRNA.
The moderate RNAi effects could presumably result from: (i) relative low
efficiency of uptake of complexes by cancer cells, which is indicated by low associated
fluorescence intensity (would be evaluated by flow cytometry and microscopy); (ii)
inadequate release of complexes from the compartments, which would be assessed by
colocalization analysis and quantified by PCC; (iii) insufficient dissociation of siRNA
from the complexes because of the steric hindrance from the polymer chains (i.e.,
HPMA). On the other hand, the similar gene downregulation efficiency from serumabsence treatment suggests that the delivery of AuNP/siRNA in our case is serumindependent as discussed before.
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Figure VII-3. Relative Gaussia luciferase (Gluc) protein expression level in Gluc-KB.
The Gluc-KB cells were seeded in 96-well plate with ~40% confluency 24 h before the
transfection. The preformed complexes or siRNA were then added into the cell medium
to make the siRNA concentration of 100 nM. The cell medium was changes 6 h later and
the cells were kept culturing for 18 h before luciferase activity assay conducted. The
experimental controls included non-treated, DharmaFECT/siCon, free siGLuc, and
DharmaFECT/siGLuc treated cells (from left to right). The neutral AuNPs/siGLuc
complexes (N/P = 1.85) treated the cells at the absence and present of 10% FCS. Protein
expression levels were measured 24 h after treatment. All experiments were repeated in
triplicate and the error bars represent ± S.D. (n=5).

Time course study shows the best gene downregulation efficiency from
AuNP/siGLuc occurs after one day, which is different from the two-day optimum of
FAPol13. This discrepancy suggests the distinct internalization mechanism and
trafficking processes between these two siRNA delivery strategies.
Nontoxic AuNP as a siRNA Carrier
After gene downregulation experiments, the cytotoxicity of AuNP were assessed
using a CellTitr 96 Aqueous one solution cell proliferation (MTS) assay, which is a
colorimetric method for determining the number of viable cells in cytotoxicity or
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proliferation. The principle of method has been discussed in Chapter IV. Basically, the
dehydrogenase in the viable cells can convert the MTS substrate to blue/brown formazan
which is detectable with a plate reader via monitoring absorbance at 490 nm (Ab490);
while the dying or dead cells cannot reduce the MTS and change the color. Importantly,
the quantity of product as measure by the amount of Ab490 is proportional to the number
of living cells.
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Figure VII-4. Cytotoxicity studies of Au nanoparticles (AuNPs). KB cells were first
seeded into a 96-well plate 24 h prior to treatment. Six different AuNP concentrations
ranging from 0.5 µM to 100 µM were tested and allowed to incubate for 48 h. A small
amount (20 µL) of the CellTiter 96 AQueous One Solution Reagent was added directly to
wells (100 µL) and incubated for 2 hours before recording Ab490 with Synergy 2 multimode microplate reader (BioTeck, Winooski, VT). The relative cell viability has been
normalized to the non-treated cells. All experiments were performed in triplicate, and
error bars represent ± S.D. The concentration of DMAPMA utilized in gene delivery
studies is 1 µM.

As shown in Figure VII-4, AuNP has negligible toxicity over the concentration
from 0.5 µM to 100 µM regarding the concentration of DMAPMA in the experiments is
1 µM (to make complexes with N/P=1.85, [siRNA] = 100 nM), suggesting that the AuNP

139

is cyto-friendly and suitable for gene delivery applications. These results are also in
agreement with morphological observations through microscopy. The biocompatibility of
AuNP is of fundamental importance for its potential therapeutic, and diagnostic
applications 236.

Conclusions
A rational design Au nanoparticle (P(HPMA70-b-DMAPMA24)) is reported here.
This copolymer is synthesized through aqueous RAFT polymerization and has a narrow
polydispersity (PDI=1.08), controlled MW (Mn = 15,000), dual-functionalized blocks
(HPMA for solubility, DMAPMA for polycation), and small size. This copolymer is
employed as stabilizing ligands of neutral Au nanoparticles (zeta potential = -1.1mV),
which have a high loading capability for oligonucleotides (siRNA duplexes and plasmid
DNA) through electrostatic effects. Additionally, the ability of the AuNPs as a siRNA
delivery vehicle has been intensively investigated and characterized by demonstrating
cellular uptake of complexes in a variety of human cancer cells without the aid of
transfection agents, and the downregulation of luciferase activity in Gluc-KB cells. Taken
together, these findings shred lights on the potential biomedical applications of this
AuNP.
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CHAPTER VIII
FUTURE RESEARCH
Although major aims of my research have been achieved, there are still some
aspects of investigations that deserve further exploitation, which are likely to lead to
other projects. Some remaining questions include: which mechanism of endocytosis
underlies the delivery of FApol13/siRNA and AuNP/siRNA, how to improve the efficacy
of endosomal release of FAPol13/siRNA complexes, when and where does the
dissociation of FApol13/siRNA occur, how to improve of inhibition effects of
FApol13/siCAS in cell level.

Exploration of Cell Entry Pathways
Essentially, there are at least five different routes for the entry of macromolecules
via endocytosis pathway: macropinocytosis, phagocytosis, clathrin-dependent
endocytosis, caveolae-dependent endocytosis, and clathrin/caveolae-independent
endocytosis. Among them, the clathrin-mediated and caveolae-mediated deliveries are
the major routes for the uptake of polyplexes and lipoplexes.
In recent years, numerous innovative drug/gene delivery strategies have emerged
and exhibited great potential in biomedical applications. In many systems, the mechanism
for the cellular internalization of complexes is mainly elusive. For example, in the cases
of peptide transduction domain (PTD)/dsRNA binding domain (DRBD)/siRNA delivery
system from Dowdy group, the serum protein-dependent AuNP from Mirkin group, and
serum protein-independent AuNP from our group, the membrane penetration machinery
is not well understood.
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To this issue, the specific inhibitors to certain enzymes that play roles in special
entry pathways are valuable and commonly utilized.240 Besides, the energy- or
temperature-dependence are usually characterized. Combining our expertise in
fluorescence imaging and colocalization analysis, we might gain plenty of valuable data
from conducting it.

Spatiotemporal Analysis of the Dissociation of FAPol13/siRNA
Our data have demonstrated that FAPol13/siRNA polyplexes can release from
endosome compartment through PCC-equipped colocalization analysis. However, when
and where dissociation of FAPol13/siRNA occurs in a cell is ambiguous. It is one of the
important steps for siRNA intracellular trafficking.
We have an opportunity to clarify it by utilizing a NHS-activated black hole
quencher (BHQ). BHQ is a dye with absorption range of 550-650 nm and an absorption
max at 579 nm. BHQ can be facilely conjugated to the backbone of a copolymer (i.e.,
FAPol13). Via complexation with Cy3-siRNA electrostatically, BHQ will quench the
fluorescence from Cy3 because of their overlapped emission spectrums. Furthermore, this
BHQ-conjugated FAPol13 can facilitate fluorescence resonance energy transfer (FRET)
analysis (Cy3: donor, BHQ: acceptor). When the Cy3-siRNA is encapsulated with BHQFAPol13, the fluorescence from Cy3 is invisible; upon release, fluorescence is restored.
According to this change, the dynamic process of dissociation of polyplex could be
calculated by FRET. In addition to the colocalization of endolysosome, we can determine
the cellular distribution of siRNAs or polyplexes. Taken together, the special and
temporal dissociation of polyplexes within a cell will be evaluated.
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Improvement of the Endosomal Escape of FAPol13/siRNA
Complex release in the endosome is the result of interplays between the complex,
siRNAs, carriers, and compartmental environment, and it is an efficiency-limiting step in
many nonviral delivery systems. Additionally, endosomal release plays a pivotal role in
connecting siRNA uptake and RNAi pathway, and insufficient release might be the major
reason for the fact that efficient binding and uptake of siRNA yield suboptimal siRNA
effects. 221, 241 To address this issue, efforts have been dedicated to conjugate pHstimulable, 242 temperature-sensible, 243 light-tiggerable, 244 fusogenic245 compounds with
nanocarriers for spatiotemporally controllable, enhanced releasing of therapeutic
cargoes.233
The PCC quantification (PCC48h = 0.51) of endosomal escape of FAPol13/siRNA
in KB indicates the possible insufficiency. Thus, the conjugation of some fusogenic
peptides with FAPol13 is recommended.

143

REFERENCES
1.
2.

3.
4.
5.
6.

7.

8.

9.
10.
11.
12.
13.
14.

Hanahan, D.; Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100 (1), 5770.
(a) Jemal, A.; Siegel, R.; Ward, E.; Hao, Y. P.; Xu, J. Q.; Thun, M. J., Cancer
Statistics, 2009. Ca-a Cancer Journal for Clinicians 2009, 59 (4), 225-249; (b) Ho,
Q. T.; Kuo, C. J., Vascular endothelial growth factor: biology and therapeutic
applications. Int J Biochem Cell Biol 2007, 39 (7-8), 1349-57.
Fitch, M. I.; Turner, F., Ovarian cancer. Can Nurse 2006, 102 (1), 16-20.
Yamamoto, H.; Ngan, C. Y.; Monden, M., Cancer cells survive with survivin.
Cancer Sci 2008, 99 (9), 1709-14.
Kerbel, R. S., Molecular origins of cancer: Tumor angiogenesis. New England
Journal of Medicine 2008, 358 (19), 2039-49.
(a) Song, S.; Liu, D.; Peng, J.; Sun, Y.; Li, Z.; Gu, J. R.; Xu, Y., Peptide ligandmediated liposome distribution and targeting to EGFR expressing tumor in vivo.
Int J Pharm 2008, 363 (1-2), 155-61; (b) Kim, B.; Tang, Q.; Biswas, P. S.; Xu, J.;
Schiffelers, R. M.; Xie, F. Y.; Ansari, A. M.; Scaria, P. V.; Woodle, M. C.; Lu, P.;
Rouse, B. T., Inhibition of ocular angiogenesis by siRNA targeting vascular
endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal
keratitis. Am J Pathol 2004, 165 (6), 2177-85.
(a) Antony, A. C., Folate receptors. Annu Rev Nutr 1996, 16, 501-21; (b) Kalli,
K. R.; Oberg, A. L.; Keeney, G. L.; Christianson, T. J.; Low, P. S.; Knutson, K.
L.; Hartmann, L. C., Folate receptor alpha as a tumor target in epithelial ovarian
cancer. Gynecol Oncol 2008, 108 (3), 619-26.
(a) Scholtka, B.; Schneider, M.; Melcher, R.; Katzenberger, T.; Friedrich, D.;
Berghof-Jager, K.; Scheppach, W.; Steinberg, P., A gene marker panel covering
the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene
mutations in 80% of early (UICC I) colon cancer stages in humans. Cancer
Epidemiol 2009, 33 (2), 123-9; (b) Salh, B.; Marotta, A.; Matthewson, C.;
Ahluwalia, M.; Flint, J.; Owen, D.; Pelech, S., Investigation of the Mek-MAP
kinase-Rsk pathway in human breast cancer. Anticancer Res 1999, 19 (1B), 73140.
Thornberry, N. A., Caspases: key mediators of apoptosis. Chem Biol 1998, 5 (5),
R97-103.
Shi, Y. G., Mechanisms of caspase activation and inhibition during apoptosis.
Molecular Cell 2002, 9 (3), 459-70.
Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W., Apoptosis: a link between cancer
genetics and chemotherapy. Cell 2002, 108 (2), 153-64.
Fukuda, S.; Pelus, L. M., Survivin, a cancer target with an emerging role in
normal adult tissues. Mol Cancer Ther 2006, 5 (5), 1087-98.
Sporn, M. B., The war on cancer. Lancet 1996, 347 (9012), 1377-81.
(a) Kinsella, A. R.; Green, B.; Lepts, G. C.; Hill, C. L.; Bowie, G.; Taylor, B. A.,
The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell
invasion and metastasis. Br J Cancer 1993, 67 (5), 904-9; (b) Behrens, J., The role
of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res
Treat 1993, 24 (3), 175-84.

144

15.

16.

17.
18.
19.

20.

21.

22.
23.
24.

25.
26.
27.
28.
29.
30.

31.

32.

Balakin, K. V.; Ivanenkov, Y. A.; Tkachenko, S. E.; Kiselyov, A. S.;
Ivachtchenko, A. V., Regulators of chemokine receptor activity as promising
anticancer therapeutics. Curr Cancer Drug Targets 2008, 8 (4), 299-340.
Qian, F.; Vaux, D. L.; Weissman, I. L., Expression of the integrin alpha 4 beta 1
on melanoma cells can inhibit the invasive stage of metastasis formation. Cell
1994, 77 (3), 335-47.
Burger, J. A.; Kipps, T. J., CXCR4: a key receptor in the crosstalk between tumor
cells and their microenvironment. Blood 2006, 107 (5), 1761-7.
Torchilin, V. P., Passive and active drug targeting: drug delivery to tumors as an
example. Handb Exp Pharmacol 2010, (197), 3-53.
Matsumura, Y.; Maeda, H., A new concept for macromolecular therapeutics in
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and
the antitumor agent smancs. Cancer Res 1986, 46 (12 Pt 1), 6387-92.
(a) Ferrara, N.; Gerber, H. P.; LeCouter, J., The biology of VEGF and its
receptors. Nat Med 2003, 9 (6), 669-76; (b) Ferrara, N., VEGF and the quest for
tumour angiogenesis factors. Nat Rev Cancer 2002, 2 (10), 795-803.
Tassi, E.; Wellstein, A., Tumor angiogenesis: initiation and targeting - therapeutic
targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator
of early stages of gastrointestinal adenocarcinomas. Cancer Res Treat 2006, 38
(4), 189-97.
Evan, G. I.; Vousden, K. H., Proliferation, cell cycle and apoptosis in cancer.
Nature 2001, 411 (6835), 342-8.
Taylor, A.; Powell, M. E., Intensity-modulated radiotherapy--what is it? Cancer
Imaging 2004, 4 (2), 68-73.
Sirikantaramas, S.; Asano, T.; Sudo, H.; Yamazaki, M.; Saito, K., Camptothecin:
therapeutic potential and biotechnology. Curr Pharm Biotechnol 2007, 8 (4), 196202.
Basili, S.; Moro, S., Novel camptothecin derivatives as topoisomerase I inhibitors.
Expert Opin Ther Pat 2009, 19 (5), 555-74.
Mayani, D. D., Proton therapy for cancer treatment. J Oncol Pharm Pract 2010.
Rochlitz, C. F., Gene therapy of cancer. Swiss Medical Weekly 2001, 131 (1-2),
4-9.
Blaese, R. M., Steps toward gene therapy: 1. The initial trials. Hosp Pract
(Minneap) 1995, 30 (11), 33-40.
El-Aneed, A., Current strategies in cancer gene therapy. Eur J Pharmacol 2004,
498 (1-3), 1-8.
Celli, J. P.; Spring, B. Q.; Rizvi, I.; Evans, C. L.; Samkoe, K. S.; Verma, S.;
Pogue, B. W.; Hasan, T., Imaging and photodynamic therapy: mechanisms,
monitoring, and optimization. Chem Rev 2010, 110 (5), 2795-838.
Bedognetti, D.; Wang, E.; Sertoli, M. R.; Marincola, F. M., Gene-expression
profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines
2010, 9 (6), 555-65.
Sone, S.; Kuramoto, T.; Sato, S.; Mitsuhashi, A.; Kakiuchi, S.; Goto, H.; Tada,
H.; Nishioka, Y., [Molecular targeted therapy for cancer]. Nippon Rinsho 2010,
68 (6), 997-1006.

145

33.

34.
35.

36.

37.

38.
39.

40.

41.

42.

43.

Christensen, C. L.; Zandi, R.; Gjetting, T.; Cramer, F.; Poulsen, H. S.,
Specifically targeted gene therapy for small-cell lung cancer. Expert Rev
Anticancer Ther 2009, 9 (4), 437-52.
Cohnheim, J., Congenitales, quergestreiftes Muskelsarkom der Nieren. Virchows
Archiv 1875, 65 (1), 64-69.
(a) Park, C. H.; Bergsagel, D. E.; McCulloch, E. A., Mouse myeloma tumor stem
cells: a primary cell culture assay. J. Natl. Cancer Inst. 1971, 46, 411-22; (b)
Makino, S., Further evidence favoring the concept of the stem cell in ascites
tumors of rats. Ann. NY Acad. Sci. 1956, 63, 818-30; (c) Bruce, W. R.; Van Der
Gaag, H., A Quantitative assay for the number of murine lymphoma cells capable
of proliferation in vivo. Nature 1963, 199, 79-80; (d) Kleinsmith, L. J.; Pierce, G.
B., Multipotentiality of single embryonal carcinoma cells. Cancer Res. 1964, 24,
1544-51.
(a) Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L., Stem cells, cancer,
and cancer stem cells. Nature 2001, 414 (6859), 105-11; (b) Al-Hajj, M.; Clarke,
M. F., Self-renewal and solid tumor stem cells. Oncogene 2004, 23 (43), 7274-82.
(a) Shimono, Y.; Zabala, M.; Cho, R. W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn,
M.; Liu, H.; Panula, S. P.; Chiao, E.; Dirbas, F. M.; Somlo, G.; Pera, R. A.; Lao,
K.; Clarke, M. F., Downregulation of miRNA-200c links breast cancer stem cells
with normal stem cells. Cell 2009, 138 (3), 592-603; (b) He, S.; Nakada, D.;
Morrison, S. J., Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol
2009, 25, 377-406; (c) Lobo, N. A.; Shimono, Y.; Qian, D.; Clarke, M. F., The
biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23, 675-99.
Polyak, K.; Hahn, W. C., Roots and stems: stem cells in cancer. Nat Med 2006,
12 (3), 296-300.
Blick, T.; Hugo, H.; Widodo, E.; Waltham, M.; Pinto, C.; Mani, S. A.; Weinberg,
R. A.; Neve, R. M.; Lenburg, M. E.; Thompson, E. W., Epithelial mesenchymal
transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia
2010, 15 (2), 235-52.
(a) Glinsky, G. V., Stem cell origin of death-from-cancer phenotypes of human
prostate and breast cancers. Stem Cell Rev 2007, 3 (1), 79-93; (b) Stingl, J.;
Caldas, C., Molecular heterogeneity of breast carcinomas and the cancer stem cell
hypothesis. Nat Rev Cancer 2007, 7 (10), 791-9; (c) Croce, C. M.; Calin, G. A.,
miRNAs, cancer, and stem cell division. Cell 2005, 122 (1), 6-7.
(a) Ebben, J. D.; Treisman, D. M.; Zorniak, M.; Kutty, R. G.; Clark, P. A.; Kuo, J.
S., The cancer stem cell paradigm: a new understanding of tumor development
and treatment. Expert Opin Ther Targets 2010, 14 (6), 621-32; (b) Donnenberg,
V. S.; Donnenberg, A. D., Multiple drug resistance in cancer revisited: the cancer
stem cell hypothesis. J Clin Pharmacol 2005, 45 (8), 872-7.
(a) Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T., Identification of
novel genes coding for small expressed RNAs. Science 2001, 294 (5543), 853-8;
(b) Ambros, V., microRNAs: tiny regulators with great potential. Cell 2001, 107
(7), 823-6.
Friedman, R. C.; Farh, K. K.; Burge, C. B.; Bartel, D. P., Most mammalian
mRNAs are conserved targets of microRNAs. Genome Res 2009, 19 (1), 92-105.

146

44.

45.

46.
47.

48.
49.

50.
51.

52.
53.

54.
55.

Filipowicz, W.; Bhattacharyya, S. N.; Sonenberg, N., Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet
2008, 9 (2), 102-14.
Berezikov, E.; van Tetering, G.; Verheul, M.; van de Belt, J.; van Laake, L.; Vos,
J.; Verloop, R.; van de Wetering, M.; Guryev, V.; Takada, S.; van Zonneveld, A.
J.; Mano, H.; Plasterk, R.; Cuppen, E., Many novel mammalian microRNA
candidates identified by extensive cloning and RAKE analysis. Genome Res
2006, 16 (10), 1289-98.
Riedmann, L. T.; Schwentner, R., miRNA, siRNA, piRNA and argonautes: news
in small matters. RNA Biol 2010, 7 (2), 133-9.
Valencia-Sanchez, M. A.; Liu, J.; Hannon, G. J.; Parker, R., Control of translation
and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006, 20 (5), 51524.
Moss, E. G., MicroRNAs: hidden in the genome. Curr Biol 2002, 12 (4), R13840.
(a) He, L.; He, X.; Lim, L. P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.;
Zender, L.; Magnus, J.; Ridzon, D.; Jackson, A. L.; Linsley, P. S.; Chen, C.;
Lowe, S. W.; Cleary, M. A.; Hannon, G. J., A microRNA component of the p53
tumour suppressor network. Nature 2007, 447 (7148), 1130-4; (b) Martello, G.;
Rosato, A.; Ferrari, F.; Manfrin, A.; Cordenonsi, M.; Dupont, S.; Enzo, E.;
Guzzardo, V.; Rondina, M.; Spruce, T.; Parenti, A. R.; Daidone, M. G.; Bicciato,
S.; Piccolo, S., A MicroRNA targeting dicer for metastasis control. Cell 2010, 141
(7), 1195-207; (c) Vidic, S.; Markelc, B.; Sersa, G.; Coer, A.; Kamensek, U.;
Tevz, G.; Kranjc, S.; Cemazar, M., MicroRNAs targeting mutant K-ras by
electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and
in vivo. Cancer Gene Ther 2010, 17 (6), 409-19; (d) Yu, F.; Yao, H.; Zhu, P.;
Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E.,
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007,
131 (6), 1109-23.
Tong, A. W.; Nemunaitis, J., Modulation of miRNA activity in human cancer: a
new paradigm for cancer gene therapy? Cancer Gene Ther 2008, 15 (6), 341-55.
(a) Mishra, P. J.; Merlino, G., MicroRNA reexpression as differentiation therapy
in cancer. J Clin Invest 2009, 119 (8), 2119-23; (b) Olive, V.; Bennett, M. J.;
Walker, J. C.; Ma, C.; Jiang, I.; Cordon-Cardo, C.; Li, Q. J.; Lowe, S. W.;
Hannon, G. J.; He, L., miR-19 is a key oncogenic component of mir-17-92. Genes
Dev 2009, 23 (24), 2839-49.
Zhang, B.; Pan, X.; Cobb, G. P.; Anderson, T. A., microRNAs as oncogenes and
tumor suppressors. Dev Biol 2007, 302 (1), 1-12.
Fire, A.; Xu, S.; Montgomery, M.; Kostas, S.; Driver, S.; Mello, C., Potent and
specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
Nature 1998, 391, 806-11.
Kim, D.; Rossi, J., Strategies for silencing human disease using RNA
interference. Nat Rev Genet 2007, 8, 173-84.
Mittal, V., Improving the efficiency of RNA interference in mammals. Nat Rev
Genet 2004, 5 (5), 355-65.

147

56.

57.

58.
59.
60.

61.

62.

63.

64.

65.

66.

67.
68.

69.

70.
71.

Napoli, C.; Lemieux, C.; Jorgensen, R., Introduction of a Chimeric Chalcone
Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous
Genes in trans. Plant Cell 1990, 2 (4), 279-89.
van der Krol, A. R.; Mur, L. A.; Beld, M.; Mol, J. N.; Stuitje, A. R., Flavonoid
genes in petunia: addition of a limited number of gene copies may lead to a
suppression of gene expression. Plant Cell 1990, 2 (4), 291-9.
Sharp, P. A., RNAi and double-strand RNA. Genes Dev 1999, 13 (2), 139-41.
Stark, G. R.; Kerr, I. M.; Williams, B. R.; Silverman, R. H.; Schreiber, R. D.,
How cells respond to interferons. Annu Rev Biochem 1998, 67, 227-64.
Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T.,
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured
mammalian cells. Nature 2001, 411 (6836), 494-8.
Kennerdell, J. R.; Carthew, R. W., Use of dsRNA-mediated genetic interference
to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell 1998,
95 (7), 1017-26.
Ngo, H.; Tschudi, C.; Gull, K.; Ullu, E., Double-stranded RNA induces mRNA
degradation in Trypanosoma brucei. Proc Natl Acad Sci U S A 1998, 95 (25),
14687-92.
(a) Yang, S.; Tutton, S.; Pierce, E.; Yoon, K., Specific double-stranded RNA
interference in undifferentiated mouse embryonic stem cells. Mol Cell Biol 2001,
21 (22), 7807-16; (b) Elbashir, S. M.; Harborth, J.; Weber, K.; Tuschl, T.,
Analysis of gene function in somatic mammalian cells using small interfering
RNAs. Methods 2002, 26 (2), 199-213.
Bernstein, E.; Caudy, A. A.; Hammond, S. M.; Hannon, G. J., Role for a bidentate
ribonuclease in the initiation step of RNA interference. Nature 2001, 409 (6818),
363-6.
Hammond, S. M.; Bernstein, E.; Beach, D.; Hannon, G. J., An RNA-directed
nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature
2000, 404 (6775), 293-6.
Martinez, J.; Patkaniowska, A.; Urlaub, H.; Luhrmann, R.; Tuschl, T., Singlestranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110
(5), 563-74.
Meister, G.; Tuschl, T., Mechanisms of gene silencing by double-stranded RNA.
Nature 2004, 431 (7006), 343-9.
Aravin, A.; Gaidatzis, D.; Pfeffer, S.; Lagos-Quintana, M.; Landgraf, P.; Iovino,
N.; Morris, P.; Brownstein, M. J.; Kuramochi-Miyagawa, S.; Nakano, T.; Chien,
M.; Russo, J. J.; Ju, J.; Sheridan, R.; Sander, C.; Zavolan, M.; Tuschl, T., A novel
class of small RNAs bind to MILI protein in mouse testes. Nature 2006, 442
(7099), 203-7.
(a) Eddy, S. R., Non-coding RNA genes and the modern RNA world. Nat Rev
Genet 2001, 2 (12), 919-29; (b) Hall, P. A.; Russell, S. H., New perspectives on
neoplasia and the RNA world. Hematol Oncol 2005, 23 (2), 49-53.
Pei, Y.; Tuschl, T., On the art of identifying effective and specific siRNAs. Nat
Methods 2006, 3 (9), 670-6.
Reynolds, A.; Anderson, E. M.; Vermeulen, A.; Fedorov, Y.; Robinson, K.;
Leake, D.; Karpilow, J.; Marshall, W. S.; Khvorova, A., Induction of the

148

72.

73.

74.

75.

76.

77.

78.

79.
80.
81.

82.

83.

84.
85.

interferon response by siRNA is cell type- and duplex length-dependent. RNA
2006, 12 (6), 988-93.
Holen, T.; Amarzguioui, M.; Wiiger, M. T.; Babaie, E.; Prydz, H., Positional
effects of short interfering RNAs targeting the human coagulation trigger Tissue
Factor. Nucleic Acids Res 2002, 30 (8), 1757-66.
Huesken, D.; Lange, J.; Mickanin, C.; Weiler, J.; Asselbergs, F.; Warner, J.;
Meloon, B.; Engel, S.; Rosenberg, A.; Cohen, D.; Labow, M.; Reinhardt, M.;
Natt, F.; Hall, J., Design of a genome-wide siRNA library using an artificial
neural network. Nat Biotechnol 2005, 23 (8), 995-1001.
(a) Saetrom, P.; Snove, O., Jr., A comparison of siRNA efficacy predictors.
Biochem Biophys Res Commun 2004, 321 (1), 247-53; (b) Zhao, H. F.; L'Abbe,
D.; Jolicoeur, N.; Wu, M.; Li, Z.; Yu, Z.; Shen, S. H., High-throughput screening
of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat
Methods 2005, 2 (12), 967-73.
(a) Chalk, A. M.; Warfinge, R. E.; Georgii-Hemming, P.; Sonnhammer, E. L.,
siRNAdb: a database of siRNA sequences. Nucleic Acids Res 2005, 33 (Database
issue), D131-4; (b) Truss, M.; Swat, M.; Kielbasa, S. M.; Schafer, R.; Herzel, H.;
Hagemeier, C., HuSiDa--the human siRNA database: an open-access database for
published functional siRNA sequences and technical details of efficient transfer
into recipient cells. Nucleic Acids Res 2005, 33 (Database issue), D108-11.
Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W. S.; Khvorova, A.,
Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22 (3), 32630.
Zamore, P. D.; Tuschl, T.; Sharp, P. A.; Bartel, D. P., RNAi: double-stranded
RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide
intervals. Cell 2000, 101 (1), 25-33.
Lum, L.; Yao, S.; Mozer, B.; Rovescalli, A.; Von Kessler, D.; Nirenberg, M.;
Beachy, P. A., Identification of Hedgehog pathway components by RNAi in
Drosophila cultured cells. Science 2003, 299 (5615), 2039-45.
Carpenter, A. E.; Sabatini, D. M., Systematic genome-wide screens of gene
function. Nat Rev Genet 2004, 5 (1), 11-22.
Sioud, M., Therapeutic siRNAs. Trends Pharmacol Sci 2004, 25 (1), 22-8.
Zhang, L.; Yang, N.; Mohamed-Hadley, A.; Rubin, S. C.; Coukos, G., Vectorbased RNAi, a novel tool for isoform-specific knock-down of VEGF and antiangiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003, 303
(4), 1169-78.
Takei, Y.; Kadomatsu, K.; Yuzawa, Y.; Matsuo, S.; Muramatsu, T., A small
interfering RNA targeting vascular endothelial growth factor as cancer
therapeutics. Cancer Res 2004, 64 (10), 3365-70.
Hughes, M. D.; Hussain, M.; Nawaz, Q.; Sayyed, P.; Akhtar, S., The cellular
delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001, 6
(6), 303-15.
Dorsett, Y.; Tuschl, T., siRNAs: applications in functional genomics and potential
as therapeutics. Nat Rev Drug Discov 2004, 3 (4), 318-29.
Behlke, M. A., Progress towards in vivo use of siRNAs. Mol Ther 2006, 13 (4),
644-70.

149

86.

87.
88.

89.
90.

91.
92.

93.
94.

95.

96.

97.

98.

Xie, F. Y.; Woodle, M. C.; Lu, P. Y., Harnessing in vivo siRNA delivery for drug
discovery and therapeutic development. Drug Discov Today 2006, 11 (1-2), 6773.
Kim, V. N., Small RNAs: classification, biogenesis, and function. Mol Cells
2005, 19 (1), 1-15.
(a) Lotze, M. T.; Kost, T. A., Viruses as gene delivery vectors: application to gene
function, target validation, and assay development. Cancer Gene Ther 2002, 9 (8),
692-9; (b) Ni, Y. H., In vivo hepatic gene therapy. Acta Paediatr Taiwan 2001, 42
(4), 191-200.
Ekblad, M.; Hallden, G., Adenovirus-based therapy for prostate cancer. Curr Opin
Mol Ther 2010, 12 (4), 421-31.
Brunetti-Pierri, N.; Ng, P., Progress and prospects: gene therapy for genetic
diseases with helper-dependent adenoviral vectors. Gene Ther 2008, 15 (8), 55360.
D'Costa, J.; Mansfield, S. G.; Humeau, L. M., Lentiviral vectors in clinical trials:
Current status. Curr Opin Mol Ther 2009, 11 (5), 554-64.
(a) Gao, K.; Huang, L., Nonviral methods for siRNA delivery. Mol Pharm 2009, 6
(3), 651-8; (b) Medina-Kauwe, L. K.; Xie, J.; Hamm-Alvarez, S., Intracellular
trafficking of nonviral vectors. Gene Ther 2005, 12 (24), 1734-51; (c) Pun, S.;
Davis, M., Development of a nonviral gene delivery vehicle for systemic
application. Bioconjug Chem 2002, 13, 630-39.
Smyth Templeton, N., Cationic liposomes as in vivo delivery vehicles. Curr Med
Chem 2003, 10 (14), 1279-87.
Boussif, O.; Lezoualc'h, F.; Zanta, M. A.; Mergny, M. D.; Scherman, D.;
Demeneix, B.; Behr, J. P., A versatile vector for gene and oligonucleotide transfer
into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A
1995, 92 (16), 7297-301.
Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A., RNAimediated gene-targeting through systemic application of polyethylenimine (PEI)complexed siRNA in vivo. Gene Ther 2005, 12, 461-66.
Thomas, M.; Lu, J. J.; Ge, Q.; Zhang, C.; Chen, J.; Klibanov, A. M., Full
deacylation of polyethylenimine dramatically boosts its gene delivery efficiency
and specificity to mouse lung. Proc Natl Acad Sci U S A 2005, 102 (16), 5679-84.
(a) York, A. W.; Kirkland, S. E.; McCormick, C. L., Advances in the synthesis of
amphiphilic block copolymers via RAFT polymerization: Stimuli-responsive drug
and gene delivery. Advanced Drug Delivery Reviews 2008, 60, 1018-1036; (b)
Park, T. G.; Jeong, J. H.; Kim, S. W., Current status of polymeric gene delivery
systems. Advanced Drug Delivery Reviews 2006, 58 (4), 467-486; (c) Pack, D.
W.; Hoffman, A. S.; Pun, S.; Stayton, P. S., Design and development of polymers
for gene delivery. Nature Reviews Drug Discovery 2005, 4 (7), 581-593; (d)
Kabanov, A. V.; Kabanov, V. A., Interpolyelectrolyte and block ionomer
complexes for gene delivery: physico-chemical aspects. Advanced Drug Delivery
Reviews 1998, 30, 49-60.
(a) Xia, C. F.; Boado, R. J.; Pardridge, W. M., Antibody-mediated targeting of
siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm
2009, 6 (3), 747-751; (b) Wen, W. H.; Liu, J. Y.; Qin, W. J.; Zhao, J.; Wang, T.;

150

99.

100.

Jia, L. T.; Meng, Y. L.; Gao, H.; Xue, C. F.; Jin, B. Q.; Yao, L. B.; Chen, S. Y.;
Yang, A. G., Targeted inhibition of HBV gene expression by single-chain
antibody mediated small interfering RNA delivery. Hepatology 2007, 46 (1), 8494; (c) Vornlocher, H. P., Antibody-directed cell-type-specific delivery of siRNA.
Trends Mol Med 2006, 12 (1), 1-3; (d) Song, E.; Zhu, P.; Lee, S. K.; Chowdhury,
D.; Kussman, S.; Dykxhoorn, D. M.; Feng, Y.; Palliser, D.; Weiner, D. B.;
Shankar, P.; Marasco, W. A.; Lieberman, J., Antibody mediated in vivo delivery
of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23 (6),
709-17; (e) Liu, H.; Rajasekaran, A.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.;
Rahmati, R.; Bander, N., Constitutive and antibody-induced internalization of
prostate-specific membrane antigen. Cancer Res 1998, 58, 4055-60; (f) De Potter,
C. R.; Schelfhout, A. M.; De Smet, F. H.; Van Damme, S.; de Ridder, L.; Dhont,
E.; van Emmelo, J., A monoclonal antibody directed against a human cell
membrane antigen prevents cell substrate adhesion and tumor invasion. Am J
Pathol 1994, 144 (1), 95-103; (g) Courtete, J.; Sibler, A. P.; Zeder-Lutz, G.;
Dalkara, D.; Oulad-Abdelghani, M.; Zuber, G.; Weiss, E., Suppression of cervical
carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6
antibody and small interfering RNA. Mol Cancer Ther 2007, 6 (6), 1728-35.
(a) Pangburn, T. O.; Petersen, M. A.; Waybrant, B.; Adil, M. M.; Kokkoli, E.,
Peptide- and aptamer-functionalized nanovectors for targeted delivery of
therapeutics. J Biomech Eng 2009, 131 (7), 074005; (b) Pandey, K. N., Ligandmediated endocytosis and intracellular sequestration of guanylyl
cyclase/natriuretic peptide receptors: role of GDAY motif. Mol Cell Biochem
2009; (c) Liu, S., Radiolabeled multimeric cyclic RGD peptides as integrin
alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3 (5), 47287; (d) Blackburn, W. H.; Dickerson, E. B.; Smith, M. H.; McDonald, J. F.; Lyon,
L. A., Peptide-Functionalized Nanogels for Targeted siRNA Delivery. Bioconjug
Chem 2009, 20 (5), 960-8.
(a) Ng, E. W.; Shima, D. T.; Calias, P.; Cunningham, E. T., Jr.; Guyer, D. R.;
Adamis, A. P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular
disease. Nat Rev Drug Discov 2006, 5 (2), 123-32; (b) McNamara, J.; Andrechek,
E.; Wang, Y.; Viles, K.; Rempel, R.; Gilboa, E.; Sullenger, B.; Giangrande, P.,
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat
Biotechnol 2006, 24, 1005-15; (c) Levy-Nissenbaum, E.; Radovic-Moreno, A.;
Wang, A.; Langer, R.; Farokhzad, O., Nanotechnology and aptamers: applications
in drug delivery. Trends Biotechnol 2008, 26, 442-9; (d) Hicke, B.; Stephens, A.;
Gould, T.; Chang, Y.; Lynott, C.; Heil, J.; Borkowski, S.; Hilger, C.; Cook, G.;
Warren, S.; Schmidt, P., Tumor targeting by an aptamer. J Nucl Med 2006, 47,
668-78; (e) Ferreira, C.; Cheung, M.; Missailidis, S.; Bisland, S.; Gariepy, J.,
Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic
Acids Res 2009, 37, 866-76; (f) Barbas, A. S.; Mi, J.; Clary, B. M.; White, R. R.,
Aptamer applications for targeted cancer therapy. Future Oncol 2010, 6 (7), 111726; (g) Bagalkot, V.; Farokhzad, O.; Langer, R.; Jon, S., An aptamer-doxorubicin
physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int
Ed Engl 2006, 45, 8149-152.

151

101.

(a) York, A. W.; Huang, F.; McCormick, C. L., Rational Design of Targeted
Cancer Therapeutics through the Multiconjugation of Folate and Cleavable
siRNA to RAFT-Synthesized (HPMA-s-APMA) Copolymers.
Biomacromolecules 2010, 11 (2) 505-14; (b) York, A. W.; Zhang, Y.; Holley, A.
C.; Guo, Y.; Huang, F.; McCormick, C. L., Facile synthesis of multivalent folateblock copolymer conjugates via aqueous RAFT polymerization: targeted delivery
of siRNA and subsequent gene suppression. Biomacromolecules 2009, 10 (4),
936-43; (c) Xia, W.; Hilgenbrink, A. R.; Matteson, E. L.; Lockwood, M. B.;
Cheng, J. X.; Low, P. S., A functional folate receptor is induced during
macrophage activation and can be used to target drugs to activated macrophages.
Blood 2009, 113 (2), 438-46; (d) Low, P. S.; Kularatne, S. A., Folate-targeted
therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009, 13 (3),
256-62; (e) Yoshizawa, T.; Hattori, Y.; Hakoshima, M.; Koga, K.; Maitani, Y.,
Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor
xenografts. European Journal of Pharmaceutics and Biopharmaceutics 2008, 70
(3), 718-25; (f) Sega, E. I.; Low, P. S., Tumor detection using folate receptortargeted imaging agents. Cancer Metastasis Rev 2008, 27 (4), 655-64; (g) Lu, Y.;
You, F.; Vlahov, I.; Westrick, E.; Fan, M.; Low, P. S.; Leamon, C. P., Folatetargeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on
antitumor activity and allergic potential. Mol Pharm 2007, 4 (5), 695-706; (h)
Hwa Kim, S.; Hoon Jeong, J.; Chul Cho, K.; Wan Kim, S.; Gwan Park, T.,
Target-specific gene silencing by siRNA plasmid DNA complexed with folatemodified poly(ethylenimine). J Control Release 2005, 104 (1), 223-32; (i) Low, P.
S.; Antony, A. C., Folate receptor-targeted drugs for cancer and inflammatory
diseases. Adv Drug Deliv Rev 2004, 56 (8), 1055-8; (j) Leamon, C. P.; Reddy, J.
A., Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004, 56 (8), 1127-41; (k)
Reddy, J. A.; Low, P. S., Enhanced folate receptor mediated gene therapy using a
novel pH-sensitive lipid formulation. J Control Release 2000, 64 (1-3), 27-37; (l)
Lee, R. J.; Low, P. S., Delivery of liposomes into cultured KB cells via folate
receptor-mediated endocytosis. J Biol Chem 1994, 269 (5), 3198-204; (m)
Leamon, C. P.; Low, P. S., Selective targeting of malignant cells with cytotoxinfolate conjugates. J Drug Target 1994, 2 (2), 101-12; (n) Turek, J. J.; Leamon, C.
P.; Low, P. S., Endocytosis of folate-protein conjugates: ultrastructural
localization in KB cells. J Cell Sci 1993, 106 ( Pt 1), 423-30; (o) Leamon, C. P.;
Pastan, I.; Low, P. S., Cytotoxicity of folate-Pseudomonas exotoxin conjugates
toward tumor cells. Contribution of translocation domain. J Biol Chem 1993, 268
(33), 24847-54; (p) Leamon, C. P.; Low, P. S., Membrane folate-binding proteins
are responsible for folate-protein conjugate endocytosis into cultured cells.
Biochem J 1993, 291 ( Pt 3), 855-60; (q) Leamon, C. P.; Low, P. S., Cytotoxicity
of momordin-folate conjugates in cultured human cells. J Biol Chem 1992, 267
(35), 24966-71; (r) Leamon, C. P.; Low, P. S., Delivery of macromolecules into
living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad
Sci U S A 1991, 88 (13), 5572-6; (s) Campbell, I. G.; Jones, T. A.; Foulkes, W.
D.; Trowsdale, J., Folate-binding protein is a marker for ovarian cancer. Cancer
Res 1991, 51 (19), 5329-38.

152

102.
103.
104.
105.

106.

107.

108.

109.
110.

111.

112.

113.

Daugherty, A. L.; Mrsny, R. J., Formulation and delivery issues for monoclonal
antibody therapeutics. Adv Drug Deliv Rev 2006, 58 (5-6), 686-706.
Yu, B.; Zhao, X.; Lee, L. J.; Lee, R. J., Targeted delivery systems for
oligonucleotide therapeutics. AAPS J 2009, 11 (1), 195-203.
Baker, M., Upping the ante on antibodies. Nat Biotechnol 2005, 23 (9), 1065-72.
(a) Venisnik, K. M.; Olafsen, T.; Gambhir, S. S.; Wu, A. M., Fusion of Gaussia
luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in
vivo optical imaging. Mol Imaging Biol 2007, 9 (5), 267-77; (b) Kwong, P.;
Wyatt, R.; Robinson, J.; Sweet, R.; Sodroski, J.; Hendrickson, W., Structure of an
HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 1998, 393, 648-59.
Abes, S.; Moulton, H.; Turner, J.; Clair, P.; Richard, J. P.; Iversen, P.; Gait, M. J.;
Lebleu, B., Peptide-based delivery of nucleic acids: design, mechanism of uptake
and applications to splice-correcting oligonucleotides. Biochem Soc Trans 2007,
35 (Pt 1), 53-5.
Midoux, P.; Pichon, C.; Yaouanc, J. J.; Jaffres, P. A., Chemical vectors for gene
delivery: a current review on polymers, peptides and lipids containing histidine or
imidazole as nucleic acids carriers. Br J Pharmacol 2009, 157 (2), 166-78.
(a) Wu, X.; Yan, Q.; Huang, Y.; Huang, H.; Su, Z.; Xiao, J.; Zeng, Y.; Wang, Y.;
Nie, C.; Yang, Y.; Li, X., Isolation of a novel basic FGF-binding peptide with
potent antiangiogenetic activity. J Cell Mol Med 2010, 14 (1-2), 351-6; (b) Abes,
S.; Ivanova, G. D.; Abes, R.; Arzumanov, A. A.; Williams, D.; Owen, D.; Lebleu,
B.; Gait, M. J., Peptide-based delivery of steric-block PNA oligonucleotides.
Methods Mol Biol 2009, 480, 85-99; (c) Meade, B. R.; Dowdy, S. F., Exogenous
siRNA delivery using peptide transduction domains/cell penetrating peptides.
Adv Drug Deliv Rev 2007, 59 (2-3), 134-40; (d) Abes, R.; Arzumanov, A. A.;
Moulton, H. M.; Abes, S.; Ivanova, G. D.; Iversen, P. L.; Gait, M. J.; Lebleu, B.,
Cell-penetrating-peptide-based delivery of oligonucleotides: an overview.
Biochem Soc Trans 2007, 35 (Pt 4), 775-9.
Ikeda, Y.; Taira, K., Ligand-targeted delivery of therapeutic siRNA. Pharm Res
2006, 23 (8), 1631-40.
(a) Eble, J. A., Collagen-binding integrins as pharmaceutical targets. Curr Pharm
Des 2005, 11 (7), 867-80; (b) Vanderslice, P.; Woodside, D. G., Integrin
antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs
2006, 15 (10), 1235-55.
Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.;
Lu, P. Y.; Scaria, P. V.; Woodle, M. C., Cancer siRNA therapy by tumor selective
delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res
2004, 32 (19), e149.
Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F., In vivo protein
transduction: delivery of a biologically active protein into the mouse. Science
1999, 285 (5433), 1569-72.
Chiu, Y. L.; Ali, A.; Chu, C. Y.; Cao, H.; Rana, T. M., Visualizing a correlation
between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol
2004, 11 (8), 1165-75.

153

114.

115.
116.

117.

118.
119.

120.

121.

122.

123.

124.

125.

Rudolph, C.; Plank, C.; Lausier, J.; Schillinger, U.; Muller, R. H.; Rosenecker, J.,
Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of
transferring plasmid DNA into cells. J Biol Chem 2003, 278 (13), 11411-8.
Juliano, R. L., Intracellular delivery of oligonucleotide conjugates and dendrimer
complexes. Ann N Y Acad Sci 2006, 1082, 18-26.
Kang, H.; DeLong, R.; Fisher, M. H.; Juliano, R. L., Tat-conjugated PAMAM
dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm
Res 2005, 22 (12), 2099-106.
Kumar, P.; Wu, H.; McBride, J. L.; Jung, K. E.; Kim, M. H.; Davidson, B. L.;
Lee, S. K.; Shankar, P.; Manjunath, N., Transvascular delivery of small
interfering RNA to the central nervous system. Nature 2007, 448 (7149), 39-43.
Zhou, J.; Rossi, J., Aptamer-targeted cell-specific RNA interference. Silence
2010, 1 (1), 4.
Tuerk, C.; Gold, L., Systematic evolution of ligands by exponential enrichment:
RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249 (4968),
505-10.
(a) Zhang, Y.; Chen, Y.; Han, D.; Ocsoy, I.; Tan, W., Aptamers selected by cellSELEX for application in cancer studies. Bioanalysis 2010, 2 (5), 907-918; (b)
Sefah, K.; Shangguan, D.; Xiong, X.; O'Donoghue, M. B.; Tan, W., Development
of DNA aptamers using Cell-SELEX. Nat Protoc 2010, 5 (6), 1169-85; (c) Fang,
X.; Tan, W., Aptamers generated from cell-SELEX for molecular medicine: a
chemical biology approach. Acc Chem Res 2010, 43 (1), 48-57.
(a) Zhou, J.; Swiderski, P.; Li, H.; Zhang, J.; Neff, C.; Akkina, R.; Rossi, J.,
Selection, characterization and application of new RNA HIV gp 120 aptamers for
facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids
Res 2009, 37, 3094-109; (b) Zhou, J.; Li, H.; Li, S.; Zaia, J.; Rossi, J., Novel dual
inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther
2008, 16, 1481-9; (c) Wullner, U.; Neef, I.; Eller, A.; Kleines, M.; Tur, M.; Barth,
S., Cell-specific induction of apoptosis by rationally designed bivalent aptamersiRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug
Targets 2008, 8, 554-65; (d) Dassie, J.; Liu, X.; Thomas, G.; Whitaker, R.; Thiel,
K.; Stockdale, K.; Meyerholz, D.; McCaffrey, A.; McNamara, J.; Giangrande, P.,
Systemic administration of optimized aptamer-siRNA chimeras promotes
regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27, 839-49.
Chen, C. H.; Dellamaggiore, K. R.; Ouellette, C. P.; Sedano, C. D.; Lizadjohry,
M.; Chernis, G. A.; Gonzales, M.; Baltasar, F. E.; Fan, A. L.; Myerowitz, R.;
Neufeld, E. F., Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl
Acad Sci U S A 2008, 105 (41), 15908-13.
Tong, G.; Hsiao, S.; Carrico, Z.; Francis, M., Viral capsid DNA aptamer
conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 2009, 131,
11174-8.
Chu, T.; Marks, J.; Lavery, L.; Faulkner, S.; Rosenblum, M.; Ellington, A.; Levy,
M., Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer
Res 2006, 66, 5989-92.
Mi, J.; Zhang, X.; Rabbani, Z. N.; Liu, Y.; Reddy, S. K.; Su, Z.; Salahuddin, F.
K.; Viles, K.; Giangrande, P. H.; Dewhirst, M. W.; Sullenger, B. A.; Kontos, C.

154

126.

127.

128.

129.
130.

131.
132.

133.

134.
135.

136.

137.
138.

139.
140.

D.; Clary, B. M., RNA aptamer-targeted inhibition of NF-kappa B suppresses
non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008, 16 (1), 6673.
Lupold, S.; Hicke, B.; Lin, Y.; Coffey, D., Identification and characterization of
nuclease-stabilized RNA molecules that bind human prostate cancer cells via the
prostate-specific membrane antigen. Cancer Res 2002, 62, 4029-33.
Clifford, A. J.; Arjomand, A.; Dueker, S. R.; Schneider, P. D.; Buchholz, B. A.;
Vogel, J. S., The dynamics of folic acid metabolism in an adult given a small
tracer dose of 14C-folic acid. Adv Exp Med Biol 1998, 445, 239-51.
de Crecy-Lagard, V.; El Yacoubi, B.; de la Garza, R. D.; Noiriel, A.; Hanson, A.
D., Comparative genomics of bacterial and plant folate synthesis and salvage:
predictions and validations. BMC Genomics 2007, 8, 245.
Jackman, A. L.; Theti, D. S.; Gibbs, D. D., Antifolates targeted specifically to the
folate receptor. Adv Drug Deliv Rev 2004, 56 (8), 1111-25.
Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M.,
Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997, 74
(2), 193-8.
Kamen, B. A.; Capdevila, A., Receptor-mediated folate accumulation is regulated
by the cellular folate content. Proc Natl Acad Sci U S A 1986, 83 (16), 5983-7.
Shen, F.; Ross, J. F.; Wang, X.; Ratnam, M., Identification of a novel folate
receptor, a truncated receptor, and receptor type beta in hematopoietic cells:
cDNA cloning, expression, immunoreactivity, and tissue specificity.
Biochemistry 1994, 33 (5), 1209-15.
Reddy, J. A.; Haneline, L. S.; Srour, E. F.; Antony, A. C.; Clapp, D. W.; Low, P.
S., Expression and functional characterization of the beta-isoform of the folate
receptor on CD34(+) cells. Blood 1999, 93 (11), 3940-8.
Lee, R. J.; Wang, S.; Low, P. S., Measurement of endosome pH following folate
receptor-mediated endocytosis. Biochim Biophys Acta 1996, 1312 (3), 237-42.
Low, P. S.; Henne, W. A.; Doorneweerd, D. D., Discovery and Development of
Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and
Inflammatory Diseases. Acc Chem Res 2008, 41 (1), 120-9.
(a) Rijnboutt, S.; Jansen, G.; Posthuma, G.; Hynes, J. B.; Schornagel, J. H.;
Strous, G. J., Endocytosis of GPI-linked membrane folate receptor-alpha. J Cell
Biol 1996, 132 (1-2), 35-47; (b) Smart, E. J.; Mineo, C.; Anderson, R. G.,
Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of
MA104 cells. J Cell Biol 1996, 134 (5), 1169-77.
Lu, Y.; Low, P. S., Folate-mediated delivery of macromolecular anticancer
therapeutic agents. Adv Drug Deliv Rev 2002, 54 (5), 675-93.
Bueno, R.; Appasani, K.; Mercer, H.; Lester, S.; Sugarbaker, D., The alpha folate
receptor is highly activated in malignant pleural mesothelioma. J Thorac
Cardiovasc Surg 2001, 121 (2), 225-33.
Leamon, C. P.; DePrince, R. B.; Hendren, R. W., Folate-mediated drug delivery:
effect of alternative conjugation chemistry. J Drug Target 1999, 7 (3), 157-69.
Ebel, W.; Routhier, E. L.; Foley, B.; Jacob, S.; McDonough, J. M.; Patel, R. K.;
Turchin, H. A.; Chao, Q.; Kline, J. B.; Old, L. J.; Phillips, M. D.; Nicolaides, N.
C.; Sass, P. M.; Grasso, L., Preclinical evaluation of MORAb-003, a humanized

155

141.

142.

143.

144.

145.

146.
147.
148.

149.
150.
151.

monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007, 7,
6.
Low, P. S.; Henne, W. A.; Doorneweerd, D. D., Discovery and development of
folic-acid-based receptor targeting for imaging and therapy of cancer and
inflammatory diseases. Acc Chem Res 2008, 41 (1), 120-9.
Reddy, J. A.; Dorton, R.; Dawson, A.; Vetzel, M.; Parker, N.; Nicoson, J. S.;
Westrick, E.; Klein, P. J.; Wang, Y.; Vlahov, I. R.; Leamon, C. P., In Vivo
Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates.
Molecular Pharmaceutics 2009, 6 (5), 1518-25.
Leamon, C. P.; Reddy, J. A.; Vetzel, M.; Dorton, R.; Westrick, E.; Parker, N.;
Wang, Y.; Vlahov, I., Folate targeting enables durable and specific antitumor
responses from a therapeutically null tubulysin B analogue. Cancer Res 2008, 68
(23), 9839-44.
Reddy, J. A.; Westrick, E.; Santhapuram, H. K.; Howard, S. J.; Miller, M. L.;
Vetzel, M.; Vlahov, I.; Chari, R. V.; Goldmacher, V. S.; Leamon, C. P., Folate
receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Cancer Res 2007, 67 (13), 6376-82.
(a) Vlahov, I. R.; Santhapuram, H. K.; You, F.; Wang, Y.; Kleindl, P. J.; Hahn, S.
J.; Vaughn, J. F.; Reno, D. S.; Leamon, C. P., Carbohydrate-based synthetic
approach to control toxicity profiles of folate-drug conjugates. J Org Chem 2010,
75 (11), 3685-91; (b) Reddy, J. A.; Dorton, R.; Westrick, E.; Dawson, A.; Smith,
T.; Xu, L. C.; Vetzel, M.; Kleindl, P.; Vlahov, I. R.; Leamon, C. P., Preclinical
evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007, 67 (9),
4434-2; (c) Li, J.; Sausville, E. A.; Klein, P. J.; Morgenstern, D.; Leamon, C. P.;
Messmann, R. A.; LoRusso, P., Clinical pharmacokinetics and exposure-toxicity
relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin
Pharmacol 2009, 49 (12), 1467-76; (d) Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.;
Westrick, E.; Parker, N.; Nicoson, J. S.; Vetzel, M., Comparative preclinical
activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J
Cancer 2007, 121 (7), 1585-92.
Reddy, J. A.; Low, P. S., Folate-mediated targeting of therapeutic and imaging
agents to cancers. Crit Rev Ther Drug Carrier Syst 1998, 15 (6), 587-627.
Lee, R. J.; Low, P. S., Folate-mediated tumor cell targeting of liposome-entrapped
doxorubicin in vitro. Biochim Biophys Acta 1995, 1233 (2), 134-44.
Paulos, C. M.; Turk, M. J.; Breur, G. J.; Low, P. S., Folate receptor-mediated
targeting of therapeutic and imaging agents to activated macrophages in
rheumatoid arthritis. Adv Drug Deliv Rev 2004, 56 (8), 1205-17.
Oh, Y. K.; Park, T. G., siRNA delivery systems for cancer treatment. Adv Drug
Deliv Rev 2009, 61 (10), 850-62.
Ashihara, E.; Kawata, E.; Maekawa, T., Future prospect of RNA interference for
cancer therapies. Curr Drug Targets 2010, 11 (3), 345-60.
Pradeep, C. R.; Sunila, E. S.; Kuttan, G., Expression of vascular endothelial
growth factor (VEGF) and VEGF receptors in tumor angiogenesis and
malignancies. Integr Cancer Ther 2005, 4 (4), 315-21.

156

152.

153.
154.
155.

156.

157.
158.

159.

160.
161.

162.

163.

164.

Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash,
J., Vascular-specific growth factors and blood vessel formation. Nature 2000, 407
(6801), 242-8.
Sumpio, B. E.; Riley, J. T.; Dardik, A., Cells in focus: endothelial cell. Int J
Biochem Cell Biol 2002, 34 (12), 1508-12.
Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6
(4), 389-95.
Muller, Y. A.; Li, B.; Christinger, H. W.; Wells, J. A.; Cunningham, B. C.; de
Vos, A. M., Vascular endothelial growth factor: crystal structure and functional
mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A
1997, 94 (14), 7192-7.
Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J.
C.; Abraham, J. A., The human gene for vascular endothelial growth factor.
Multiple protein forms are encoded through alternative exon splicing. J Biol
Chem 1991, 266 (18), 11947-54.
Karkkainen, M. J.; Makinen, T.; Alitalo, K., Lymphatic endothelium: a new
frontier of metastasis research. Nat Cell Biol 2002, 4 (1), E2-5.
Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L., VEGF receptor
signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7 (5),
359-71.
Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.;
Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.;
Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; Vandendriessche,
T.; Ponten, A.; Eriksson, U.; Plate, K. H.; Foidart, J. M.; Schaper, W.; CharnockJones, D. S.; Hicklin, D. J.; Herbert, J. M.; Collen, D.; Persico, M. G., Synergism
between vascular endothelial growth factor and placental growth factor
contributes to angiogenesis and plasma extravasation in pathological conditions.
Nat Med 2001, 7 (5), 575-83.
Perona, R., Cell signalling: growth factors and tyrosine kinase receptors. Clin
Transl Oncol 2006, 8 (2), 77-82.
Aiello, L. P.; Pierce, E. A.; Foley, E. D.; Takagi, H.; Chen, H.; Riddle, L.;
Ferrara, N.; King, G. L.; Smith, L. E., Suppression of retinal neovascularization in
vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble
VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995, 92 (23),
10457-61.
Shen, J.; Samul, R.; Silva, R. L.; Akiyama, H.; Liu, H.; Saishin, Y.; Hackett, S.
F.; Zinnen, S.; Kossen, K.; Fosnaugh, K.; Vargeese, C.; Gomez, A.; Bouhana, K.;
Aitchison, R.; Pavco, P.; Campochiaro, P. A., Suppression of ocular
neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006, 13
(3), 225-34.
Kim, D. H.; Longo, M.; Han, Y.; Lundberg, P.; Cantin, E.; Rossi, J. J., Interferon
induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat
Biotechnol 2004, 22 (3), 321-5.
Ambrosini, G.; Adida, C.; Altieri, D. C., A novel anti-apoptosis gene, survivin,
expressed in cancer and lymphoma. Nat Med 1997, 3 (8), 917-21.

157

165.

166.
167.
168.

169.
170.

171.

172.

173.
174.

175.
176.

177.

(a) Wheatley, S. P.; McNeish, I. A., Survivin: a protein with dual roles in mitosis
and apoptosis. Int Rev Cytol 2005, 247, 35-88; (b) Mita, A. C.; Mita, M. M.;
Nawrocki, S. T.; Giles, F. J., Survivin: key regulator of mitosis and apoptosis and
novel target for cancer therapeutics. Clin Cancer Res 2008, 14 (16), 5000-5.
Altieri, D. C., Survivin, cancer networks and pathway-directed drug discovery.
Nat Rev Cancer 2008, 8 (1), 61-70.
Duffy, M. J.; O'Donovan, N.; Brennan, D. J.; Gallagher, W. M.; Ryan, B. M.,
Survivin: a promising tumor biomarker. Cancer Lett 2007, 249 (1), 49-60.
Minematsu, T.; Iwai, M.; Umehara, K.; Usui, T.; Kamimura, H., Characterization
of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155
monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos
2010, 38 (1), 1-4.
Pennati, M.; Folini, M.; Zaffaroni, N., Targeting survivin in cancer therapy:
fulfilled promises and open questions. Carcinogenesis 2007, 28 (6), 1133-9.
Nakahara, T.; Takeuchi, M.; Kinoyama, I.; Minematsu, T.; Shirasuna, K.;
Matsuhisa, A.; Kita, A.; Tominaga, F.; Yamanaka, K.; Kudoh, M.; Sasamata, M.,
YM155, a novel small-molecule survivin suppressant, induces regression of
established human hormone-refractory prostate tumor xenografts. Cancer Res
2007, 67 (17), 8014-21.
Tolcher, A. W.; Mita, A.; Lewis, L. D.; Garrett, C. R.; Till, E.; Daud, A. I.;
Patnaik, A.; Papadopoulos, K.; Takimoto, C.; Bartels, P.; Keating, A.; Antonia,
S., Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of
survivin. J Clin Oncol 2008, 26 (32), 5198-203.
(a) Sato, A.; Ito, K.; Asano, T.; Sumitomo, M.; Hayakawa, M., Topotecan and
small interfering RNA suppress survivin expression synergistically in Caki-1
renal cancer cells: Direct suppression of survivin and enhancement of transfection
efficiency by topotecan. Int J Oncol 2008, 32 (1), 171-6; (b) Sato, A.; Ito, K.;
Asano, T.; Sumitomo, M.; Hayakawa, M., Synergistic effect of survivin-specific
small interfering RNA and topotecan in renal cancer cells: topotecan enhances
liposome-mediated transfection by increasing cellular uptake. Int J Oncol 2007,
30 (3), 695-700.
Li, B.; Fan, J.; Liu, X.; Qi, R.; Bo, L.; Gu, J.; Qian, C., Suppression of colorectal
tumor growth by regulated survivin targeting. J Mol Med 2006, 84 (12), 1077-86.
Vogel, C.; Hager, C.; Bastians, H., Mechanisms of mitotic cell death induced by
chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007, 67 (1), 33945.
Knauer, S. K.; Mann, W.; Stauber, R. H., Survivin's dual role: an export's view.
Cell Cycle 2007, 6 (5), 518-21.
Wang, Z.; Sampath, J.; Fukuda, S.; Pelus, L. M., Disruption of the inhibitor of
apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced
apoptosis. Cancer Res 2005, 65 (18), 8224-32.
Wolanin, K.; Magalska, A.; Mosieniak, G.; Klinger, R.; McKenna, S.; Vejda, S.;
Sikora, E.; Piwocka, K., Curcumin affects components of the chromosomal

158

178.

179.
180.

181.
182.

183.

184.

185.

186.

passenger complex and induces mitotic catastrophe in apoptosis-resistant BcrAbl-expressing cells. Mol Cancer Res 2006, 4 (7), 457-69.
Imai, Y.; Kimura, T.; Murakami, A.; Yajima, N.; Sakamaki, K.; Yonehara, S.,
The CED-4-homologous protein FLASH is involved in Fas-mediated activation
of caspase-8 during apoptosis. Nature 1999, 398 (6730), 777-85.
Krieghoff, E.; Milovic-Holm, K.; Hofmann, T. G., FLASH meets nuclear bodies:
CD95 receptor signals via a nuclear pathway. Cell Cycle 2007, 6 (7), 771-5.
Barcaroli, D.; Bongiorno-Borbone, L.; Terrinoni, A.; Hofmann, T. G.; Rossi, M.;
Knight, R. A.; Matera, A. G.; Melino, G.; De Laurenzi, V., FLASH is required for
histone transcription and S-phase progression. Proc Natl Acad Sci U S A 2006,
103 (40), 14808-12.
Shi, Y., Mechanical aspects of apoptosome assembly. Current Opinion in Cell
Biology 2006, 18 (6), 677-84.
Kittler, R.; Putz, G.; Pelletier, L.; Poser, I.; Heninger, A. K.; Drechsel, D.;
Fischer, S.; Konstantinova, I.; Habermann, B.; Grabner, H.; Yaspo, M. L.;
Himmelbauer, H.; Korn, B.; Neugebauer, K.; Pisabarro, M. T.; Buchholz, F., An
endoribonuclease-prepared siRNA screen in human cells identifies genes essential
for cell division. Nature 2004, 432 (7020), 1036-40.
Flotho, C.; Coustan-Smith, E.; Pei, D.; Iwamoto, S.; Song, G.; Cheng, C.; Pui, C.
H.; Downing, J. R.; Campana, D., Genes contributing to minimal residual disease
in childhood acute lymphoblastic leukemia: prognostic significance of
CASP8AP2. Blood 2006, 108 (3), 1050-7.
Yang, Y. L.; Lin, S. R.; Chen, J. S.; Lin, S. W.; Yu, S. L.; Chen, H. Y.; Yen, C.
T.; Lin, C. Y.; Lin, J. F.; Lin, K. H.; Jou, S. T.; Hu, C. Y.; Chang, S. K.; Lu, M.
Y.; Chang, H. H.; Chang, W. H.; Lin, K. S.; Lin, D. T., Expression and prognostic
significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in
childhood acute lymphoblastic leukemia. Leuk Res 2010, 34 (1), 18-23.
(a) Kino, T.; Chrousos, G. P., Tumor necrosis factor alpha receptor- and Fasassociated FLASH inhibit transcriptional activity of the glucocorticoid receptor
by binding to and interfering with its interaction with p160 type nuclear receptor
coactivators. J Biol Chem 2003, 278 (5), 3023-9; (b) Barcaroli, D.; Dinsdale, D.;
Neale, M. H.; Bongiorno-Borbone, L.; Ranalli, M.; Munarriz, E.; Sayan, A. E.;
McWilliam, J. M.; Smith, T. M.; Fava, E.; Knight, R. A.; Melino, G.; De
Laurenzi, V., FLASH is an essential component of Cajal bodies. Proc Natl Acad
Sci U S A 2006, 103 (40), 14802-7; (c) Milovic-Holm, K.; Krieghoff, E.; Jensen,
K.; Will, H.; Hofmann, T. G., FLASH links the CD95 signaling pathway to the
cell nucleus and nuclear bodies. EMBO J 2007, 26 (2), 391-401; (d) AlmKristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O.
S., FLASH acts as a co-activator of the transcription factor c-Myb and localizes to
active RNA polymerase II foci. Oncogene 2008, 27 (34), 4644-56; (e) Yang, X.
C.; Burch, B. D.; Yan, Y.; Marzluff, W. F.; Dominski, Z., FLASH, a proapoptotic
protein involved in activation of caspase-8, is essential for 3' end processing of
histone pre-mRNAs. Mol Cell 2009, 36 (2), 267-78.
(a) Scales, C. W.; Huang, F.; Li, N.; Vasilieva, Y. A.; Ray, J.; Convertine, A. J.;
McCormick, C. L., Corona-Stabilized Interpolyelectrolyte Complexes of SiRNA
with Nonimmunogenic, Hydrophilic/Cationic Block Copolymers Prepared by

159

187.
188.

189.
190.
191.

192.
193.

Aqueous RAFT Polymerization. Macromolecules 2006, 39 (20), 6881; (b) Li, N.;
Yu, C.; Huang, F., Novel cyanine-AMP conjugates for efficient 5' RNA
fluorescent labeling by one-step transcription and replacement of [gamma32P]ATP in RNA structural investigation. Nucleic Acids Res 2005, 33 (4), e37;
(c) Li, N.; Huang, F., Ribozyme-catalyzed aminoacylation from CoA thioesters.
Biochemistry 2005, 44 (11), 4582-90; (d) Kirkland-York, S.; Zhang, Y.; Smith,
A. E.; York, A. W.; Huang, F.; McCormick, C. L., Tailored Design of Au
Nanoparticle-siRNA Carriers Utilizing Reversible Addition-Fragmentation Chain
Transfer Polymers. Biomacromolecules 2010, 11 (4), 1052-9; (e) Huang, F.;
Wang, G.; Coleman, T.; Li, N., Synthesis of adenosine derivatives as transcription
initiators and preparation of 5' fluorescein- and biotin-labeled RNA through onestep in vitro transcription. RNA 2003, 9 (12), 1562-70; (f) Huang, F.; He, J.;
Zhang, Y.; Guo, Y., Synthesis of biotin-AMP conjugate for 5' biotin labeling of
RNA through one-step in vitro transcription. Nat Protoc 2008, 3 (12), 1848-61;
(g) Huang, F.; Bugg, C. W.; Yarus, M., RNA-Catalyzed CoA, NAD, and FAD
synthesis from phosphopantetheine, NMN, and FMN. Biochemistry 2000, 39
(50), 15548-55; (h) Huang, F., Efficient incorporation of CoA, NAD and FAD
into RNA by in vitro transcription. Nucleic Acids Res 2003, 31 (3), e8; (i) Guo,
S.; Huang, F.; Guo, P., Construction of folate-conjugated pRNA of bacteriophage
phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal
carcinoma cells. Gene Ther 2006, 13 (10), 814-20; (j) Coleman, T. M.; Wang, G.;
Huang, F., Superior 5' homogeneity of RNA from ATP-initiated transcription
under the T7 phi 2.5 promoter. Nucleic Acids Res 2004, 32 (1), e14; (k) Coleman,
T. M.; Li, N.; Huang, F., A simple and efficient method to prepare thioesters in
aqueous solutions. Tetrahedron Letters 2005, 46 (25), 4310; (l) Coleman, T. M.;
Huang, F., Optimal random libraries for the isolation of catalytic RNA. RNA Biol
2005, 2 (4), 129-36; (m) Coleman, T. M.; Huang, F., RNA-catalyzed thioester
synthesis. Chem Biol 2002, 9 (11), 1227-36.
Donze, O.; Picard, D., RNA interference in mammalian cells using siRNAs
synthesized with T7 RNA polymerase. Nucleic Acids Res 2002, 30 (10), e46.
Li, L.; Liu, J.; Diao, Z.; Shu, D.; Guo, P.; Shen, G., Evaluation of specific
delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells.
Mol Biosyst 2009, 5, 1361-8.
Collins, T. J., ImageJ for microscopy. Biotechniques 2007, 43 (1 Suppl), 25-30.
Russ, V.; Wagner, E., Cell and tissue targeting of nucleic acids for cancer gene
therapy. Pharm Res 2007, 24 (6), 1047-57.
(a) Moore, A.; Medarova, Z., Imaging of siRNA delivery and silencing. Methods
Mol. Biol. 2009, 487, 93-110; (b) Cerchia, L.; Giangrande, P. H.; McNamara, J.
O.; de Franciscis, V., Cell-specific aptamers for targeted therapies. Methods Mol.
Biol. 2009, 535, 59-78.
Endoh, T.; Ohtsuki, T., Cellular siRNA delivery using cell-penetrating peptides
modified for endosomal escape. Adv Drug Deliv Rev 2009, 61 (9), 704-9.
Han, S. E.; Kang, H.; Shim, G. Y.; Suh, M. S.; Kim, S. J.; Kim, J. S.; Oh, Y. K.,
Novel cationic cholesterol derivative-based liposomes for serum-enhanced
delivery of siRNA. Int J Pharm 2008, 353 (1-2), 260-9.

160

194.

195.

196.
197.

198.
199.

200.

201.

202.

203.
204.

205.

206.

Nishina, K.; Unno, T.; Uno, Y.; Kubodera, T.; Kanouchi, T.; Mizusawa, H.;
Yokota, T., Efficient in vivo delivery of siRNA to the liver by conjugation of
alpha-tocopherol. Mol Ther 2008, 16, 734-40.
Zhang, K.; Wang, Q.; Xie, Y.; Mor, G.; Sega, E.; Low, P. S.; Huang, Y.,
Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired
interactions. RNA 2008, 14 (3), 577-83.
Sega, E. I.; Low, P. S., Tumor detection using folate receptor-targeted imaging
agents. Cancer Metastasis Rev. 2008, 27 (4), 655-64.
Thomas, M.; Kularatne, S. A.; Qi, L.; Kleindl, P.; Leamon, C. P.; Hansen, M. J.;
Low, P. S., Ligand-targeted delivery of small interfering RNAs to malignant cells
and tissues. Ann. N. Y. Acad. Sci. 2009, 1175, 32-9.
Gross, S.; Piwnica-Worms, D., Spying on cancer: Molecular imaging in vivo with
genetically encoded reporters. Cancer Cell2005, 7 (1), 5-15.
(a) Contag, C. H.; Bachmann, M. H., Advances in in vivo bioluminescence
imaging of gene expression. Annu Rev Biomed Eng 2002, 4, 235-60; (b) Wilson,
T.; Hastings, J. W., Bioluminescence. Annu Rev Cell Dev Biol 1998, 14, 197230.
(a) Malik, I.; Garrido, M.; Bahr, M.; Kugler, S.; Michel, U., Comparison of test
systems for RNAinterference. Biochem Biophys Res Commun 2006, 341 (1),
245-53; (b) Rousseau, J.; Escriou, V.; Perrot, P.; Picarda, G.; Charrier, C.;
Scherman, D.; Heymann, D.; Redini, F.; Trichet, V., Advantages of
bioluminescence imaging to follow siRNA or chemotherapeutic treatments in
osteosarcoma preclinical models. Cancer Gene Ther 2010, 17 (6), 387-97.
McElroy, W. D.; Seliger, H. H.; White, E. H., Mechanism of bioluminescence,
chemiluminescence and enzyme function in the oxidation of firefly luciferin.
Photochem Photobiol 1969, 10 (3), 153-70.
(a) Widder, E. A., Bioluminescence in the ocean: origins of biological, chemical,
and ecological diversity. Science 2010, 328 (5979), 704-8; (b) Greer, L. F., 3rd;
Szalay, A. A., Imaging of light emission from the expression of luciferases in
living cells and organisms: a review. Luminescence 2002, 17 (1), 43-74.
Tannous, B. A., Gaussia luciferase reporter assay for monitoring biological
processes in culture and in vivo. Nat Protoc 2009, 4 (4), 582-91.
(a) Verhaegent, M.; Christopoulos, T. K., Recombinant Gaussia luciferase.
Overexpression, purification, and analytical application of a bioluminescent
reporter for DNA hybridization. Anal Chem 2002, 74 (17), 4378-85; (b) Tannous,
B. A.; Kim, D. E.; Fernandez, J. L.; Weissleder, R.; Breakefield, X. O., Codonoptimized Gaussia luciferase cDNA for mammalian gene expression in culture
and in vivo. Mol Ther 2005, 11 (3), 435-43.
Guo, S.; Tschammer, N.; Mohammed, S.; Guo, P., Specific delivery of
therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor
pRNA. Hum Gene Ther 2005, 16, 1097-109.
Yuan, B.; Latek, R.; Hossbach, M.; Tuschl, T.; Lewitter, F., siRNA Selection
Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res
2004, 32 (Web Server issue), W130-4.

161

207.

208.
209.

210.

211.

212.

213.

214.

Lu, J. Y.; Lowe, D. A.; Kennedy, M. D.; Low, P. S., Folate-targeted enzyme
prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
J Drug Target 1999, 7 (1), 43-53.
Nguyen, T.; Menocal, E. M.; Harborth, J.; Fruehauf, J. H., RNAi therapeutics: an
update on delivery. Curr Opin Mol Ther 2008, 10 (2), 158-67.
(a) Pack, D. W.; Hoffman, A. S.; Pun, S.; Stayton, P. S., Design and development
of polymers for gene delivery. Nat. Rev. Drug Discov. 2005, 4 (7), 581-93; (b)
Jeong, J. H.; Mok, H.; Oh, Y. K.; Park, T. G., siRNA conjugate delivery systems.
Bioconjug. Chem. 2009, 20 (1), 5-14.
(a) Kabanov, V. A.; Kabanov, A. V., Interpolyelectrolyte and block ionomer
complexes for gene delivery: physico-chemical aspects. Adv. Drug Deliv. Rev.
1998, 30 (1-3), 49-60; (b) Lam, J. K.; Ma, Y.; Armes, S. P.; Lewis, A. L.;
Baldwin, T.; Stolnik, S., Phosphorylcholine-polycation diblock copolymers as
synthetic vectors for gene delivery. J. Control. Release 2004, 100 (2), 293-312.
(a) Merdan, T.; Kunath, K.; Fischer, D.; Kopecek, J.; Kissel, T., Intracellular
processing of poly(ethylene imine)/ribozyme complexes can be observed in living
cells by using confocal laser scanning microscopy and inhibitor experiments.
Pharm. Res. 2002, 19 (2), 140-6; (b) Leonetti, J. P.; Degols, G.; Lebleu, B.,
Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of
cell uptake. Bioconjug. Chem. 1990, 1 (2), 149-53; (c) Deshpande, M. C.; Davies,
M. C.; Garnett, M. C.; Williams, P. M.; Armitage, D.; Bailey, L.; Vamvakaki, M.;
Armes, S. P.; Stolnik, S., The effect of poly(ethylene glycol) molecular
architecture on cellular interaction and uptake of DNA complexes. J. Control.
Release 2004, 97 (1), 143-56.
(a) Zou, S. M.; Erbacher, P.; Remy, J. S.; Behr, J. P., Systemic linear
polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J. Gene Med.
2000, 2 (2), 128-34; (b) Dash, P. R.; Read, M. L.; Barrett, L. B.; Wolfert, M. A.;
Seymour, L. W., Factors affecting blood clearance and in vivo distribution of
polyelectrolyte complexes for gene delivery. Gene Ther. 1999, 6 (4), 643-50.
(a) Wagner, E., Advances in cancer gene therapy: tumor-targeted delivery of
therapeutic pDNA, siRNA, and dsRNA nucleic acids. J BUON 2007, 12 Suppl 1,
S77-82; (b) Yan, A.; Levy, M., Aptamers and aptamer targeted delivery. RNA
Biol 2009, 6, 316-20.
(a) Hobel, S.; Aigner, A., Polyethylenimine (PEI)/siRNA-mediated gene
knockdown in vitro and in vivo. Methods Mol. Biol. 2010, 623 (623), 283-97; (b)
Biswal, B. K.; Debata, N. B.; Verma, R. S., Development of a targeted siRNA
delivery system using FOL-PEG-PEI conjugate. Mol. Biol. Rep. 2010, 37 (6),
2919-26 (c) Merkel, O. M.; Beyerle, A.; Librizzi, D.; Pfestroff, A.; Behr, T. M.;
Sproat, B.; Barth, P. J.; Kissel, T., Nonviral siRNA delivery to the lung:
investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm.
2009, 6 (4), 1246-1260; (d) Patil, Y.; Panyam, J., Polymeric nanoparticles for
siRNA delivery and gene silencing. Int. J. Pharm. 2009, 367 (1-2), 195-203; (e)
Heredia, K. L.; Nguyen, T. H.; Chang, C. W.; Bulmus, V.; Davis, T. P.; Maynard,
H. D., Reversible siRNA-polymer conjugates by RAFT polymerization. Chem.
Commun. 2008, (28), 3245-7; (f) Boyer, C.; Bulmus, V.; Davis, T. P.; Ladmiral,
V.; Liu, J.; Perrier, S., Bioapplications of RAFT polymerization. Chem Rev 2009,

162

215.

216.

217.

218.

109 (11), 5402-36; (g) Convertine, A. J.; Benoit, D. S.; Duvall, C. L.; Hoffman,
A. S.; Stayton, P. S., Development of a novel endosomolytic diblock copolymer
for siRNA delivery. J. Control. Release 2009, 133 (3), 221-9; (h) Lee, S. H.; Kim,
S. H.; Park, T. G., Intracellular siRNA delivery system using polyelectrolyte
complex micelles prepared from VEGF siRNA-PEG conjugate and cationic
fusogenic peptide. Biochem. Biophys. Res. Commun. 2007, 357 (2), 511-6; (i)
Lee, S. H.; Bae, K. H.; Kim, S. H.; Lee, K. R.; Park, T. G., Amine-functionalized
gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery
carriers. Int J Pharm 2008, 364 (1), 94-101; (j) Oishi, M.; Nagasaki, Y.; Itaka, K.;
Nishiyama, N.; Kataoka, K., Lactosylated poly(ethylene glycol)-siRNA conjugate
through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion
complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am.
Chem. Soc. 2005, 127 (6), 1624-5; (k) Oishi, M.; Nagasaki, Y.; Nishiyama, N.;
Itaka, K.; Takagi, M.; Shimamoto, A.; Furuichi, Y.; Kataoka, K., Enhanced
growth inhibition of hepatic multicellular tumor spheroids by lactosylated
poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes.
ChemMedChem 2007, 2 (9), 1290-7; (l) York, A. W.; Huang, F.; McCormick, C.
L., Rational Design of Targeted Cancer Therapeutics through the
Multiconjugation of Folate and Cleavable siRNA to RAFT-Synthesized (HPMAs-APMA) Copolymers. Biomacromolecules 2010, 11, 505-14; (m) Scales, C. W.;
Huang, F.; Li, N.; Vasilieva, Y. A.; Ray, J.; Convertine, A. J.; McCormick, C. L.,
Corona-Stabilized Interpolyelectrolyte Complexes of SiRNA with
Nonimmunogenic, Hydrophilic/Cationic Block Copolymers Prepared by Aqueous
RAFT Polymerization. Macromolecules 2006, 39 (20), 6871-81.
(a) Medina-Kauwe, L. K.; Xie, J.; Hamm-Alvarez, S., Intracellular trafficking of
nonviral vectors. Gene Ther. 2005, 12 (24), 1734-51; (b) Christie, R. J.;
Nishiyama, N.; Kataoka, K., Minireview: Delivering the Code: Polyplex Carriers
for Deoxyribonucleic Acid and Ribonucleic Acid Interference Therapies.
Endocrinology 2009, 151, 466-73; (c) Tseng, Y. C.; Mozumdar, S.; Huang, L.,
Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 2009, 61 (9),
721-31.
(a) Mathias, C. J.; Wang, S.; Low, P. S.; Waters, D. J.; Green, M. A., Receptormediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive
human KB tumor xenografts. Nucl Med Biol 1999, 26 (1), 23-5; (b) Pal, A.;
Ahmad, A.; Khan, S.; Sakabe, I.; Zhang, C.; Kasid, U.; Ahmad, I., Systemic
delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1
expression and inhibits tumor growth in xenograft model of human prostate
cancer. Int J Oncol 2005, 26, 1087-91.
Dreher, M. R.; Liu, W.; Michelich, C. R.; Dewhirst, M. W.; Yuan, F.; Chilkoti,
A., Tumor vascular permeability, accumulation, and penetration of
macromolecular drug carriers. J Natl Cancer Inst 2006, 98 (5), 335-44.
Low, P. S.; Henne, W. A.; Doorneweerd, D. D., Discovery and development of
folic-acid-based receptor targeting for imaging and therapy of cancer and
inflammatory diseases. Acc. Chem. Res. 2008, 41 (1), 120-9.

163

219.

220.
221.

222.

223.

224.

225.

226.

227.

228.

Magzoub, M.; Pramanik, A.; Graslund, A., Modeling the endosomal escape of
cell-penetrating peptides: transmembrane pH gradient driven translocation across
phospholipid bilayers. Biochemistry 2005, 44 (45), 14890-7.
Bolte, S.; Cordelieres, F. P., A guided tour into subcellular colocalization analysis
in light microscopy. J. Microsc. 2006, 224 (Pt 3), 213-32.
(a) Manders, E. M.; Stap, J.; Brakenhoff, G. J.; van Driel, R.; Aten, J. A.,
Dynamics of three-dimensional replication patterns during the S-phase, analysed
by double labelling of DNA and confocal microscopy. J. Cell Sci. 1992, 103 ( Pt
3), 857-62; (b) Manders, E. M. M.; VERBEEK, F. J.; ATEN, J. A., Measurement
of co-localization of objects in dual-colour confocal images. J. Microsc. 1993,
169 (3), 375-82.
Leamon, C. P.; Pastan, I.; Low, P. S., Cytotoxicity of folate-Pseudomonas
exotoxin conjugates toward tumor cells. Contribution of translocation domain. J.
Biol. Chem. 1993, 268 (33), 24847-54.
Filion, M. C.; Phillips, N. C., Toxicity and immunomodulatory activity of
liposomal vectors formulated with cationic lipids toward immune effector cells.
Biochimica et Biophysica Acta (BBA) - Biomembranes 1997, 1329 (2), 345-56.
(a) Tannous, B. A.; Kim, D. E.; Fernandez, J. L.; Weissleder, R.; Breakefield, X.
O., Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in
culture and in vivo. Mol. Ther. 2005, 11 (3), 435-43; (b) Tannous, B. A., Gaussia
luciferase reporter assay for monitoring biological processes in culture and in
vivo. Nat. Protoc. 2009, 4 (4), 582-91; (c) Chung, E.; Yamashita, H.; Au, P.;
Tannous, B. A.; Fukumura, D.; Jain, R. K., Secreted gaussia luciferase as a
biomarker for monitoring tumor progression and treatment response of systemic
metastases. PLoS One 2009, 4 (12), e8316.
Prasad, P. D.; Ramamoorthy, S.; Moe, A. J.; Smith, C. H.; Leibach, F. H.;
Ganapathy, V., Selective expression of the high-affinity isoform of the folate
receptor (FR-alpha) in the human placental syncytiotrophoblast and
choriocarcinoma cells. Biochim Biophys Acta 1994, 1223 (1), 71-5.
(a) Chello, P. L.; Sirotnak, F. M.; Wong, E.; Kisliuk, R. L.; Gaumont, Y.;
Combepine, G., Further studies stereospecificity at carbon 6 for membrane
transport of tetrahydrofolates. Diastereoisomers of 5-methyltetrahydrofolates as
competitive inhibitors of transport of methotrexate in L1210 cells. Biochem
Pharmacol 1982, 31 (8), 1527-30; (b) Fry, D. W.; Besserer, J. A.; Boritzki, T. J.,
Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the
reduced folate carrier system. Cancer Res 1984, 44 (8), 3366-70.
(a) Gorlick, R.; Cole, P.; Banerjee, D.; Longo, G.; Li, W. W.; Hochhauser, D.;
Bertino, J. R., Mechanisms of methotrexate resistance in acute leukemia.
Decreased transport and polyglutamylation. Adv Exp Med Biol 1999, 457, 54350; (b) Guo, W.; Healey, J. H.; Meyers, P. A.; Ladanyi, M.; Huvos, A. G.;
Bertino, J. R.; Gorlick, R., Mechanisms of methotrexate resistance in
osteosarcoma. Clin Cancer Res 1999, 5 (3), 621-7.
Lu, Y.; Low, P. S., Folate targeting of haptens to cancer cell surfaces mediates
immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 2002,
51 (3), 153-62.

164

229.

230.

231.
232.

233.

234.

235.

236.

237.

238.
239.

Ross, J. F.; Chaudhuri, P. K.; Ratnam, M., Differential regulation of folate
receptor isoforms in normal and malignant tissues in vivo and in established cell
lines. Physiologic and clinical implications. Cancer 1994, 73 (9), 2432-43.
Paulos, C. M.; Reddy, J. A.; Leamon, C. P.; Turk, M. J.; Low, P. S., Ligand
binding and kinetics of folate receptor recycling in vivo: impact on receptormediated drug delivery. Mol Pharmacol 2004, 66 (6), 1406-14.
Dincer, S.; Turk, M.; Piskin, E., Intelligent polymers as nonviral vectors. Gene
Ther 2005, 12 Suppl 1, S139-45.
(a) Gilmore, I. R.; Fox, S. P.; Hollins, A. J.; Sohail, M.; Akhtar, S., The design
and exogenous delivery startegies of siRNA for post-transcriptional gene
silencing. Journal of Drug Targeting 2004, 12, 315-40; (b) Gilmore, I. R.; Fox, S.
P.; Hollins, A. J.; Akhtar, S., Delivery strategies for siRNA-mediated gene
silencing. Current Drug Delivery 2006, 3, 147-55; (c) Aigner, A., Delivery
systems for the direct application of siRNAs to induce RNA interference (RNAi)
in vivo. Journal of Biomedicine and Biotechnology 2006, 71659.
(a) Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.;
Mirkin, C. A., Gold nanoparticles for biology and medicine. Angew Chem Int Ed
Engl 2010, 49 (19), 3280-94; (b) Jennings, T.; Strouse, G., Past, present, and
future of gold nanoparticles. Adv Exp Med Biol 2007, 620, 34-47.
Boisselier, E.; Astruc, D., Gold nanoparticles in nanomedicine: preparations,
imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38 (6), 175982.
Giljohann, D. A.; Seferos, D. S.; Prigodich, A. E.; Patel, P. C.; Mirkin, C. A.,
Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc
2009, 131 (6), 2072-3.
Oishi, M.; Nakaogami, J.; Ishii, T.; Nagasaki, Y., Smart PEGylated Gold
Nanoparticles for the Cytoplasmic Delivery of siRNA to Induce Enhanced Gene
Silencing. Chemistry Letters 2006, 35 (9), 1046-7.
(a) Chiefari, J.; Chong, Y. K.; Ercole, F.; Krstina, J.; Jeffery, J.; Le, T. P. T.;
Mayadunne, R. T. A.; Meijs, G. F.; Moad, C. L.; Moad, G.; Rizzardo, E.; Thang,
S. H., Living free-radical polymerization by reversible addition-fragmentation
chain transfer: the RAFT process. Macromolecules 1998, 31, 5559-62; (b) Lowe,
A. B.; McCormick, C. L., Reversible addition-fragmentation chain transfer
(RAFT) radical polymerization and the synthesis of water-soluble (co)polymers
under homogeneous conditions in organic and aqueous media. Prog. Polym. Sci.
2007, 32 (3), 283-351; (c) McCormick, C. L.; Lowe, A. B., Aqueous RAFT
polymerization: Recent developments in synthesis of functional water-soluble
(co)polymers with controlled structures. Acc. Chem. Res. 2004, 37 (5), 312-25;
(d) Moad, G.; Rizzardo, E.; Thang, S. H., Living radical polymerization by the
RAFT process. Aust. J. Chem. 2005, 58, 379-410; (e) Moad, G.; Rizzardo, E.;
Thang, S. H., Living radical polymerization by the RAFT process—A first
update. Aust. J. Chem. 2006, 59, 669-92.
Khalil, I. A., Uptake Pathways and Subsequent Intracellular Trafficking in
Nonviral Gene Delivery. Pharmacological Reviews 2006, 58 (1), 32-45.
Akita, H.; Kogure, K.; Moriguchi, R.; Nakamura, Y.; Higashi, T.; Nakamura, T.;
Serada, S.; Fujimoto, M.; Naka, T.; Futaki, S.; Harashima, H., Nanoparticles for

165

240.

241.

242.

243.

ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed
endosomal escape and dissociation. J. Control. Release 2010, 143, 311-7.
(a) Dehousse, V.; Garbacki, N.; Colige, A.; Evrard, B., Development of pHresponsive nanocarriers using trimethylchitosans and methacrylic acid copolymer
for siRNA delivery. Biomaterials 2010, 31 (7), 1839-49; (b) Wang, X. L.; Xu, R.;
Lu, Z. R., A peptide-targeted delivery system with pH-sensitive amphiphilic cell
membrane disruption for efficient receptor-mediated siRNA delivery. J Control
Release 2009, 134 (3), 207-13; (c) Hatakeyama, H.; Ito, E.; Akita, H.; Oishi, M.;
Nagasaki, Y.; Futaki, S.; Harashima, H., A pH-sensitive fusogenic peptide
facilitates endosomal escape and greatly enhances the gene silencing of siRNAcontaining nanoparticles in vitro and in vivo. J Control Release 2009, 139 (2),
127-32.
Lee, S. H.; Choi, S. H.; Kim, S. H.; Park, T. G., Thermally sensitive cationic
polymer nanocapsules for specific cytosolic delivery and efficient gene silencing
of siRNA: swelling induced physical disruption of endosome by cold shock. J
Control Release 2008, 125 (1), 25-32.
(a) Febvay, S.; Marini, D. M.; Belcher, A. M.; Clapham, D. E., Targeted cytosolic
delivery of cell-impermeable compounds by nanoparticle-mediated, lighttriggered endosome disruption. Nano Lett 2010, 10 (6), 2211-9; (b) Fretz, M. M.;
Hogset, A.; Koning, G. A.; Jiskoot, W.; Storm, G., Cytosolic delivery of
liposomally targeted proteins induced by photochemical internalization. Pharm
Res 2007, 24 (11), 2040-7; (c) Oliveira, S.; Fretz, M. M.; Hogset, A.; Storm, G.;
Schiffelers, R. M., Photochemical internalization enhances silencing of epidermal
growth factor receptor through improved endosomal escape of siRNA. Biochim
Biophys Acta 2007, 1768 (5), 1211-7.
(a) Moore, N. M.; Sheppard, C. L.; Barbour, T. R.; Sakiyama-Elbert, S. E., The
effect of endosomal escape peptides on in vitro gene delivery of polyethylene
glycol-based vehicles. J Gene Med 2008, 10 (10), 1134-49; (b) Oliveira, S.; van
Rooy, I.; Kranenburg, O.; Storm, G.; Schiffelers, R. M., Fusogenic peptides
enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int
J Pharm 2007, 331 (2), 211-4.

